Introduction  ||| S:24 E:54 ||| NNP
c-fos  ||| S:54 E:60 ||| NNP
is  ||| S:60 E:63 ||| VBZ
a  ||| S:63 E:65 ||| DT
member  ||| S:65 E:72 ||| NN
of  ||| S:72 E:75 ||| IN
the  ||| S:75 E:79 ||| DT
family  ||| S:79 E:86 ||| NN
of  ||| S:86 E:97 ||| IN
immediate  ||| S:97 E:107 ||| JJ
early  ||| S:107 E:113 ||| JJ
genes ||| S:113 E:118 ||| NNS
,  ||| S:118 E:120 ||| ,
and  ||| S:120 E:124 ||| CC
its  ||| S:124 E:128 ||| PRP$
transcription  ||| S:128 E:142 ||| NN
is  ||| S:142 E:145 ||| VBZ
transiently  ||| S:145 E:165 ||| VBN
induced  ||| S:165 E:173 ||| VBN
in  ||| S:173 E:176 ||| IN
response  ||| S:176 E:185 ||| NN
to  ||| S:185 E:188 ||| TO
mitogenic  ||| S:188 E:198 ||| VB
signals  ||| S:198 E:206 ||| NNS
[  ||| S:206 E:208 ||| -LRB-
1 ||| S:208 E:209 ||| LS
] ||| S:209 E:210 ||| -RRB-
.  ||| S:210 E:212 ||| .
The  ||| S:212 E:216 ||| DT
serum  ||| S:216 E:230 ||| JJ
response  ||| S:230 E:239 ||| NN
element  ||| S:239 E:247 ||| NN
( ||| S:247 E:248 ||| -LRB-
SRE ||| S:248 E:251 ||| NNP
)  ||| S:251 E:253 ||| -RRB-
is  ||| S:253 E:256 ||| VBZ
located  ||| S:256 E:264 ||| VBN
approximately  ||| S:264 E:278 ||| RB
300  ||| S:278 E:282 ||| CD
bp  ||| S:282 E:293 ||| JJ
upstream  ||| S:293 E:302 ||| NN
of  ||| S:302 E:305 ||| IN
the  ||| S:305 E:309 ||| DT
transcriptional  ||| S:309 E:325 ||| JJ
start  ||| S:325 E:331 ||| NN
site  ||| S:331 E:336 ||| NN
in  ||| S:336 E:339 ||| IN
the  ||| S:339 E:352 ||| DT
c-fos  ||| S:352 E:358 ||| JJ
promoter  ||| S:358 E:367 ||| NN
and  ||| S:367 E:371 ||| CC
is  ||| S:371 E:374 ||| VBZ
necessary  ||| S:374 E:384 ||| JJ
for  ||| S:384 E:396 ||| IN
serum  ||| S:396 E:402 ||| JJ
induction  ||| S:402 E:412 ||| NN
of  ||| S:412 E:424 ||| IN
c-fos  ||| S:424 E:430 ||| NNP
[  ||| S:430 E:432 ||| -LRB-
2 ||| S:432 E:433 ||| LS
] ||| S:433 E:434 ||| -RRB-
.  ||| S:434 E:436 ||| .
The  ||| S:436 E:440 ||| DT
SRE  ||| S:440 E:444 ||| NNP
binds  ||| S:444 E:450 ||| VBD
a  ||| S:450 E:460 ||| DT
transcription  ||| S:460 E:474 ||| JJ
factor  ||| S:474 E:481 ||| NN
named  ||| S:481 E:487 ||| VBN
serum  ||| S:487 E:493 ||| JJ
response  ||| S:493 E:502 ||| NN
factor  ||| S:502 E:509 ||| NN
( ||| S:509 E:510 ||| -LRB-
SRF ||| S:510 E:513 ||| NNP
)  ||| S:513 E:523 ||| -RRB-
which  ||| S:523 E:529 ||| WDT
was  ||| S:529 E:533 ||| VBD
found  ||| S:533 E:539 ||| VBN
to  ||| S:539 E:542 ||| TO
be  ||| S:542 E:545 ||| VB
necessary ||| S:545 E:554 ||| JJ
,  ||| S:554 E:556 ||| ,
but  ||| S:556 E:560 ||| CC
not  ||| S:560 E:564 ||| RB
sufficient ||| S:564 E:574 ||| JJ
,  ||| S:574 E:576 ||| ,
for  ||| S:576 E:588 ||| IN
serum  ||| S:588 E:594 ||| JJ
induction  ||| S:594 E:604 ||| NN
of  ||| S:604 E:607 ||| IN
the  ||| S:607 E:611 ||| DT
SRE  ||| S:611 E:615 ||| NNP
[  ||| S:615 E:617 ||| -LRB-
3 ||| S:617 E:618 ||| LS
,  ||| S:618 E:620 ||| ,
4 ||| S:620 E:621 ||| CD
,  ||| S:621 E:623 ||| ,
5 ||| S:623 E:624 ||| CD
] ||| S:624 E:625 ||| -RRB-
.  ||| S:625 E:636 ||| .
In  ||| S:636 E:639 ||| IN
vivo  ||| S:639 E:644 ||| JJ
footprinting  ||| S:644 E:657 ||| JJ
analysis  ||| S:657 E:666 ||| NN
shows  ||| S:666 E:680 ||| NNS
that  ||| S:680 E:685 ||| IN
SRF  ||| S:685 E:689 ||| NNP
is  ||| S:689 E:692 ||| VBZ
constitutively  ||| S:692 E:707 ||| VBN
bound  ||| S:707 E:713 ||| VBN
to  ||| S:713 E:716 ||| TO
the  ||| S:716 E:720 ||| DT
SRE  ||| S:720 E:724 ||| NNP
in  ||| S:724 E:727 ||| IN
both  ||| S:727 E:740 ||| DT
quiescent  ||| S:740 E:750 ||| NN
and  ||| S:750 E:754 ||| CC
growth  ||| S:754 E:761 ||| NN
factor  ||| S:761 E:768 ||| NN
stimulated  ||| S:768 E:779 ||| NN
cells  ||| S:779 E:785 ||| NNS
[  ||| S:785 E:787 ||| -LRB-
6 ||| S:787 E:788 ||| CD
] ||| S:788 E:789 ||| -RRB-
.  ||| S:789 E:791 ||| .
This  ||| S:791 E:804 ||| DT
suggests  ||| S:804 E:813 ||| VBZ
that  ||| S:813 E:818 ||| IN
it  ||| S:818 E:821 ||| PRP
is  ||| S:821 E:824 ||| VBZ
the  ||| S:824 E:828 ||| DT
transcriptional  ||| S:828 E:844 ||| JJ
activation  ||| S:844 E:855 ||| NN
of  ||| S:855 E:858 ||| IN
a  ||| S:858 E:868 ||| DT
complex  ||| S:868 E:876 ||| NN
of  ||| S:876 E:879 ||| IN
SRF  ||| S:879 E:883 ||| NNP
and  ||| S:883 E:887 ||| CC
its  ||| S:887 E:891 ||| PRP$
accessory  ||| S:891 E:901 ||| JJ
proteins  ||| S:901 E:910 ||| NNS
that  ||| S:910 E:915 ||| WDT
is  ||| S:915 E:918 ||| VBZ
regulated  ||| S:918 E:936 ||| VBN
rather  ||| S:936 E:943 ||| RB
than  ||| S:943 E:948 ||| IN
regulation  ||| S:948 E:959 ||| NN
of  ||| S:959 E:962 ||| IN
SRF  ||| S:962 E:966 ||| NNP
DNA  ||| S:966 E:970 ||| NNP
binding ||| S:970 E:977 ||| NN
.  ||| S:977 E:987 ||| .
The  ||| S:987 E:991 ||| DT
ternary  ||| S:991 E:999 ||| JJ
complex  ||| S:999 E:1007 ||| JJ
factors  ||| S:1007 E:1015 ||| NNS
( ||| S:1015 E:1016 ||| -LRB-
TCFs ||| S:1016 E:1020 ||| NNP
)  ||| S:1020 E:1022 ||| -RRB-
are  ||| S:1022 E:1026 ||| VBP
members  ||| S:1026 E:1034 ||| NNS
of  ||| S:1034 E:1037 ||| IN
the  ||| S:1037 E:1049 ||| DT
ets  ||| S:1049 E:1053 ||| JJ
family  ||| S:1053 E:1060 ||| NN
of  ||| S:1060 E:1063 ||| IN
transcription  ||| S:1063 E:1077 ||| JJ
factors ||| S:1077 E:1084 ||| NNS
.  ||| S:1084 E:1086 ||| .
The  ||| S:1086 E:1090 ||| DT
TCF  ||| S:1090 E:1094 ||| NNP
family  ||| S:1094 E:1101 ||| NN
members  ||| S:1101 E:1117 ||| NNS
Elk-1  ||| S:1117 E:1123 ||| VBP
[  ||| S:1123 E:1125 ||| -LRB-
7 ||| S:1125 E:1126 ||| CD
] ||| S:1126 E:1127 ||| -RRB-
,  ||| S:1127 E:1129 ||| ,
SAP-1  ||| S:1129 E:1135 ||| NNP
[  ||| S:1135 E:1137 ||| -LRB-
8 ||| S:1137 E:1138 ||| CD
] ||| S:1138 E:1139 ||| -RRB-
,  ||| S:1139 E:1141 ||| ,
and  ||| S:1141 E:1145 ||| CC
SAP-2 ||| S:1145 E:1150 ||| NNP
/ ||| S:1150 E:1151 ||| NNP
ERP ||| S:1151 E:1154 ||| NNP
/ ||| S:1154 E:1155 ||| NNP
NET  ||| S:1155 E:1159 ||| NNP
[  ||| S:1159 E:1161 ||| -LRB-
9 ||| S:1161 E:1162 ||| CD
,  ||| S:1162 E:1164 ||| ,
10 ||| S:1164 E:1166 ||| CD
]  ||| S:1166 E:1168 ||| -RRB-
have  ||| S:1168 E:1181 ||| VBP
been  ||| S:1181 E:1186 ||| VBN
found  ||| S:1186 E:1192 ||| VBN
to  ||| S:1192 E:1195 ||| TO
have  ||| S:1195 E:1200 ||| VB
a  ||| S:1200 E:1202 ||| DT
role  ||| S:1202 E:1207 ||| NN
in  ||| S:1207 E:1210 ||| IN
regulating  ||| S:1210 E:1221 ||| VBG
the  ||| S:1221 E:1225 ||| DT
SRE ||| S:1225 E:1228 ||| NNP
.  ||| S:1228 E:1230 ||| .
TCFs  ||| S:1230 E:1243 ||| JJ
cannot  ||| S:1243 E:1250 ||| NNS
bind  ||| S:1250 E:1255 ||| VBP
the  ||| S:1255 E:1259 ||| DT
SRE  ||| S:1259 E:1263 ||| NNP
autonomously ||| S:1263 E:1275 ||| NN
,  ||| S:1275 E:1277 ||| ,
but  ||| S:1277 E:1281 ||| CC
require  ||| S:1281 E:1297 ||| VB
protein-protein  ||| S:1297 E:1313 ||| JJ
interactions  ||| S:1313 E:1326 ||| NNS
with  ||| S:1326 E:1331 ||| IN
SRF  ||| S:1331 E:1335 ||| NNP
in  ||| S:1335 E:1338 ||| IN
order  ||| S:1338 E:1344 ||| NN
to  ||| S:1344 E:1347 ||| TO
bind  ||| S:1347 E:1352 ||| VB
the  ||| S:1352 E:1364 ||| DT
SRE  ||| S:1364 E:1368 ||| NNP
[  ||| S:1368 E:1370 ||| -LRB-
11 ||| S:1370 E:1372 ||| CD
,  ||| S:1372 E:1374 ||| ,
12 ||| S:1374 E:1376 ||| CD
,  ||| S:1376 E:1378 ||| ,
13 ||| S:1378 E:1380 ||| CD
,  ||| S:1380 E:1382 ||| ,
14 ||| S:1382 E:1384 ||| CD
,  ||| S:1384 E:1386 ||| ,
15 ||| S:1386 E:1388 ||| CD
] ||| S:1388 E:1389 ||| -RRB-
.  ||| S:1389 E:1391 ||| .
The  ||| S:1391 E:1395 ||| DT
TCFs  ||| S:1395 E:1400 ||| JJ
contain  ||| S:1400 E:1408 ||| NN
3  ||| S:1408 E:1410 ||| CD
conserved  ||| S:1410 E:1428 ||| CD
motifs  ||| S:1428 E:1435 ||| NNS
termed  ||| S:1435 E:1442 ||| VBD
the  ||| S:1442 E:1446 ||| DT
A ||| S:1446 E:1447 ||| NNP
,  ||| S:1447 E:1449 ||| ,
B ||| S:1449 E:1450 ||| NNP
,  ||| S:1450 E:1452 ||| ,
and  ||| S:1452 E:1456 ||| CC
C  ||| S:1456 E:1458 ||| NNP
boxes  ||| S:1458 E:1464 ||| NNS
[  ||| S:1464 E:1466 ||| -LRB-
16 ||| S:1466 E:1468 ||| CD
] ||| S:1468 E:1469 ||| -RRB-
.  ||| S:1469 E:1471 ||| .
The  ||| S:1471 E:1475 ||| DT
N-terminal  ||| S:1475 E:1494 ||| JJ
A-box  ||| S:1494 E:1500 ||| NN
( ||| S:1500 E:1501 ||| -LRB-
amino  ||| S:1501 E:1507 ||| FW
acids  ||| S:1507 E:1513 ||| FW
( ||| S:1513 E:1514 ||| -LRB-
aa ||| S:1514 E:1516 ||| LS
)  ||| S:1516 E:1518 ||| -RRB-
1-90  ||| S:1518 E:1523 ||| CD
of  ||| S:1523 E:1526 ||| IN
Elk-1 ||| S:1526 E:1531 ||| CD
)  ||| S:1531 E:1533 ||| -RRB-
is  ||| S:1533 E:1536 ||| VBZ
necessary  ||| S:1536 E:1546 ||| JJ
to  ||| S:1546 E:1549 ||| TO
bind  ||| S:1549 E:1562 ||| VB
DNA ||| S:1562 E:1565 ||| NNP
,  ||| S:1565 E:1567 ||| ,
while  ||| S:1567 E:1573 ||| IN
the  ||| S:1573 E:1577 ||| DT
central  ||| S:1577 E:1585 ||| JJ
B-box  ||| S:1585 E:1591 ||| NN
( ||| S:1591 E:1592 ||| -LRB-
aa  ||| S:1592 E:1595 ||| FW
148-168 ||| S:1595 E:1602 ||| FW
)  ||| S:1602 E:1604 ||| -RRB-
is  ||| S:1604 E:1607 ||| VBZ
the  ||| S:1607 E:1611 ||| DT
SRF  ||| S:1611 E:1623 ||| NNP
interaction  ||| S:1623 E:1635 ||| JJ
domain ||| S:1635 E:1641 ||| NN
.  ||| S:1641 E:1643 ||| .
The  ||| S:1643 E:1647 ||| DT
C-terminal  ||| S:1647 E:1658 ||| JJ
C-box  ||| S:1658 E:1664 ||| NN
( ||| S:1664 E:1665 ||| -LRB-
aa  ||| S:1665 E:1668 ||| FW
352-399 ||| S:1668 E:1675 ||| FW
) ||| S:1675 E:1676 ||| -RRB-
,  ||| S:1676 E:1686 ||| ,
harboring  ||| S:1686 E:1696 ||| VBG
the  ||| S:1696 E:1700 ||| DT
transactivation  ||| S:1700 E:1716 ||| JJ
domain ||| S:1716 E:1722 ||| NN
,  ||| S:1722 E:1724 ||| ,
contains  ||| S:1724 E:1733 ||| VBZ
several  ||| S:1733 E:1749 ||| JJ
consensus  ||| S:1749 E:1759 ||| NN
mitogen  ||| S:1759 E:1767 ||| FW
activated  ||| S:1767 E:1777 ||| FW
protein  ||| S:1777 E:1785 ||| FW
kinase  ||| S:1785 E:1792 ||| FW
( ||| S:1792 E:1793 ||| -LRB-
MAPK ||| S:1793 E:1797 ||| NNP
)  ||| S:1797 E:1807 ||| -RRB-
phosphorylation  ||| S:1807 E:1823 ||| JJ
sites ||| S:1823 E:1828 ||| NNS
.  ||| S:1828 E:1830 ||| .
Accordingly ||| S:1830 E:1841 ||| RB
,  ||| S:1841 E:1843 ||| ,
the  ||| S:1843 E:1847 ||| DT
TCFs  ||| S:1847 E:1852 ||| NNS
have  ||| S:1852 E:1857 ||| VBP
been  ||| S:1857 E:1870 ||| VBN
found  ||| S:1870 E:1876 ||| VBN
to  ||| S:1876 E:1879 ||| TO
be  ||| S:1879 E:1882 ||| VB
targets  ||| S:1882 E:1890 ||| NNS
of  ||| S:1890 E:1893 ||| IN
the  ||| S:1893 E:1897 ||| DT
Ras-Raf-MAPK  ||| S:1897 E:1910 ||| JJ
signal  ||| S:1910 E:1917 ||| NN
transduction  ||| S:1917 E:1938 ||| NN
pathway  ||| S:1938 E:1946 ||| NNS
[  ||| S:1946 E:1948 ||| -LRB-
16 ||| S:1948 E:1950 ||| CD
] ||| S:1950 E:1951 ||| -RRB-
.  ||| S:1951 E:1953 ||| .
In  ||| S:1953 E:1956 ||| IN
addition ||| S:1956 E:1964 ||| NN
,  ||| S:1964 E:1966 ||| ,
the  ||| S:1966 E:1970 ||| DT
TCFs  ||| S:1970 E:1975 ||| NNS
have  ||| S:1975 E:1980 ||| VBP
been  ||| S:1980 E:1985 ||| VBN
found  ||| S:1985 E:1991 ||| VBN
to  ||| S:1991 E:1994 ||| TO
be  ||| S:1994 E:2005 ||| VB
targets  ||| S:2005 E:2013 ||| NNS
for  ||| S:2013 E:2017 ||| IN
all  ||| S:2017 E:2021 ||| DT
three  ||| S:2021 E:2027 ||| CD
families  ||| S:2027 E:2036 ||| NNS
of  ||| S:2036 E:2039 ||| IN
MAPKs ||| S:2039 E:2044 ||| JJ
:  ||| S:2044 E:2046 ||| :
the  ||| S:2046 E:2050 ||| DT
extracellular  ||| S:2050 E:2072 ||| JJ
signal-regulated  ||| S:2072 E:2089 ||| JJ
kinases  ||| S:2089 E:2097 ||| NN
1 ||| S:2097 E:2098 ||| CD
/ ||| S:2098 E:2099 ||| CD
2  ||| S:2099 E:2101 ||| CD
( ||| S:2101 E:2102 ||| -LRB-
ERK1 ||| S:2102 E:2106 ||| CD
/ ||| S:2106 E:2107 ||| CD
2 ||| S:2107 E:2108 ||| CD
) ||| S:2108 E:2109 ||| -RRB-
,  ||| S:2109 E:2111 ||| ,
the  ||| S:2111 E:2115 ||| DT
jun-N-terminal  ||| S:2115 E:2138 ||| JJ
kinases ||| S:2138 E:2145 ||| FW
/ ||| S:2145 E:2146 ||| FW
stress  ||| S:2146 E:2153 ||| FW
activated  ||| S:2153 E:2163 ||| FW
protein  ||| S:2163 E:2171 ||| FW
kinases  ||| S:2171 E:2179 ||| FW
( ||| S:2179 E:2180 ||| -LRB-
JNK ||| S:2180 E:2183 ||| NNP
/ ||| S:2183 E:2184 ||| NNP
SAPK ||| S:2184 E:2188 ||| NNP
) ||| S:2188 E:2189 ||| -RRB-
,  ||| S:2189 E:2191 ||| ,
and  ||| S:2191 E:2203 ||| CC
the  ||| S:2203 E:2207 ||| DT
p38  ||| S:2207 E:2211 ||| CD
kinase  ||| S:2211 E:2218 ||| NNS
[  ||| S:2218 E:2220 ||| -LRB-
17 ||| S:2220 E:2222 ||| CD
,  ||| S:2222 E:2224 ||| ,
18 ||| S:2224 E:2226 ||| CD
] ||| S:2226 E:2227 ||| -RRB-
.  ||| S:2227 E:2229 ||| .
The  ||| S:2229 E:2233 ||| DT
transcriptional  ||| S:2233 E:2249 ||| JJ
activity  ||| S:2249 E:2258 ||| NN
of  ||| S:2258 E:2269 ||| IN
the  ||| S:2269 E:2273 ||| DT
TCFs  ||| S:2273 E:2278 ||| NNS
are  ||| S:2278 E:2282 ||| VBP
stimulated  ||| S:2282 E:2293 ||| VBN
by  ||| S:2293 E:2296 ||| IN
phosphorylation  ||| S:2296 E:2312 ||| NN
of  ||| S:2312 E:2315 ||| IN
the  ||| S:2315 E:2327 ||| DT
C-terminal  ||| S:2327 E:2338 ||| JJ
MAPK  ||| S:2338 E:2343 ||| NN
sites  ||| S:2343 E:2349 ||| NNS
[  ||| S:2349 E:2351 ||| -LRB-
16 ||| S:2351 E:2353 ||| CD
,  ||| S:2353 E:2355 ||| ,
17 ||| S:2355 E:2357 ||| CD
] ||| S:2357 E:2358 ||| -RRB-
.  ||| S:2358 E:2368 ||| .
Another  ||| S:2368 E:2376 ||| DT
transcription  ||| S:2376 E:2390 ||| JJ
factor  ||| S:2390 E:2397 ||| NN
that  ||| S:2397 E:2402 ||| WDT
is  ||| S:2402 E:2405 ||| VBZ
involved  ||| S:2405 E:2414 ||| VBN
in  ||| S:2414 E:2425 ||| IN
regulation  ||| S:2425 E:2436 ||| NN
of  ||| S:2436 E:2439 ||| IN
the  ||| S:2439 E:2452 ||| DT
c-fos  ||| S:2452 E:2458 ||| JJ
SRE  ||| S:2458 E:2462 ||| NNP
is  ||| S:2462 E:2465 ||| VBZ
CCAAT ||| S:2465 E:2470 ||| NNP
/ ||| S:2470 E:2471 ||| FW
Enhancer  ||| S:2471 E:2480 ||| FW
binding  ||| S:2480 E:2496 ||| FW
protein-beta  ||| S:2496 E:2509 ||| FW
( ||| S:2509 E:2510 ||| -LRB-
C ||| S:2510 E:2511 ||| NNP
/ ||| S:2511 E:2512 ||| NNP
EBPβ ||| S:2512 E:2516 ||| NNP
) ||| S:2516 E:2517 ||| -RRB-
.  ||| S:2517 E:2519 ||| .
C ||| S:2519 E:2520 ||| SYM
/ ||| S:2520 E:2521 ||| FW
EBPβ  ||| S:2521 E:2526 ||| FW
( ||| S:2526 E:2527 ||| -LRB-
also  ||| S:2527 E:2532 ||| RB
known  ||| S:2532 E:2538 ||| VBN
as  ||| S:2538 E:2541 ||| IN
NF-IL6 ||| S:2541 E:2547 ||| NNP
,  ||| S:2547 E:2549 ||| ,
LAP ||| S:2549 E:2552 ||| NNP
,  ||| S:2552 E:2562 ||| ,
NF-M ||| S:2562 E:2566 ||| NNP
,  ||| S:2566 E:2568 ||| ,
AGP ||| S:2568 E:2571 ||| NNP
/ ||| S:2571 E:2572 ||| NNP
EBP ||| S:2572 E:2575 ||| NNP
,  ||| S:2575 E:2577 ||| ,
and  ||| S:2577 E:2581 ||| CC
CRP2 ||| S:2581 E:2585 ||| CD
)  ||| S:2585 E:2587 ||| -RRB-
is  ||| S:2587 E:2590 ||| VBZ
a  ||| S:2590 E:2592 ||| DT
member  ||| S:2592 E:2599 ||| NN
of  ||| S:2599 E:2602 ||| IN
the  ||| S:2602 E:2606 ||| DT
basic-leucine  ||| S:2606 E:2628 ||| JJ
zipper  ||| S:2628 E:2635 ||| JJ
family  ||| S:2635 E:2642 ||| NN
of  ||| S:2642 E:2645 ||| IN
transcription  ||| S:2645 E:2659 ||| JJ
factors  ||| S:2659 E:2667 ||| NNS
[  ||| S:2667 E:2669 ||| -LRB-
19 ||| S:2669 E:2671 ||| CD
,  ||| S:2671 E:2673 ||| ,
20 ||| S:2673 E:2675 ||| CD
] ||| S:2675 E:2676 ||| -RRB-
.  ||| S:2676 E:2678 ||| .
The  ||| S:2678 E:2690 ||| DT
C ||| S:2690 E:2691 ||| NNP
/ ||| S:2691 E:2692 ||| NNP
EBPβ  ||| S:2692 E:2697 ||| NNP
mRNA  ||| S:2697 E:2702 ||| NNP
contains  ||| S:2702 E:2711 ||| VBZ
three  ||| S:2711 E:2717 ||| CD
in-frame  ||| S:2717 E:2726 ||| JJ
methionines  ||| S:2726 E:2738 ||| NN
which  ||| S:2738 E:2744 ||| WDT
give  ||| S:2744 E:2757 ||| VBP
rise  ||| S:2757 E:2762 ||| NN
to  ||| S:2762 E:2765 ||| TO
three  ||| S:2765 E:2771 ||| CD
different  ||| S:2771 E:2781 ||| JJ
translation  ||| S:2781 E:2793 ||| NN
products ||| S:2793 E:2801 ||| NNS
:  ||| S:2801 E:2803 ||| :
p38 ||| S:2803 E:2806 ||| CD
,  ||| S:2806 E:2808 ||| ,
p35 ||| S:2808 E:2811 ||| NNP
,  ||| S:2811 E:2813 ||| ,
and  ||| S:2813 E:2825 ||| CC
p20-C ||| S:2825 E:2830 ||| NNP
/ ||| S:2830 E:2831 ||| NNP
EBPβ  ||| S:2831 E:2836 ||| NNP
[  ||| S:2836 E:2838 ||| -LRB-
21 ||| S:2838 E:2840 ||| CD
] ||| S:2840 E:2841 ||| -RRB-
.  ||| S:2841 E:2843 ||| .
p38  ||| S:2843 E:2847 ||| FW
and  ||| S:2847 E:2851 ||| CC
p35-C ||| S:2851 E:2856 ||| NNP
/ ||| S:2856 E:2857 ||| NNP
EBPβ  ||| S:2857 E:2862 ||| NNP
both  ||| S:2862 E:2867 ||| CC
contain  ||| S:2867 E:2875 ||| VB
an  ||| S:2875 E:2886 ||| DT
N-terminal  ||| S:2886 E:2897 ||| JJ
transactivation  ||| S:2897 E:2913 ||| JJ
domain  ||| S:2913 E:2920 ||| NN
and  ||| S:2920 E:2924 ||| CC
a  ||| S:2924 E:2926 ||| DT
C-terminal  ||| S:2926 E:2937 ||| JJ
DNA  ||| S:2937 E:2949 ||| NNP
binding ||| S:2949 E:2956 ||| FW
/ ||| S:2956 E:2957 ||| FW
dimerization  ||| S:2957 E:2970 ||| FW
domain.  ||| S:2970 E:2978 ||| FW
p20-C ||| S:2978 E:2983 ||| FW
/ ||| S:2983 E:2984 ||| FW
EBPβ  ||| S:2984 E:2989 ||| FW
lacks  ||| S:2989 E:2995 ||| VBZ
the  ||| S:2995 E:3007 ||| DT
N-terminal  ||| S:3007 E:3018 ||| JJ
transactivation  ||| S:3018 E:3034 ||| JJ
domain  ||| S:3034 E:3041 ||| NN
and  ||| S:3041 E:3045 ||| CC
therefore  ||| S:3045 E:3055 ||| RB
acts  ||| S:3055 E:3060 ||| VBZ
as  ||| S:3060 E:3063 ||| IN
a  ||| S:3063 E:3073 ||| DT
repressor  ||| S:3073 E:3083 ||| NN
of  ||| S:3083 E:3086 ||| IN
transcription ||| S:3086 E:3099 ||| NN
.  ||| S:3099 E:3101 ||| .
Our  ||| S:3101 E:3105 ||| PRP$
lab  ||| S:3105 E:3109 ||| NN
has  ||| S:3109 E:3113 ||| VBZ
previously  ||| S:3113 E:3124 ||| RB
shown  ||| S:3124 E:3138 ||| VBN
that  ||| S:3138 E:3143 ||| IN
p35-C ||| S:3143 E:3148 ||| NNP
/ ||| S:3148 E:3149 ||| NNP
EBPβ  ||| S:3149 E:3154 ||| NNP
activates  ||| S:3154 E:3164 ||| VBD
an  ||| S:3164 E:3167 ||| DT
SRE-driven  ||| S:3167 E:3178 ||| JJ
reporter  ||| S:3178 E:3187 ||| NN
construct  ||| S:3187 E:3205 ||| NN
while  ||| S:3205 E:3211 ||| IN
p20-C ||| S:3211 E:3216 ||| CD
/ ||| S:3216 E:3217 ||| CD
EBPβ  ||| S:3217 E:3222 ||| JJ
inhibits  ||| S:3222 E:3231 ||| JJ
serum  ||| S:3231 E:3237 ||| JJ
stimulation  ||| S:3237 E:3249 ||| NN
of  ||| S:3249 E:3252 ||| IN
the  ||| S:3252 E:3256 ||| DT
same  ||| S:3256 E:3269 ||| JJ
reporter  ||| S:3269 E:3278 ||| NN
[  ||| S:3278 E:3280 ||| -LRB-
22 ||| S:3280 E:3282 ||| CD
] ||| S:3282 E:3283 ||| -RRB-
.  ||| S:3283 E:3285 ||| .
We  ||| S:3285 E:3288 ||| PRP
have  ||| S:3288 E:3293 ||| VBP
also  ||| S:3293 E:3298 ||| RB
shown  ||| S:3298 E:3304 ||| VBN
that  ||| S:3304 E:3309 ||| IN
both  ||| S:3309 E:3314 ||| DT
p35-C ||| S:3314 E:3319 ||| NNP
/ ||| S:3319 E:3320 ||| NNP
EBPβ  ||| S:3320 E:3325 ||| NNP
and  ||| S:3325 E:3337 ||| CC
p20-C ||| S:3337 E:3342 ||| NNP
/ ||| S:3342 E:3343 ||| NNP
EBPβ  ||| S:3343 E:3348 ||| NNP
could  ||| S:3348 E:3354 ||| MD
interact  ||| S:3354 E:3363 ||| VB
with  ||| S:3363 E:3368 ||| IN
SRF  ||| S:3368 E:3381 ||| NNP
in  ||| S:3381 E:3384 ||| IN
vivo  ||| S:3384 E:3389 ||| NN
and  ||| S:3389 E:3393 ||| CC
that  ||| S:3393 E:3398 ||| IN
the  ||| S:3398 E:3402 ||| DT
interaction  ||| S:3402 E:3422 ||| NN
between  ||| S:3422 E:3430 ||| IN
SRF  ||| S:3430 E:3434 ||| NNP
and  ||| S:3434 E:3438 ||| CC
p35-C ||| S:3438 E:3443 ||| NNP
/ ||| S:3443 E:3444 ||| NNP
EBPβ ||| S:3444 E:3448 ||| NNP
,  ||| S:3448 E:3450 ||| ,
but  ||| S:3450 E:3454 ||| CC
not  ||| S:3454 E:3458 ||| RB
between  ||| S:3458 E:3466 ||| IN
SRF  ||| S:3466 E:3470 ||| NNP
and  ||| S:3470 E:3482 ||| CC
p20-C ||| S:3482 E:3487 ||| NNP
/ ||| S:3487 E:3488 ||| NNP
EBPβ ||| S:3488 E:3492 ||| NNP
,  ||| S:3492 E:3494 ||| ,
is  ||| S:3494 E:3497 ||| VBZ
stimulated  ||| S:3497 E:3508 ||| VBN
by  ||| S:3508 E:3511 ||| IN
activated  ||| S:3511 E:3521 ||| JJ
Ras ||| S:3521 E:3524 ||| NNP
.  ||| S:3524 E:3526 ||| .
The  ||| S:3526 E:3530 ||| DT
target  ||| S:3530 E:3537 ||| NN
for  ||| S:3537 E:3549 ||| IN
this  ||| S:3549 E:3554 ||| DT
Ras  ||| S:3554 E:3558 ||| JJ
stimulation  ||| S:3558 E:3570 ||| NN
is  ||| S:3570 E:3573 ||| VBZ
Thr235  ||| S:3573 E:3580 ||| CD
in  ||| S:3580 E:3583 ||| IN
a  ||| S:3583 E:3585 ||| DT
consensus  ||| S:3585 E:3595 ||| NN
MAPK  ||| S:3595 E:3600 ||| NNP
site  ||| S:3600 E:3605 ||| NN
in  ||| S:3605 E:3616 ||| IN
C ||| S:3616 E:3617 ||| NNP
/ ||| S:3617 E:3618 ||| NNP
EBPβ  ||| S:3618 E:3623 ||| NNP
[  ||| S:3623 E:3625 ||| -LRB-
23 ||| S:3625 E:3627 ||| CD
] ||| S:3627 E:3628 ||| -RRB-
.  ||| S:3628 E:3630 ||| .
Therefore ||| S:3630 E:3639 ||| RB
,  ||| S:3639 E:3641 ||| ,
C ||| S:3641 E:3642 ||| NNP
/ ||| S:3642 E:3643 ||| NNP
EBPβ  ||| S:3643 E:3648 ||| NNP
is  ||| S:3648 E:3651 ||| VBZ
a  ||| S:3651 E:3653 ||| DT
target  ||| S:3653 E:3660 ||| NN
of  ||| S:3660 E:3663 ||| IN
a  ||| S:3663 E:3673 ||| DT
Ras-dependent  ||| S:3673 E:3687 ||| JJ
signaling  ||| S:3687 E:3697 ||| JJ
pathway  ||| S:3697 E:3705 ||| NN
that  ||| S:3705 E:3710 ||| WDT
regulates  ||| S:3710 E:3720 ||| VBZ
its  ||| S:3720 E:3732 ||| PRP$
interaction  ||| S:3732 E:3744 ||| NN
with  ||| S:3744 E:3749 ||| IN
SRF ||| S:3749 E:3752 ||| NNP
.  ||| S:3752 E:3762 ||| .
Based  ||| S:3762 E:3768 ||| VBN
on  ||| S:3768 E:3771 ||| IN
the  ||| S:3771 E:3775 ||| DT
observations  ||| S:3775 E:3788 ||| NNS
that  ||| S:3788 E:3793 ||| IN
TCF  ||| S:3793 E:3797 ||| NNP
factors  ||| S:3797 E:3805 ||| NNS
as  ||| S:3805 E:3808 ||| IN
well  ||| S:3808 E:3813 ||| RB
as  ||| S:3813 E:3824 ||| IN
p35-C ||| S:3824 E:3829 ||| NNP
/ ||| S:3829 E:3830 ||| NNP
EBPβ ||| S:3830 E:3834 ||| NNP
:  ||| S:3834 E:3836 ||| :
( ||| S:3836 E:3837 ||| -LRB-
1 ||| S:3837 E:3838 ||| LS
)  ||| S:3838 E:3840 ||| -RRB-
interact  ||| S:3840 E:3849 ||| NN
with  ||| S:3849 E:3854 ||| IN
SRF  ||| S:3854 E:3858 ||| NNP
( ||| S:3858 E:3859 ||| -LRB-
2 ||| S:3859 E:3860 ||| LS
)  ||| S:3860 E:3862 ||| -RRB-
transactivate  ||| S:3862 E:3876 ||| VBZ
the  ||| S:3876 E:3880 ||| DT
SRE  ||| S:3880 E:3892 ||| NNP
and  ||| S:3892 E:3896 ||| CC
( ||| S:3896 E:3897 ||| -LRB-
3 ||| S:3897 E:3898 ||| LS
)  ||| S:3898 E:3900 ||| -RRB-
are  ||| S:3900 E:3904 ||| VBP
responsive  ||| S:3904 E:3915 ||| JJ
to  ||| S:3915 E:3918 ||| TO
Ras-dependent  ||| S:3918 E:3932 ||| JJ
signaling  ||| S:3932 E:3942 ||| JJ
pathways ||| S:3942 E:3950 ||| NN
,  ||| S:3950 E:3960 ||| ,
we  ||| S:3960 E:3963 ||| PRP
tested  ||| S:3963 E:3970 ||| VBD
the  ||| S:3970 E:3974 ||| DT
possibility  ||| S:3974 E:3986 ||| NN
that  ||| S:3986 E:3991 ||| IN
both  ||| S:3991 E:3996 ||| DT
TCF  ||| S:3996 E:4000 ||| NNP
and  ||| S:4000 E:4004 ||| CC
p35-C ||| S:4004 E:4009 ||| CD
/ ||| S:4009 E:4010 ||| CD
EBPβ  ||| S:4010 E:4015 ||| NNS
are  ||| S:4015 E:4027 ||| VBP
necessary  ||| S:4027 E:4037 ||| JJ
for  ||| S:4037 E:4041 ||| IN
maximal  ||| S:4041 E:4049 ||| JJ
induction  ||| S:4049 E:4059 ||| NN
of  ||| S:4059 E:4062 ||| IN
the  ||| S:4062 E:4066 ||| DT
SRE  ||| S:4066 E:4070 ||| NNP
in  ||| S:4070 E:4073 ||| IN
response  ||| S:4073 E:4082 ||| NN
to  ||| S:4082 E:4093 ||| TO
mitogenic  ||| S:4093 E:4103 ||| VB
stimulation ||| S:4103 E:4114 ||| NN
.  ||| S:4114 E:4116 ||| .
In  ||| S:4116 E:4119 ||| IN
this  ||| S:4119 E:4124 ||| DT
study ||| S:4124 E:4129 ||| NN
,  ||| S:4129 E:4131 ||| ,
we  ||| S:4131 E:4134 ||| PRP
show  ||| S:4134 E:4139 ||| VBP
that  ||| S:4139 E:4152 ||| IN
p35-C ||| S:4152 E:4157 ||| NNP
/ ||| S:4157 E:4158 ||| NNP
EBPβ  ||| S:4158 E:4163 ||| NNP
and  ||| S:4163 E:4167 ||| CC
the  ||| S:4167 E:4171 ||| DT
TCF  ||| S:4171 E:4175 ||| NNP
family  ||| S:4175 E:4182 ||| NN
member  ||| S:4182 E:4189 ||| NN
Elk-1  ||| S:4189 E:4195 ||| CD
synergize  ||| S:4195 E:4205 ||| NN
in  ||| S:4205 E:4216 ||| IN
transactivation  ||| S:4216 E:4232 ||| NN
of  ||| S:4232 E:4235 ||| IN
SRF  ||| S:4235 E:4239 ||| NNP
dependent  ||| S:4239 E:4249 ||| JJ
transcription  ||| S:4249 E:4263 ||| NN
of  ||| S:4263 E:4266 ||| IN
both  ||| S:4266 E:4271 ||| PDT
a  ||| S:4271 E:4281 ||| DT
Gal4  ||| S:4281 E:4286 ||| JJ
dependent  ||| S:4286 E:4296 ||| JJ
reporter  ||| S:4296 E:4305 ||| NN
and  ||| S:4305 E:4309 ||| CC
an  ||| S:4309 E:4312 ||| DT
SRE-driven  ||| S:4312 E:4323 ||| JJ
reporter  ||| S:4323 E:4340 ||| NN
construct ||| S:4340 E:4349 ||| NN
,  ||| S:4349 E:4351 ||| ,
but  ||| S:4351 E:4355 ||| CC
only  ||| S:4355 E:4360 ||| RB
in  ||| S:4360 E:4363 ||| IN
response  ||| S:4363 E:4372 ||| NN
to  ||| S:4372 E:4375 ||| TO
mitogenic  ||| S:4375 E:4385 ||| VB
stimulation  ||| S:4385 E:4397 ||| VBN
by  ||| S:4397 E:4408 ||| IN
Ras ||| S:4408 E:4411 ||| NNP
.  ||| S:4411 E:4413 ||| .
We  ||| S:4413 E:4416 ||| PRP
further  ||| S:4416 E:4424 ||| RB
show  ||| S:4424 E:4429 ||| VB
that  ||| S:4429 E:4434 ||| IN
Elk-1  ||| S:4434 E:4440 ||| NNP
and  ||| S:4440 E:4444 ||| CC
p35-C ||| S:4444 E:4449 ||| CD
/ ||| S:4449 E:4450 ||| CD
EBPβ  ||| S:4450 E:4455 ||| JJ
interact  ||| S:4455 E:4473 ||| NN
in  ||| S:4473 E:4476 ||| IN
vitro  ||| S:4476 E:4482 ||| NN
in  ||| S:4482 E:4485 ||| IN
a  ||| S:4485 E:4495 ||| DT
glutathione-S-transferase  ||| S:4495 E:4521 ||| JJ
( ||| S:4521 E:4522 ||| -LRB-
GST ||| S:4522 E:4525 ||| NNP
) ||| S:4525 E:4526 ||| -RRB-
-pulldown  ||| S:4526 E:4536 ||| JJ
assay  ||| S:4536 E:4542 ||| NN
as  ||| S:4542 E:4545 ||| IN
well  ||| S:4545 E:4550 ||| RB
as  ||| S:4550 E:4561 ||| RB
in  ||| S:4561 E:4564 ||| IN
an  ||| S:4564 E:4576 ||| DT
in  ||| S:4576 E:4579 ||| FW
vivo  ||| S:4579 E:4584 ||| FW
coimmunoprecipitation  ||| S:4584 E:4606 ||| FW
assay ||| S:4606 E:4611 ||| FW
.  ||| S:4611 E:4621 ||| .
The  ||| S:4621 E:4634 ||| DT
in  ||| S:4634 E:4637 ||| IN
vivo  ||| S:4637 E:4642 ||| JJ
interaction  ||| S:4642 E:4654 ||| NN
is  ||| S:4654 E:4657 ||| VBZ
dependent  ||| S:4657 E:4667 ||| JJ
on  ||| S:4667 E:4678 ||| IN
the  ||| S:4678 E:4682 ||| DT
presence  ||| S:4682 E:4691 ||| NN
of  ||| S:4691 E:4694 ||| IN
activated  ||| S:4694 E:4704 ||| JJ
Ras ||| S:4704 E:4707 ||| NNP
.  ||| S:4707 E:4709 ||| .
Finally ||| S:4709 E:4716 ||| RB
,  ||| S:4716 E:4718 ||| ,
we  ||| S:4718 E:4721 ||| PRP
show  ||| S:4721 E:4726 ||| VBP
that  ||| S:4726 E:4731 ||| IN
the  ||| S:4731 E:4743 ||| DT
C-terminal  ||| S:4743 E:4754 ||| JJ
domain  ||| S:4754 E:4761 ||| NN
of  ||| S:4761 E:4764 ||| IN
C ||| S:4764 E:4765 ||| NNP
/ ||| S:4765 E:4766 ||| NNP
EBPβ  ||| S:4766 E:4771 ||| NNP
is  ||| S:4771 E:4774 ||| VBZ
sufficient  ||| S:4774 E:4785 ||| JJ
to  ||| S:4785 E:4788 ||| TO
interact  ||| S:4788 E:4797 ||| VB
with  ||| S:4797 E:4810 ||| IN
Elk-1  ||| S:4810 E:4816 ||| CD
while  ||| S:4816 E:4822 ||| IN
the  ||| S:4822 E:4826 ||| DT
N-terminal  ||| S:4826 E:4837 ||| JJ
A-box  ||| S:4837 E:4843 ||| NN
of  ||| S:4843 E:4846 ||| IN
Elk-1  ||| S:4846 E:4852 ||| NNP
is  ||| S:4852 E:4855 ||| VBZ
necessary  ||| S:4855 E:4865 ||| JJ
to  ||| S:4865 E:4876 ||| TO
interact  ||| S:4876 E:4885 ||| VB
with  ||| S:4885 E:4890 ||| IN
C ||| S:4890 E:4891 ||| NNP
/ ||| S:4891 E:4892 ||| NNP
EBPβ ||| S:4892 E:4896 ||| NNP
.  ||| S:4896 E:4898 ||| .
These  ||| S:4898 E:4904 ||| DT
results  ||| S:4904 E:4912 ||| NNS
suggest  ||| S:4912 E:4920 ||| VBP
a  ||| S:4920 E:4922 ||| DT
cooperative  ||| S:4922 E:4942 ||| JJ
role  ||| S:4942 E:4947 ||| NN
between  ||| S:4947 E:4955 ||| IN
the  ||| S:4955 E:4959 ||| DT
TCF  ||| S:4959 E:4963 ||| NNP
and  ||| S:4963 E:4967 ||| CC
C ||| S:4967 E:4968 ||| $
/ ||| S:4968 E:4969 ||| CD
EBPβ  ||| S:4969 E:4974 ||| JJ
transcription  ||| S:4974 E:4988 ||| JJ
factors  ||| S:4988 E:4996 ||| NNS
in  ||| S:4996 E:5007 ||| IN
regulation  ||| S:5007 E:5018 ||| NN
of  ||| S:5018 E:5021 ||| IN
the  ||| S:5021 E:5034 ||| DT
c-fos  ||| S:5034 E:5040 ||| JJ
SRE  ||| S:5040 E:5044 ||| NN
in  ||| S:5044 E:5047 ||| IN
response  ||| S:5047 E:5056 ||| NN
to  ||| S:5056 E:5067 ||| TO
Ras-dependent  ||| S:5067 E:5081 ||| JJ
signaling  ||| S:5081 E:5091 ||| JJ
pathways ||| S:5091 E:5099 ||| NN
.  ||| S:5099 E:5123 ||| .
Results  ||| S:5123 E:5150 ||| NNP
Elk-1  ||| S:5150 E:5156 ||| NNP
and  ||| S:5156 E:5160 ||| CC
p35-C ||| S:5160 E:5165 ||| CD
/ ||| S:5165 E:5166 ||| CD
EBPβ  ||| S:5166 E:5171 ||| JJ
synergize  ||| S:5171 E:5181 ||| NN
in  ||| S:5181 E:5184 ||| IN
transactivation  ||| S:5184 E:5210 ||| NN
of  ||| S:5210 E:5213 ||| IN
a  ||| S:5213 E:5215 ||| DT
GAL4  ||| S:5215 E:5220 ||| JJ
dependent  ||| S:5220 E:5230 ||| JJ
reporter  ||| S:5230 E:5249 ||| NN
Due  ||| S:5249 E:5253 ||| JJ
to  ||| S:5253 E:5256 ||| TO
the  ||| S:5256 E:5260 ||| DT
common  ||| S:5260 E:5267 ||| JJ
observations  ||| S:5267 E:5280 ||| NNS
that  ||| S:5280 E:5285 ||| IN
both  ||| S:5285 E:5290 ||| DT
Elk-1  ||| S:5290 E:5296 ||| NNP
and  ||| S:5296 E:5310 ||| CC
p35-C ||| S:5310 E:5315 ||| NNP
/ ||| S:5315 E:5316 ||| NNP
EBPβ  ||| S:5316 E:5321 ||| NNP
transactivate  ||| S:5321 E:5335 ||| VBD
the  ||| S:5335 E:5339 ||| DT
SRE ||| S:5339 E:5342 ||| NNP
,  ||| S:5342 E:5344 ||| ,
interact  ||| S:5344 E:5353 ||| VBG
with  ||| S:5353 E:5358 ||| IN
SRF ||| S:5358 E:5361 ||| NNP
,  ||| S:5361 E:5363 ||| ,
and  ||| S:5363 E:5377 ||| CC
are  ||| S:5377 E:5381 ||| VBP
responsive  ||| S:5381 E:5392 ||| JJ
to  ||| S:5392 E:5395 ||| TO
Ras-dependent  ||| S:5395 E:5409 ||| JJ
signaling  ||| S:5409 E:5419 ||| JJ
pathways ||| S:5419 E:5427 ||| NN
,  ||| S:5427 E:5429 ||| ,
we  ||| S:5429 E:5442 ||| PRP
hypothesized  ||| S:5442 E:5455 ||| VBD
that  ||| S:5455 E:5460 ||| IN
Elk-1  ||| S:5460 E:5466 ||| NNP
and  ||| S:5466 E:5470 ||| CC
p35-C ||| S:5470 E:5475 ||| NNP
/ ||| S:5475 E:5476 ||| NNP
EBPβ  ||| S:5476 E:5481 ||| NNP
may  ||| S:5481 E:5485 ||| MD
both  ||| S:5485 E:5490 ||| RB
be  ||| S:5490 E:5503 ||| VB
necessary  ||| S:5503 E:5513 ||| JJ
for  ||| S:5513 E:5517 ||| IN
maximal  ||| S:5517 E:5525 ||| JJ
induction  ||| S:5525 E:5535 ||| NN
of  ||| S:5535 E:5538 ||| IN
SRF  ||| S:5538 E:5542 ||| NNP
dependent  ||| S:5542 E:5562 ||| JJ
transcription ||| S:5562 E:5575 ||| NN
.  ||| S:5575 E:5577 ||| .
To  ||| S:5577 E:5580 ||| TO
begin  ||| S:5580 E:5586 ||| VB
to  ||| S:5586 E:5589 ||| TO
test  ||| S:5589 E:5594 ||| VB
this  ||| S:5594 E:5599 ||| DT
hypothesis ||| S:5599 E:5609 ||| NN
,  ||| S:5609 E:5611 ||| ,
we  ||| S:5611 E:5614 ||| PRP
used  ||| S:5614 E:5629 ||| VBD
a  ||| S:5629 E:5631 ||| DT
GAL4  ||| S:5631 E:5636 ||| JJ
dependent  ||| S:5636 E:5646 ||| JJ
reporter  ||| S:5646 E:5655 ||| NN
construct ||| S:5655 E:5664 ||| NN
,  ||| S:5664 E:5666 ||| ,
in  ||| S:5666 E:5669 ||| IN
which  ||| S:5669 E:5675 ||| WDT
a  ||| S:5675 E:5677 ||| DT
CAT  ||| S:5677 E:5691 ||| NNP
reporter  ||| S:5691 E:5700 ||| NN
gene  ||| S:5700 E:5705 ||| NN
is  ||| S:5705 E:5708 ||| VBZ
driven  ||| S:5708 E:5715 ||| VBN
by  ||| S:5715 E:5718 ||| IN
five  ||| S:5718 E:5723 ||| CD
copies  ||| S:5723 E:5730 ||| NNS
of  ||| S:5730 E:5733 ||| IN
a  ||| S:5733 E:5735 ||| DT
GAL4  ||| S:5735 E:5740 ||| JJ
binding  ||| S:5740 E:5758 ||| JJ
site  ||| S:5758 E:5763 ||| NN
upstream  ||| S:5763 E:5772 ||| NN
of  ||| S:5772 E:5775 ||| IN
the  ||| S:5775 E:5779 ||| DT
adenovirus  ||| S:5779 E:5790 ||| FW
E1B  ||| S:5790 E:5794 ||| FW
minimal  ||| S:5794 E:5802 ||| FW
promoter  ||| S:5802 E:5821 ||| FW
( ||| S:5821 E:5822 ||| -LRB-
pG5CAT ||| S:5822 E:5828 ||| NNP
) ||| S:5828 E:5829 ||| -RRB-
.  ||| S:5829 E:5831 ||| .
We  ||| S:5831 E:5834 ||| PRP
constructed  ||| S:5834 E:5846 ||| VBD
a  ||| S:5846 E:5848 ||| DT
GAL4  ||| S:5848 E:5853 ||| NNP
DNA  ||| S:5853 E:5857 ||| NNP
binding  ||| S:5857 E:5865 ||| JJ
domain-SRF  ||| S:5865 E:5886 ||| JJ
fusion  ||| S:5886 E:5893 ||| NN
protein ||| S:5893 E:5900 ||| NN
,  ||| S:5900 E:5902 ||| ,
as  ||| S:5902 E:5905 ||| RB
has  ||| S:5905 E:5909 ||| VBZ
been  ||| S:5909 E:5914 ||| VBN
described  ||| S:5914 E:5924 ||| VBN
previously  ||| S:5924 E:5935 ||| RB
[  ||| S:5935 E:5937 ||| -LRB-
23 ||| S:5937 E:5939 ||| CD
] ||| S:5939 E:5940 ||| -RRB-
.  ||| S:5940 E:5952 ||| .
GAL4-SRF  ||| S:5952 E:5961 ||| NNP
binds  ||| S:5961 E:5967 ||| VBD
to  ||| S:5967 E:5970 ||| TO
the  ||| S:5970 E:5974 ||| DT
GAL4  ||| S:5974 E:5979 ||| JJ
reporter  ||| S:5979 E:5988 ||| NN
construct ||| S:5988 E:5997 ||| NN
,  ||| S:5997 E:5999 ||| ,
thereby  ||| S:5999 E:6017 ||| RB
making  ||| S:6017 E:6024 ||| VBG
transcription  ||| S:6024 E:6038 ||| NN
of  ||| S:6038 E:6041 ||| IN
the  ||| S:6041 E:6045 ||| DT
reporter  ||| S:6045 E:6054 ||| NN
gene  ||| S:6054 E:6059 ||| NN
dependent  ||| S:6059 E:6069 ||| NN
on  ||| S:6069 E:6082 ||| IN
the  ||| S:6082 E:6086 ||| DT
presence  ||| S:6086 E:6095 ||| NN
of  ||| S:6095 E:6098 ||| IN
SRF ||| S:6098 E:6101 ||| NNP
.  ||| S:6101 E:6103 ||| .
As  ||| S:6103 E:6106 ||| RB
shown  ||| S:6106 E:6112 ||| VBN
in  ||| S:6112 E:6115 ||| IN
Fig.  ||| S:6115 E:6120 ||| CD
1 ||| S:6120 E:6121 ||| CD
,  ||| S:6121 E:6123 ||| ,
when  ||| S:6123 E:6128 ||| WRB
a  ||| S:6128 E:6130 ||| DT
GAL4-SRF  ||| S:6130 E:6149 ||| JJ
fusion  ||| S:6149 E:6156 ||| NN
construct  ||| S:6156 E:6166 ||| NN
is  ||| S:6166 E:6169 ||| VBZ
transfected  ||| S:6169 E:6181 ||| VBN
with  ||| S:6181 E:6186 ||| IN
the  ||| S:6186 E:6190 ||| DT
reporter ||| S:6190 E:6198 ||| NN
,  ||| S:6198 E:6200 ||| ,
there  ||| S:6200 E:6216 ||| EX
is  ||| S:6216 E:6219 ||| VBZ
no  ||| S:6219 E:6222 ||| DT
increase  ||| S:6222 E:6231 ||| NN
in  ||| S:6231 E:6234 ||| IN
CAT  ||| S:6234 E:6238 ||| NNP
activity ||| S:6238 E:6246 ||| NN
.  ||| S:6246 E:6248 ||| .
The  ||| S:6248 E:6252 ||| DT
SRF  ||| S:6252 E:6256 ||| NNP
transactivation  ||| S:6256 E:6282 ||| JJ
domain  ||| S:6282 E:6289 ||| NN
is  ||| S:6289 E:6292 ||| VBZ
weak ||| S:6292 E:6296 ||| JJ
,  ||| S:6296 E:6298 ||| ,
as  ||| S:6298 E:6301 ||| RB
has  ||| S:6301 E:6305 ||| VBZ
been  ||| S:6305 E:6310 ||| VBN
shown  ||| S:6310 E:6316 ||| VBN
previously  ||| S:6316 E:6327 ||| RB
[  ||| S:6327 E:6329 ||| -LRB-
24 ||| S:6329 E:6331 ||| CD
] ||| S:6331 E:6332 ||| -RRB-
.  ||| S:6332 E:6334 ||| .
When  ||| S:6334 E:6349 ||| WRB
CMV-Elk-1  ||| S:6349 E:6359 ||| NNP
is  ||| S:6359 E:6362 ||| VBZ
cotransfected  ||| S:6362 E:6376 ||| VBN
with  ||| S:6376 E:6381 ||| IN
the  ||| S:6381 E:6385 ||| DT
reporter  ||| S:6385 E:6394 ||| NN
and  ||| S:6394 E:6408 ||| CC
GAL4-SRF ||| S:6408 E:6416 ||| NNP
,  ||| S:6416 E:6418 ||| ,
there  ||| S:6418 E:6424 ||| EX
is  ||| S:6424 E:6427 ||| VBZ
little  ||| S:6427 E:6434 ||| JJ
increase  ||| S:6434 E:6443 ||| NN
in  ||| S:6443 E:6446 ||| IN
CAT  ||| S:6446 E:6450 ||| NNP
activity  ||| S:6450 E:6459 ||| NN
in  ||| S:6459 E:6462 ||| IN
the  ||| S:6462 E:6476 ||| DT
absence  ||| S:6476 E:6484 ||| NN
of  ||| S:6484 E:6487 ||| IN
activated  ||| S:6487 E:6497 ||| JJ
Ras  ||| S:6497 E:6501 ||| NNP
( ||| S:6501 E:6502 ||| -LRB-
CMV-Ras.V12 ||| S:6502 E:6513 ||| NNP
) ||| S:6513 E:6514 ||| -RRB-
.  ||| S:6514 E:6516 ||| .
This  ||| S:6516 E:6521 ||| DT
result  ||| S:6521 E:6528 ||| NN
is  ||| S:6528 E:6541 ||| VBZ
expected  ||| S:6541 E:6550 ||| VBN
since  ||| S:6550 E:6556 ||| IN
the  ||| S:6556 E:6560 ||| DT
transactivation  ||| S:6560 E:6576 ||| JJ
domain  ||| S:6576 E:6583 ||| NN
of  ||| S:6583 E:6586 ||| IN
Elk-1  ||| S:6586 E:6592 ||| NNP
is  ||| S:6592 E:6605 ||| VBZ
activated  ||| S:6605 E:6615 ||| VBN
in  ||| S:6615 E:6618 ||| IN
response  ||| S:6618 E:6627 ||| NN
to  ||| S:6627 E:6630 ||| TO
Ras ||| S:6630 E:6633 ||| NNP
.  ||| S:6633 E:6635 ||| .
Therefore ||| S:6635 E:6644 ||| RB
,  ||| S:6644 E:6646 ||| ,
when  ||| S:6646 E:6651 ||| WRB
activated  ||| S:6651 E:6671 ||| JJ
Ras  ||| S:6671 E:6675 ||| NNP
is  ||| S:6675 E:6678 ||| VBZ
transfected  ||| S:6678 E:6690 ||| VBN
with  ||| S:6690 E:6695 ||| IN
Elk-1 ||| S:6695 E:6700 ||| NNP
,  ||| S:6700 E:6702 ||| ,
GAL4-SRF ||| S:6702 E:6710 ||| NNP
,  ||| S:6710 E:6712 ||| ,
and  ||| S:6712 E:6716 ||| CC
the  ||| S:6716 E:6730 ||| DT
reporter ||| S:6730 E:6738 ||| NN
,  ||| S:6738 E:6740 ||| ,
the  ||| S:6740 E:6744 ||| DT
CAT  ||| S:6744 E:6748 ||| NNP
activity  ||| S:6748 E:6757 ||| NN
increases  ||| S:6757 E:6767 ||| NNS
to  ||| S:6767 E:6770 ||| TO
8-fold  ||| S:6770 E:6777 ||| CD
over  ||| S:6777 E:6782 ||| IN
basal  ||| S:6782 E:6798 ||| JJ
levels ||| S:6798 E:6804 ||| NNS
.  ||| S:6804 E:6806 ||| .
We  ||| S:6806 E:6809 ||| PRP
cannot  ||| S:6809 E:6816 ||| RB
determine  ||| S:6816 E:6826 ||| VB
if  ||| S:6826 E:6829 ||| IN
the  ||| S:6829 E:6833 ||| DT
increase  ||| S:6833 E:6842 ||| NN
in  ||| S:6842 E:6845 ||| IN
CAT  ||| S:6845 E:6859 ||| NNP
activity  ||| S:6859 E:6868 ||| NN
in  ||| S:6868 E:6871 ||| IN
the  ||| S:6871 E:6875 ||| DT
presence  ||| S:6875 E:6884 ||| NN
of  ||| S:6884 E:6887 ||| IN
Ras  ||| S:6887 E:6891 ||| NNP
also  ||| S:6891 E:6896 ||| RB
reflects  ||| S:6896 E:6905 ||| VBZ
a  ||| S:6905 E:6917 ||| DT
stimulation  ||| S:6917 E:6929 ||| NN
of  ||| S:6929 E:6932 ||| IN
the  ||| S:6932 E:6936 ||| DT
interaction  ||| S:6936 E:6948 ||| NN
of  ||| S:6948 E:6951 ||| IN
the  ||| S:6951 E:6955 ||| DT
Elk-1  ||| S:6955 E:6961 ||| NNP
and  ||| S:6961 E:6965 ||| CC
SRF  ||| S:6965 E:6979 ||| NNP
proteins ||| S:6979 E:6987 ||| NNS
.  ||| S:6987 E:6999 ||| .
When  ||| S:6999 E:7004 ||| WRB
CMV-LAP  ||| S:7004 E:7012 ||| JJ
( ||| S:7012 E:7013 ||| -LRB-
which  ||| S:7013 E:7019 ||| WDT
encodes  ||| S:7019 E:7027 ||| VBZ
p35-C ||| S:7027 E:7032 ||| NNP
/ ||| S:7032 E:7033 ||| NNP
EBPβ ||| S:7033 E:7037 ||| NNP
)  ||| S:7037 E:7039 ||| -RRB-
is  ||| S:7039 E:7042 ||| VBZ
transfected  ||| S:7042 E:7064 ||| VBN
with  ||| S:7064 E:7069 ||| IN
GAL4-SRF  ||| S:7069 E:7078 ||| NNP
and  ||| S:7078 E:7082 ||| CC
the  ||| S:7082 E:7086 ||| DT
reporter  ||| S:7086 E:7095 ||| NN
construct ||| S:7095 E:7104 ||| NN
,  ||| S:7104 E:7106 ||| ,
we  ||| S:7106 E:7109 ||| PRP
see  ||| S:7109 E:7113 ||| VBP
a  ||| S:7113 E:7115 ||| DT
7-fold  ||| S:7115 E:7132 ||| JJ
increase  ||| S:7132 E:7141 ||| NN
in  ||| S:7141 E:7144 ||| IN
CAT  ||| S:7144 E:7148 ||| NNP
activity  ||| S:7148 E:7157 ||| NN
that  ||| S:7157 E:7162 ||| WDT
is  ||| S:7162 E:7165 ||| VBZ
potentiated  ||| S:7165 E:7177 ||| VBN
to  ||| S:7177 E:7180 ||| TO
75-fold  ||| S:7180 E:7198 ||| CD
when  ||| S:7198 E:7203 ||| WRB
activated  ||| S:7203 E:7213 ||| JJ
Ras  ||| S:7213 E:7217 ||| NNP
is  ||| S:7217 E:7220 ||| VBZ
cotransfected ||| S:7220 E:7233 ||| VBN
.  ||| S:7233 E:7235 ||| .
Therefore ||| S:7235 E:7244 ||| RB
,  ||| S:7244 E:7246 ||| ,
C ||| S:7246 E:7247 ||| NNP
/ ||| S:7247 E:7248 ||| NNP
EBPβ  ||| S:7248 E:7263 ||| JJ
results  ||| S:7263 E:7271 ||| NNS
in  ||| S:7271 E:7274 ||| IN
a  ||| S:7274 E:7276 ||| DT
much  ||| S:7276 E:7281 ||| RB
larger  ||| S:7281 E:7288 ||| JJR
increase  ||| S:7288 E:7297 ||| NN
in  ||| S:7297 E:7300 ||| IN
transcription  ||| S:7300 E:7314 ||| NN
than  ||| S:7314 E:7329 ||| IN
Elk-1 ||| S:7329 E:7334 ||| CD
.  ||| S:7334 E:7336 ||| .
We  ||| S:7336 E:7339 ||| PRP
have  ||| S:7339 E:7344 ||| VBP
previously  ||| S:7344 E:7355 ||| RB
shown  ||| S:7355 E:7361 ||| VBN
that  ||| S:7361 E:7366 ||| IN
Ras  ||| S:7366 E:7370 ||| NNP
does  ||| S:7370 E:7375 ||| VBZ
not  ||| S:7375 E:7389 ||| RB
activate  ||| S:7389 E:7398 ||| VBP
the  ||| S:7398 E:7402 ||| DT
transactivation  ||| S:7402 E:7418 ||| JJ
domain  ||| S:7418 E:7425 ||| NN
of  ||| S:7425 E:7428 ||| IN
p35-C ||| S:7428 E:7433 ||| NNP
/ ||| S:7433 E:7434 ||| NNP
EBPβ  ||| S:7434 E:7439 ||| NNP
[  ||| S:7439 E:7441 ||| -LRB-
23 ||| S:7441 E:7443 ||| CD
] ||| S:7443 E:7444 ||| -RRB-
.  ||| S:7444 E:7456 ||| .
Thus ||| S:7456 E:7460 ||| RB
,  ||| S:7460 E:7462 ||| ,
the  ||| S:7462 E:7466 ||| DT
increase  ||| S:7466 E:7475 ||| NN
in  ||| S:7475 E:7478 ||| IN
transcription  ||| S:7478 E:7492 ||| NN
in  ||| S:7492 E:7495 ||| IN
this  ||| S:7495 E:7500 ||| DT
assay  ||| S:7500 E:7506 ||| NN
is  ||| S:7506 E:7509 ||| VBZ
due  ||| S:7509 E:7523 ||| JJ
to  ||| S:7523 E:7526 ||| TO
Ras  ||| S:7526 E:7530 ||| NNP
stimulation  ||| S:7530 E:7542 ||| NN
of  ||| S:7542 E:7545 ||| IN
the  ||| S:7545 E:7549 ||| DT
SRF-p35-C ||| S:7549 E:7558 ||| CD
/ ||| S:7558 E:7559 ||| CD
EBPβ  ||| S:7559 E:7564 ||| JJ
interaction ||| S:7564 E:7575 ||| NN
.  ||| S:7575 E:7587 ||| .
Interestingly ||| S:7587 E:7600 ||| RB
,  ||| S:7600 E:7602 ||| ,
when  ||| S:7602 E:7607 ||| WRB
all  ||| S:7607 E:7611 ||| DT
three  ||| S:7611 E:7617 ||| CD
constructs  ||| S:7617 E:7628 ||| NNS
-  ||| S:7628 E:7630 ||| :
SRF ||| S:7630 E:7633 ||| NNP
,  ||| S:7633 E:7635 ||| ,
Elk-1 ||| S:7635 E:7640 ||| NNP
,  ||| S:7640 E:7652 ||| ,
and  ||| S:7652 E:7656 ||| CC
p35-C ||| S:7656 E:7661 ||| CD
/ ||| S:7661 E:7662 ||| CD
EBPβ-are  ||| S:7662 E:7671 ||| JJ
cotransfected  ||| S:7671 E:7685 ||| NN
with  ||| S:7685 E:7690 ||| IN
the  ||| S:7690 E:7694 ||| DT
reporter  ||| S:7694 E:7713 ||| NN
construct ||| S:7713 E:7722 ||| NN
,  ||| S:7722 E:7724 ||| ,
there  ||| S:7724 E:7730 ||| EX
is  ||| S:7730 E:7733 ||| VBZ
an  ||| S:7733 E:7736 ||| DT
average  ||| S:7736 E:7744 ||| JJ
260-fold  ||| S:7744 E:7753 ||| CD
increase  ||| S:7753 E:7762 ||| NN
in  ||| S:7762 E:7765 ||| IN
CAT  ||| S:7765 E:7779 ||| NNP
activity  ||| S:7779 E:7788 ||| NN
in  ||| S:7788 E:7791 ||| IN
the  ||| S:7791 E:7795 ||| DT
presence  ||| S:7795 E:7804 ||| NN
of  ||| S:7804 E:7807 ||| IN
activated  ||| S:7807 E:7817 ||| JJ
Ras ||| S:7817 E:7820 ||| NNP
.  ||| S:7820 E:7822 ||| .
The  ||| S:7822 E:7826 ||| DT
values  ||| S:7826 E:7833 ||| NNS
of  ||| S:7833 E:7846 ||| IN
fold  ||| S:7846 E:7851 ||| NNS
activation  ||| S:7851 E:7862 ||| VBP
varied  ||| S:7862 E:7869 ||| VBN
from  ||| S:7869 E:7874 ||| IN
as  ||| S:7874 E:7877 ||| IN
low  ||| S:7877 E:7881 ||| JJ
as  ||| S:7881 E:7884 ||| IN
60-fold  ||| S:7884 E:7892 ||| CD
to  ||| S:7892 E:7895 ||| TO
as  ||| S:7895 E:7898 ||| RB
high  ||| S:7898 E:7913 ||| JJ
as  ||| S:7913 E:7916 ||| IN
725-fold  ||| S:7916 E:7925 ||| CD
over  ||| S:7925 E:7930 ||| IN
basal  ||| S:7930 E:7936 ||| JJ
levels ||| S:7936 E:7942 ||| NNS
,  ||| S:7942 E:7944 ||| ,
and  ||| S:7944 E:7948 ||| CC
we  ||| S:7948 E:7951 ||| PRP
are  ||| S:7951 E:7955 ||| VBP
unsure  ||| S:7955 E:7962 ||| VBN
of  ||| S:7962 E:7965 ||| IN
the  ||| S:7965 E:7979 ||| DT
reason  ||| S:7979 E:7986 ||| NN
for  ||| S:7986 E:7990 ||| IN
this  ||| S:7990 E:7995 ||| DT
variability ||| S:7995 E:8006 ||| NN
.  ||| S:8006 E:8008 ||| .
However ||| S:8008 E:8015 ||| RB
,  ||| S:8015 E:8017 ||| ,
regardless  ||| S:8017 E:8028 ||| RB
of  ||| S:8028 E:8031 ||| IN
the  ||| S:8031 E:8045 ||| DT
extent  ||| S:8045 E:8052 ||| NN
of  ||| S:8052 E:8055 ||| IN
activation ||| S:8055 E:8065 ||| NN
,  ||| S:8065 E:8067 ||| ,
in  ||| S:8067 E:8070 ||| IN
every  ||| S:8070 E:8076 ||| DT
experiment  ||| S:8076 E:8087 ||| NN
there  ||| S:8087 E:8093 ||| EX
was  ||| S:8093 E:8097 ||| VBD
a  ||| S:8097 E:8109 ||| DT
synergy  ||| S:8109 E:8117 ||| NN
observed  ||| S:8117 E:8126 ||| VBD
when  ||| S:8126 E:8131 ||| WRB
both  ||| S:8131 E:8136 ||| DT
Elk-1  ||| S:8136 E:8142 ||| NNP
and  ||| S:8142 E:8146 ||| CC
p35-C ||| S:8146 E:8151 ||| CD
/ ||| S:8151 E:8152 ||| CD
EBPβ  ||| S:8152 E:8157 ||| NNS
are  ||| S:8157 E:8171 ||| VBP
transfected  ||| S:8171 E:8183 ||| VBN
in  ||| S:8183 E:8186 ||| IN
the  ||| S:8186 E:8190 ||| DT
presence  ||| S:8190 E:8199 ||| NN
of  ||| S:8199 E:8202 ||| IN
Ras ||| S:8202 E:8205 ||| NNP
.  ||| S:8205 E:8207 ||| .
There  ||| S:8207 E:8213 ||| EX
is  ||| S:8213 E:8216 ||| VBZ
only  ||| S:8216 E:8221 ||| RB
a  ||| S:8221 E:8233 ||| DT
slight  ||| S:8233 E:8240 ||| JJ
increase  ||| S:8240 E:8249 ||| NN
in  ||| S:8249 E:8252 ||| IN
CAT  ||| S:8252 E:8256 ||| NNP
activity  ||| S:8256 E:8265 ||| NN
in  ||| S:8265 E:8268 ||| IN
the  ||| S:8268 E:8272 ||| DT
absence  ||| S:8272 E:8280 ||| NN
of  ||| S:8280 E:8283 ||| IN
Ras ||| S:8283 E:8286 ||| NNP
.  ||| S:8286 E:8298 ||| .
Therefore ||| S:8298 E:8307 ||| RB
,  ||| S:8307 E:8309 ||| ,
Elk-1  ||| S:8309 E:8315 ||| NNP
and  ||| S:8315 E:8319 ||| CC
p35-C ||| S:8319 E:8324 ||| CD
/ ||| S:8324 E:8325 ||| CD
EBPβ  ||| S:8325 E:8330 ||| NNS
are  ||| S:8330 E:8334 ||| VBP
working  ||| S:8334 E:8352 ||| VBG
synergistically  ||| S:8352 E:8368 ||| NN
to  ||| S:8368 E:8371 ||| TO
transactivate  ||| S:8371 E:8385 ||| VB
the  ||| S:8385 E:8389 ||| DT
reporter  ||| S:8389 E:8398 ||| NN
construct  ||| S:8398 E:8418 ||| NN
in  ||| S:8418 E:8421 ||| IN
the  ||| S:8421 E:8425 ||| DT
presence  ||| S:8425 E:8434 ||| NN
of  ||| S:8434 E:8437 ||| IN
SRF ||| S:8437 E:8440 ||| NNP
.  ||| S:8440 E:8442 ||| .
This  ||| S:8442 E:8447 ||| DT
synergism  ||| S:8447 E:8457 ||| NN
is  ||| S:8457 E:8460 ||| VBZ
only  ||| S:8460 E:8465 ||| RB
observed  ||| S:8465 E:8484 ||| VBN
in  ||| S:8484 E:8487 ||| IN
response  ||| S:8487 E:8496 ||| NN
to  ||| S:8496 E:8499 ||| TO
activation  ||| S:8499 E:8510 ||| VB
of  ||| S:8510 E:8513 ||| IN
mitogenic  ||| S:8513 E:8523 ||| JJ
signaling  ||| S:8523 E:8533 ||| JJ
pathways  ||| S:8533 E:8552 ||| NN
by  ||| S:8552 E:8555 ||| IN
Ras ||| S:8555 E:8558 ||| NNP
.  ||| S:8558 E:8588 ||| .
Elk-1  ||| S:8588 E:8594 ||| NNP
and  ||| S:8594 E:8598 ||| CC
p35-C ||| S:8598 E:8603 ||| CD
/ ||| S:8603 E:8604 ||| CD
EBPβ  ||| S:8604 E:8609 ||| JJ
synergize  ||| S:8609 E:8619 ||| NN
in  ||| S:8619 E:8622 ||| IN
transactivation  ||| S:8622 E:8648 ||| NN
of  ||| S:8648 E:8651 ||| IN
the  ||| S:8651 E:8655 ||| DT
SRE  ||| S:8655 E:8669 ||| NNP
Since  ||| S:8669 E:8675 ||| IN
Elk-1  ||| S:8675 E:8681 ||| NNP
and  ||| S:8681 E:8685 ||| CC
p35-C ||| S:8685 E:8690 ||| CD
/ ||| S:8690 E:8691 ||| CD
EBPβ  ||| S:8691 E:8696 ||| JJ
synergize  ||| S:8696 E:8706 ||| NN
in  ||| S:8706 E:8719 ||| IN
transactivation  ||| S:8719 E:8735 ||| NN
of  ||| S:8735 E:8738 ||| IN
SRF-dependent  ||| S:8738 E:8752 ||| JJ
transcription  ||| S:8752 E:8766 ||| NNS
using  ||| S:8766 E:8772 ||| VBG
a  ||| S:8772 E:8784 ||| DT
GAL4-dependent  ||| S:8784 E:8799 ||| JJ
promoter ||| S:8799 E:8807 ||| NN
,  ||| S:8807 E:8809 ||| ,
we  ||| S:8809 E:8812 ||| PRP
next  ||| S:8812 E:8817 ||| RB
tested  ||| S:8817 E:8824 ||| VBN
if  ||| S:8824 E:8827 ||| IN
Elk-1  ||| S:8827 E:8833 ||| NNP
and  ||| S:8833 E:8847 ||| CC
p35-C ||| S:8847 E:8852 ||| NNP
/ ||| S:8852 E:8853 ||| NNP
EBPβ  ||| S:8853 E:8858 ||| NNP
could  ||| S:8858 E:8864 ||| MD
also  ||| S:8864 E:8869 ||| RB
synergize  ||| S:8869 E:8879 ||| VBN
in  ||| S:8879 E:8882 ||| IN
transactivation  ||| S:8882 E:8898 ||| NN
of  ||| S:8898 E:8901 ||| IN
a  ||| S:8901 E:8913 ||| DT
native  ||| S:8913 E:8920 ||| JJ
SRF  ||| S:8920 E:8924 ||| NNP
binding  ||| S:8924 E:8932 ||| JJ
site ||| S:8932 E:8936 ||| NN
,  ||| S:8936 E:8938 ||| ,
namely  ||| S:8938 E:8945 ||| RB
the  ||| S:8945 E:8960 ||| DT
c-fos  ||| S:8960 E:8966 ||| JJ
SRE ||| S:8966 E:8969 ||| NNP
.  ||| S:8969 E:8971 ||| .
To  ||| S:8971 E:8974 ||| TO
test  ||| S:8974 E:8979 ||| VB
this  ||| S:8979 E:8994 ||| DT
possibility ||| S:8994 E:9005 ||| NN
,  ||| S:9005 E:9007 ||| ,
NIH  ||| S:9007 E:9011 ||| NNP
3T3  ||| S:9011 E:9015 ||| NNP
cells  ||| S:9015 E:9021 ||| NNS
were  ||| S:9021 E:9026 ||| VBD
transiently  ||| S:9026 E:9038 ||| JJ
transfected  ||| S:9038 E:9060 ||| NN
with  ||| S:9060 E:9065 ||| IN
a  ||| S:9065 E:9067 ||| DT
CAT  ||| S:9067 E:9071 ||| NNP
reporter  ||| S:9071 E:9080 ||| NN
gene  ||| S:9080 E:9085 ||| NN
driven  ||| S:9085 E:9092 ||| VBN
by  ||| S:9092 E:9095 ||| IN
one  ||| S:9095 E:9099 ||| CD
copy  ||| S:9099 E:9104 ||| NN
of  ||| S:9104 E:9107 ||| IN
the  ||| S:9107 E:9111 ||| DT
wild  ||| S:9111 E:9126 ||| JJ
type  ||| S:9126 E:9131 ||| NN
SRE  ||| S:9131 E:9135 ||| NNP
upstream  ||| S:9135 E:9144 ||| NN
of  ||| S:9144 E:9147 ||| IN
the  ||| S:9147 E:9151 ||| DT
Rous  ||| S:9151 E:9156 ||| JJ
sarcoma  ||| S:9156 E:9164 ||| JJ
virus  ||| S:9164 E:9170 ||| NN
long  ||| S:9170 E:9175 ||| JJ
terminal  ||| S:9175 E:9194 ||| NN
repeat  ||| S:9194 E:9201 ||| NN
minimal  ||| S:9201 E:9209 ||| JJ
promoter ||| S:9209 E:9217 ||| NN
.  ||| S:9217 E:9219 ||| .
As  ||| S:9219 E:9222 ||| RB
shown  ||| S:9222 E:9228 ||| VBN
in  ||| S:9228 E:9231 ||| IN
Fig.  ||| S:9231 E:9236 ||| CD
2 ||| S:9236 E:9237 ||| CD
,  ||| S:9237 E:9239 ||| ,
when  ||| S:9239 E:9254 ||| WRB
p35-C ||| S:9254 E:9259 ||| NNP
/ ||| S:9259 E:9260 ||| NNP
EBPβ  ||| S:9260 E:9265 ||| NNP
is  ||| S:9265 E:9268 ||| VBZ
co-transfected  ||| S:9268 E:9283 ||| JJ
with  ||| S:9283 E:9288 ||| IN
the  ||| S:9288 E:9292 ||| DT
reporter  ||| S:9292 E:9301 ||| NN
construct ||| S:9301 E:9310 ||| NN
,  ||| S:9310 E:9322 ||| ,
there  ||| S:9322 E:9328 ||| EX
is  ||| S:9328 E:9331 ||| VBZ
a  ||| S:9331 E:9333 ||| DT
13-fold  ||| S:9333 E:9341 ||| JJ
increase  ||| S:9341 E:9350 ||| NN
in  ||| S:9350 E:9353 ||| IN
CAT  ||| S:9353 E:9357 ||| NNP
activity  ||| S:9357 E:9366 ||| NN
in  ||| S:9366 E:9369 ||| IN
the  ||| S:9369 E:9383 ||| DT
absence  ||| S:9383 E:9391 ||| NN
of  ||| S:9391 E:9394 ||| IN
activated  ||| S:9394 E:9404 ||| JJ
Ras  ||| S:9404 E:9408 ||| NNS
that  ||| S:9408 E:9413 ||| WDT
is  ||| S:9413 E:9416 ||| VBZ
increased  ||| S:9416 E:9426 ||| VBN
to  ||| S:9426 E:9429 ||| TO
24-fold  ||| S:9429 E:9447 ||| CD
when  ||| S:9447 E:9452 ||| WRB
CMV-Ras.V12  ||| S:9452 E:9464 ||| NNP
is  ||| S:9464 E:9467 ||| VBZ
co-transfected ||| S:9467 E:9481 ||| JJ
.  ||| S:9481 E:9493 ||| .
When  ||| S:9493 E:9498 ||| WRB
CMV-Elk-1  ||| S:9498 E:9508 ||| NNP
is  ||| S:9508 E:9511 ||| VBZ
co-transfected  ||| S:9511 E:9526 ||| JJ
with  ||| S:9526 E:9531 ||| IN
the  ||| S:9531 E:9535 ||| DT
SRE  ||| S:9535 E:9539 ||| NNP
reporter  ||| S:9539 E:9558 ||| NN
construct ||| S:9558 E:9567 ||| NN
,  ||| S:9567 E:9569 ||| ,
there  ||| S:9569 E:9575 ||| EX
is  ||| S:9575 E:9578 ||| VBZ
no  ||| S:9578 E:9581 ||| DT
additional  ||| S:9581 E:9592 ||| JJ
stimulation  ||| S:9592 E:9604 ||| NN
in  ||| S:9604 E:9617 ||| IN
transactivation  ||| S:9617 E:9633 ||| NN
in  ||| S:9633 E:9636 ||| IN
either  ||| S:9636 E:9643 ||| RB
the  ||| S:9643 E:9647 ||| DT
absence  ||| S:9647 E:9655 ||| NN
or  ||| S:9655 E:9658 ||| CC
presence  ||| S:9658 E:9667 ||| NN
of  ||| S:9667 E:9670 ||| IN
Ras  ||| S:9670 E:9684 ||| NNP
compared  ||| S:9684 E:9693 ||| VBN
to  ||| S:9693 E:9696 ||| TO
the  ||| S:9696 E:9700 ||| DT
reporter  ||| S:9700 E:9709 ||| NN
alone ||| S:9709 E:9714 ||| RB
.  ||| S:9714 E:9716 ||| .
However ||| S:9716 E:9723 ||| RB
,  ||| S:9723 E:9725 ||| ,
when  ||| S:9725 E:9730 ||| WRB
both  ||| S:9730 E:9735 ||| DT
Elk-1  ||| S:9735 E:9751 ||| NNP
and  ||| S:9751 E:9755 ||| CC
p35-C ||| S:9755 E:9760 ||| CD
/ ||| S:9760 E:9761 ||| CD
EBPβ  ||| S:9761 E:9766 ||| NNS
are  ||| S:9766 E:9770 ||| VBP
transfected  ||| S:9770 E:9782 ||| VBN
with  ||| S:9782 E:9787 ||| IN
the  ||| S:9787 E:9791 ||| DT
SRE  ||| S:9791 E:9795 ||| NNP
reporter  ||| S:9795 E:9814 ||| NN
construct ||| S:9814 E:9823 ||| NN
,  ||| S:9823 E:9825 ||| ,
there  ||| S:9825 E:9831 ||| EX
is  ||| S:9831 E:9834 ||| VBZ
a  ||| S:9834 E:9836 ||| DT
synergistic  ||| S:9836 E:9848 ||| JJ
effect  ||| S:9848 E:9855 ||| NN
in  ||| S:9855 E:9868 ||| IN
transactivation  ||| S:9868 E:9884 ||| NN
of  ||| S:9884 E:9887 ||| IN
the  ||| S:9887 E:9891 ||| DT
SRE ||| S:9891 E:9894 ||| NNP
,  ||| S:9894 E:9896 ||| ,
with  ||| S:9896 E:9901 ||| IN
a  ||| S:9901 E:9903 ||| DT
72-fold  ||| S:9903 E:9911 ||| JJ
increase  ||| S:9911 E:9920 ||| NN
in  ||| S:9920 E:9933 ||| IN
CAT  ||| S:9933 E:9937 ||| NNP
activity  ||| S:9937 E:9946 ||| NN
over  ||| S:9946 E:9951 ||| IN
reporter  ||| S:9951 E:9960 ||| NN
construct  ||| S:9960 E:9970 ||| VBZ
alone ||| S:9970 E:9975 ||| RB
.  ||| S:9975 E:9977 ||| .
As  ||| S:9977 E:9980 ||| RB
was  ||| S:9980 E:9984 ||| VBD
seen  ||| S:9984 E:9999 ||| VBN
with  ||| S:9999 E:10004 ||| IN
the  ||| S:10004 E:10008 ||| DT
Gal4  ||| S:10008 E:10013 ||| JJ
reporter ||| S:10013 E:10021 ||| NN
,  ||| S:10021 E:10023 ||| ,
this  ||| S:10023 E:10028 ||| DT
synergism  ||| S:10028 E:10038 ||| NN
is  ||| S:10038 E:10041 ||| VBZ
only  ||| S:10041 E:10046 ||| RB
observed  ||| S:10046 E:10065 ||| VBN
in  ||| S:10065 E:10068 ||| IN
the  ||| S:10068 E:10072 ||| DT
presence  ||| S:10072 E:10081 ||| NN
of  ||| S:10081 E:10084 ||| IN
activated  ||| S:10084 E:10094 ||| JJ
Ras ||| S:10094 E:10097 ||| NNP
.  ||| S:10097 E:10099 ||| .
These  ||| S:10099 E:10105 ||| DT
data  ||| S:10105 E:10110 ||| NNS
suggest  ||| S:10110 E:10118 ||| VBP
that  ||| S:10118 E:10133 ||| IN
both  ||| S:10133 E:10138 ||| DT
Elk-1  ||| S:10138 E:10144 ||| NNP
and  ||| S:10144 E:10148 ||| CC
p35-C ||| S:10148 E:10153 ||| CD
/ ||| S:10153 E:10154 ||| CD
EBPβ  ||| S:10154 E:10159 ||| NNS
are  ||| S:10159 E:10163 ||| VBP
necessary  ||| S:10163 E:10173 ||| JJ
for  ||| S:10173 E:10177 ||| IN
maximal  ||| S:10177 E:10195 ||| JJ
Ras-stimulated  ||| S:10195 E:10210 ||| JJ
transactivation  ||| S:10210 E:10226 ||| NN
of  ||| S:10226 E:10229 ||| IN
the  ||| S:10229 E:10233 ||| DT
SRE ||| S:10233 E:10236 ||| NNP
.  ||| S:10236 E:10266 ||| .
The  ||| S:10266 E:10270 ||| DT
TCF  ||| S:10270 E:10274 ||| NNP
family  ||| S:10274 E:10281 ||| NN
member  ||| S:10281 E:10288 ||| NN
Elk-1  ||| S:10288 E:10294 ||| NN
and  ||| S:10294 E:10298 ||| CC
C ||| S:10298 E:10299 ||| $
/ ||| S:10299 E:10300 ||| CD
EBPβ  ||| S:10300 E:10305 ||| JJ
interact  ||| S:10305 E:10314 ||| NN
in  ||| S:10314 E:10327 ||| IN
vitro  ||| S:10327 E:10343 ||| VBG
We  ||| S:10343 E:10346 ||| PRP
next  ||| S:10346 E:10351 ||| RB
tested  ||| S:10351 E:10358 ||| VBN
the  ||| S:10358 E:10362 ||| DT
possibility  ||| S:10362 E:10374 ||| NN
that  ||| S:10374 E:10379 ||| IN
there  ||| S:10379 E:10385 ||| EX
could  ||| S:10385 E:10391 ||| MD
be  ||| S:10391 E:10394 ||| VB
a  ||| S:10394 E:10406 ||| DT
direct  ||| S:10406 E:10413 ||| JJ
protein-protein  ||| S:10413 E:10429 ||| JJ
interaction  ||| S:10429 E:10441 ||| NN
between  ||| S:10441 E:10449 ||| IN
Elk-1  ||| S:10449 E:10455 ||| NNP
and  ||| S:10455 E:10469 ||| CC
p35-C ||| S:10469 E:10474 ||| CD
/ ||| S:10474 E:10475 ||| CD
EBPβ  ||| S:10475 E:10480 ||| NNS
based  ||| S:10480 E:10486 ||| VBN
on  ||| S:10486 E:10489 ||| IN
the  ||| S:10489 E:10493 ||| DT
fact  ||| S:10493 E:10498 ||| NN
that  ||| S:10498 E:10503 ||| IN
they  ||| S:10503 E:10508 ||| PRP
synergize  ||| S:10508 E:10518 ||| VBD
in  ||| S:10518 E:10531 ||| IN
transactivation  ||| S:10531 E:10547 ||| NN
of  ||| S:10547 E:10550 ||| IN
the  ||| S:10550 E:10554 ||| DT
SRE ||| S:10554 E:10557 ||| NNP
.  ||| S:10557 E:10559 ||| .
Therefore ||| S:10559 E:10568 ||| RB
,  ||| S:10568 E:10570 ||| ,
we  ||| S:10570 E:10573 ||| PRP
used  ||| S:10573 E:10578 ||| VBD
a  ||| S:10578 E:10590 ||| DT
GST-pulldown  ||| S:10590 E:10603 ||| JJ
assay  ||| S:10603 E:10609 ||| NN
to  ||| S:10609 E:10612 ||| TO
determine  ||| S:10612 E:10622 ||| VB
if  ||| S:10622 E:10625 ||| IN
the  ||| S:10625 E:10629 ||| DT
proteins  ||| S:10629 E:10638 ||| NNS
could  ||| S:10638 E:10654 ||| MD
interact  ||| S:10654 E:10674 ||| VB
in  ||| S:10674 E:10677 ||| IN
vitro  ||| S:10677 E:10683 ||| NN
.  ||| S:10683 E:10685 ||| .
p35-C ||| S:10685 E:10690 ||| FW
/ ||| S:10690 E:10691 ||| FW
EBPβ  ||| S:10691 E:10696 ||| NNP
was  ||| S:10696 E:10700 ||| VBD
expressed  ||| S:10700 E:10720 ||| VBN
as  ||| S:10720 E:10723 ||| IN
a  ||| S:10723 E:10725 ||| DT
chimeric  ||| S:10725 E:10734 ||| JJ
GST  ||| S:10734 E:10738 ||| NNP
protein  ||| S:10738 E:10746 ||| NN
and  ||| S:10746 E:10750 ||| CC
immobilized  ||| S:10750 E:10762 ||| NN
on  ||| S:10762 E:10775 ||| IN
glutathione-agarose  ||| S:10775 E:10795 ||| JJ
beads ||| S:10795 E:10800 ||| NN
.  ||| S:10800 E:10802 ||| .
Beads  ||| S:10802 E:10808 ||| FW
containing  ||| S:10808 E:10829 ||| FW
GST-p35-C ||| S:10829 E:10838 ||| FW
/ ||| S:10838 E:10839 ||| FW
EBPβ  ||| S:10839 E:10844 ||| FW
or  ||| S:10844 E:10847 ||| CC
GST  ||| S:10847 E:10851 ||| NNP
alone  ||| S:10851 E:10857 ||| RB
were  ||| S:10857 E:10862 ||| VBD
incubated  ||| S:10862 E:10872 ||| VBN
with  ||| S:10872 E:10888 ||| IN
in  ||| S:10888 E:10891 ||| IN
vitro  ||| S:10891 E:10897 ||| JJ
-translated  ||| S:10897 E:10909 ||| JJ
Elk-1  ||| S:10909 E:10915 ||| NN
labeled  ||| S:10915 E:10933 ||| VBN
with  ||| S:10933 E:10938 ||| IN
[  ||| S:10938 E:10940 ||| -LRB-
35S ||| S:10940 E:10943 ||| NNP
]  ||| S:10943 E:10945 ||| -RRB-
methionine ||| S:10945 E:10955 ||| NN
.  ||| S:10955 E:10957 ||| .
As  ||| S:10957 E:10960 ||| RB
shown  ||| S:10960 E:10966 ||| VBN
in  ||| S:10966 E:10969 ||| IN
Fig.  ||| S:10969 E:10974 ||| CD
3 ||| S:10974 E:10975 ||| CD
,  ||| S:10975 E:10977 ||| ,
lane  ||| S:10977 E:10982 ||| CD
2 ||| S:10982 E:10983 ||| CD
,  ||| S:10983 E:10995 ||| ,
approximately  ||| S:10995 E:11009 ||| RB
35-45 ||| S:11009 E:11014 ||| CD
%  ||| S:11014 E:11016 ||| NN
of  ||| S:11016 E:11019 ||| IN
the  ||| S:11019 E:11023 ||| DT
input  ||| S:11023 E:11029 ||| NN
Elk-1  ||| S:11029 E:11035 ||| NN
was  ||| S:11035 E:11039 ||| VBD
retained  ||| S:11039 E:11048 ||| VBN
on  ||| S:11048 E:11061 ||| IN
the  ||| S:11061 E:11065 ||| DT
GST-p35-C ||| S:11065 E:11074 ||| CD
/ ||| S:11074 E:11075 ||| CD
EBPβ  ||| S:11075 E:11080 ||| JJ
beads ||| S:11080 E:11085 ||| NN
.  ||| S:11085 E:11087 ||| .
A  ||| S:11087 E:11089 ||| DT
small  ||| S:11089 E:11095 ||| JJ
amount  ||| S:11095 E:11102 ||| NN
of  ||| S:11102 E:11105 ||| IN
Elk-1  ||| S:11105 E:11111 ||| CD
bound  ||| S:11111 E:11127 ||| VBN
to  ||| S:11127 E:11130 ||| TO
the  ||| S:11130 E:11134 ||| DT
beads  ||| S:11134 E:11140 ||| NN
containing  ||| S:11140 E:11151 ||| VBG
GST  ||| S:11151 E:11155 ||| NNP
alone  ||| S:11155 E:11161 ||| RB
( ||| S:11161 E:11162 ||| -LRB-
Fig.  ||| S:11162 E:11167 ||| CD
3 ||| S:11167 E:11168 ||| CD
,  ||| S:11168 E:11170 ||| ,
lane  ||| S:11170 E:11175 ||| CD
3 ||| S:11175 E:11176 ||| CD
)  ||| S:11176 E:11178 ||| -RRB-
which  ||| S:11178 E:11194 ||| WDT
we  ||| S:11194 E:11197 ||| PRP
have  ||| S:11197 E:11202 ||| VBP
been  ||| S:11202 E:11207 ||| VBN
unable  ||| S:11207 E:11214 ||| JJ
to  ||| S:11214 E:11217 ||| TO
eliminate  ||| S:11217 E:11227 ||| VB
even  ||| S:11227 E:11232 ||| RB
after  ||| S:11232 E:11238 ||| IN
blocking  ||| S:11238 E:11247 ||| VBG
with  ||| S:11247 E:11262 ||| IN
unprogrammed  ||| S:11262 E:11275 ||| JJ
translation  ||| S:11275 E:11287 ||| NN
lysate ||| S:11287 E:11293 ||| NN
.  ||| S:11293 E:11295 ||| .
However ||| S:11295 E:11302 ||| RB
,  ||| S:11302 E:11304 ||| ,
it  ||| S:11304 E:11307 ||| PRP
is  ||| S:11307 E:11310 ||| VBZ
clear  ||| S:11310 E:11326 ||| JJ
that  ||| S:11326 E:11331 ||| IN
the  ||| S:11331 E:11335 ||| DT
binding  ||| S:11335 E:11343 ||| NN
of  ||| S:11343 E:11346 ||| IN
Elk-1  ||| S:11346 E:11352 ||| NNP
is  ||| S:11352 E:11355 ||| VBZ
substantially  ||| S:11355 E:11369 ||| RB
increased  ||| S:11369 E:11379 ||| VBN
when  ||| S:11379 E:11394 ||| WRB
the  ||| S:11394 E:11398 ||| DT
GST-p35-C ||| S:11398 E:11407 ||| CD
/ ||| S:11407 E:11408 ||| CD
EBPβ  ||| S:11408 E:11413 ||| JJ
fusion  ||| S:11413 E:11420 ||| NN
protein  ||| S:11420 E:11428 ||| NN
is  ||| S:11428 E:11431 ||| VBZ
present  ||| S:11431 E:11439 ||| JJ
on  ||| S:11439 E:11442 ||| IN
the  ||| S:11442 E:11456 ||| DT
beads ||| S:11456 E:11461 ||| NN
.  ||| S:11461 E:11463 ||| .
These  ||| S:11463 E:11469 ||| DT
data  ||| S:11469 E:11474 ||| NNS
indicate  ||| S:11474 E:11483 ||| VBP
that  ||| S:11483 E:11488 ||| IN
Elk-1  ||| S:11488 E:11494 ||| NNP
and  ||| S:11494 E:11498 ||| CC
p35-C ||| S:11498 E:11503 ||| CD
/ ||| S:11503 E:11504 ||| CD
EBPβ  ||| S:11504 E:11509 ||| NNS
are  ||| S:11509 E:11523 ||| VBP
capable  ||| S:11523 E:11531 ||| JJ
of  ||| S:11531 E:11534 ||| IN
interacting  ||| S:11534 E:11557 ||| NN
in  ||| S:11557 E:11560 ||| IN
vitro  ||| S:11560 E:11566 ||| NN
.  ||| S:11566 E:11596 ||| .
Elk-1  ||| S:11596 E:11602 ||| NNP
and  ||| S:11602 E:11606 ||| CC
p35-C ||| S:11606 E:11611 ||| CD
/ ||| S:11611 E:11612 ||| CD
EBPβ  ||| S:11612 E:11617 ||| JJ
interact  ||| S:11617 E:11626 ||| NN
in  ||| S:11626 E:11629 ||| IN
vivo ||| S:11629 E:11633 ||| NN
,  ||| S:11633 E:11635 ||| ,
but  ||| S:11635 E:11639 ||| CC
only  ||| S:11639 E:11644 ||| RB
in  ||| S:11644 E:11657 ||| IN
the  ||| S:11657 E:11661 ||| DT
presence  ||| S:11661 E:11670 ||| NN
of  ||| S:11670 E:11673 ||| IN
activated  ||| S:11673 E:11683 ||| JJ
Ras  ||| S:11683 E:11697 ||| NNS
Since  ||| S:11697 E:11703 ||| IN
we  ||| S:11703 E:11706 ||| PRP
observed  ||| S:11706 E:11715 ||| VBD
an  ||| S:11715 E:11729 ||| DT
in  ||| S:11729 E:11732 ||| IN
vitro  ||| S:11732 E:11738 ||| JJ
interaction  ||| S:11738 E:11750 ||| NN
between  ||| S:11750 E:11758 ||| IN
the  ||| S:11758 E:11772 ||| DT
Elk-1  ||| S:11772 E:11778 ||| NNP
and  ||| S:11778 E:11782 ||| CC
C ||| S:11782 E:11783 ||| $
/ ||| S:11783 E:11784 ||| CD
EBPβ  ||| S:11784 E:11789 ||| JJ
proteins ||| S:11789 E:11797 ||| NNS
,  ||| S:11797 E:11799 ||| ,
we  ||| S:11799 E:11802 ||| PRP
next  ||| S:11802 E:11807 ||| RB
tested  ||| S:11807 E:11814 ||| VBN
whether  ||| S:11814 E:11822 ||| IN
the  ||| S:11822 E:11836 ||| DT
proteins  ||| S:11836 E:11845 ||| NNS
could  ||| S:11845 E:11851 ||| MD
interact  ||| S:11851 E:11871 ||| VB
in  ||| S:11871 E:11874 ||| IN
vivo  ||| S:11874 E:11879 ||| NN
as  ||| S:11879 E:11882 ||| IN
well ||| S:11882 E:11886 ||| RB
.  ||| S:11886 E:11888 ||| .
To  ||| S:11888 E:11891 ||| TO
do  ||| S:11891 E:11894 ||| VB
this ||| S:11894 E:11898 ||| DT
,  ||| S:11898 E:11900 ||| ,
we  ||| S:11900 E:11913 ||| PRP
used  ||| S:11913 E:11918 ||| VBD
a  ||| S:11918 E:11920 ||| DT
co-immunoprecipitation  ||| S:11920 E:11943 ||| JJ
approach ||| S:11943 E:11951 ||| NN
.  ||| S:11951 E:11953 ||| .
COS-7  ||| S:11953 E:11959 ||| NNP
cells  ||| S:11959 E:11965 ||| NNS
were  ||| S:11965 E:11980 ||| VBD
transfected  ||| S:11980 E:11992 ||| VBN
with  ||| S:11992 E:11997 ||| IN
an  ||| S:11997 E:12000 ||| DT
expression  ||| S:12000 E:12011 ||| NN
vector  ||| S:12011 E:12018 ||| NN
for  ||| S:12018 E:12022 ||| IN
a  ||| S:12022 E:12024 ||| DT
6X  ||| S:12024 E:12027 ||| FW
histidine  ||| S:12027 E:12047 ||| FW
tagged  ||| S:12047 E:12054 ||| FW
construct  ||| S:12054 E:12064 ||| FW
of  ||| S:12064 E:12067 ||| IN
p35-C ||| S:12067 E:12072 ||| CD
/ ||| S:12072 E:12073 ||| CD
EBPβ  ||| S:12073 E:12078 ||| JJ
carrying  ||| S:12078 E:12087 ||| VBG
the  ||| S:12087 E:12091 ||| DT
φ  ||| S:12091 E:12093 ||| JJ
10  ||| S:12093 E:12096 ||| CD
( ||| S:12096 E:12097 ||| -LRB-
T7  ||| S:12097 E:12100 ||| NNP
tag ||| S:12100 E:12103 ||| NN
)  ||| S:12103 E:12115 ||| -RRB-
epitope  ||| S:12115 E:12123 ||| JJ
sequence  ||| S:12123 E:12132 ||| NN
either  ||| S:12132 E:12139 ||| CC
in  ||| S:12139 E:12142 ||| IN
the  ||| S:12142 E:12146 ||| DT
presence  ||| S:12146 E:12155 ||| NN
or  ||| S:12155 E:12158 ||| CC
absence  ||| S:12158 E:12166 ||| NN
of  ||| S:12166 E:12179 ||| IN
Elk-1 ||| S:12179 E:12184 ||| CD
.  ||| S:12184 E:12186 ||| .
Cell  ||| S:12186 E:12191 ||| NN
lysates  ||| S:12191 E:12199 ||| NNS
were  ||| S:12199 E:12204 ||| VBD
incubated  ||| S:12204 E:12214 ||| VBN
with  ||| S:12214 E:12219 ||| IN
T7  ||| S:12219 E:12222 ||| FW
tag  ||| S:12222 E:12226 ||| FW
Ab  ||| S:12226 E:12229 ||| FW
agarose  ||| S:12229 E:12247 ||| FW
beads  ||| S:12247 E:12253 ||| FW
followed  ||| S:12253 E:12262 ||| VBN
by  ||| S:12262 E:12265 ||| IN
immunoblotting  ||| S:12265 E:12280 ||| NN
of  ||| S:12280 E:12283 ||| IN
the  ||| S:12283 E:12287 ||| DT
precipitated  ||| S:12287 E:12310 ||| JJ
proteins  ||| S:12310 E:12319 ||| NNS
with  ||| S:12319 E:12324 ||| IN
Elk-1  ||| S:12324 E:12330 ||| NNP
Ab ||| S:12330 E:12332 ||| NNP
.  ||| S:12332 E:12334 ||| .
As  ||| S:12334 E:12337 ||| RB
shown  ||| S:12337 E:12343 ||| VBN
in  ||| S:12343 E:12346 ||| IN
Fig.  ||| S:12346 E:12351 ||| CD
4 ||| S:12351 E:12352 ||| CD
,  ||| S:12352 E:12354 ||| ,
there  ||| S:12354 E:12360 ||| EX
is  ||| S:12360 E:12363 ||| VBZ
no  ||| S:12363 E:12376 ||| DT
Elk-1  ||| S:12376 E:12382 ||| JJ
protein  ||| S:12382 E:12390 ||| NN
precipitated  ||| S:12390 E:12403 ||| VBD
with  ||| S:12403 E:12408 ||| IN
the  ||| S:12408 E:12412 ||| DT
tagged  ||| S:12412 E:12419 ||| JJ
C ||| S:12419 E:12420 ||| $
/ ||| S:12420 E:12421 ||| CD
EBPβ  ||| S:12421 E:12426 ||| JJ
protein  ||| S:12426 E:12444 ||| NN
when  ||| S:12444 E:12449 ||| WRB
both  ||| S:12449 E:12454 ||| DT
are  ||| S:12454 E:12458 ||| VBP
transfected  ||| S:12458 E:12470 ||| NNS
( ||| S:12470 E:12471 ||| -LRB-
lane  ||| S:12471 E:12476 ||| CD
5 ||| S:12476 E:12477 ||| CD
) ||| S:12477 E:12478 ||| -RRB-
.  ||| S:12478 E:12480 ||| .
However ||| S:12480 E:12487 ||| RB
,  ||| S:12487 E:12489 ||| ,
since  ||| S:12489 E:12495 ||| IN
the  ||| S:12495 E:12509 ||| DT
synergism  ||| S:12509 E:12519 ||| NN
of  ||| S:12519 E:12522 ||| IN
Elk-1  ||| S:12522 E:12528 ||| NNP
and  ||| S:12528 E:12532 ||| CC
p35-C ||| S:12532 E:12537 ||| NNP
/ ||| S:12537 E:12538 ||| NNP
EBPβ  ||| S:12538 E:12543 ||| NNP
is  ||| S:12543 E:12546 ||| VBZ
observed  ||| S:12546 E:12555 ||| VBN
when  ||| S:12555 E:12570 ||| WRB
activated  ||| S:12570 E:12580 ||| JJ
Ras  ||| S:12580 E:12584 ||| NNP
is  ||| S:12584 E:12587 ||| VBZ
present ||| S:12587 E:12594 ||| JJ
,  ||| S:12594 E:12596 ||| ,
we  ||| S:12596 E:12599 ||| PRP
thought  ||| S:12599 E:12607 ||| VBD
it  ||| S:12607 E:12610 ||| PRP
likely  ||| S:12610 E:12617 ||| RB
that  ||| S:12617 E:12622 ||| IN
the  ||| S:12622 E:12636 ||| DT
interaction  ||| S:12636 E:12648 ||| NN
between  ||| S:12648 E:12656 ||| IN
the  ||| S:12656 E:12660 ||| DT
two  ||| S:12660 E:12664 ||| CD
proteins  ||| S:12664 E:12673 ||| NNS
could  ||| S:12673 E:12679 ||| MD
be  ||| S:12679 E:12692 ||| VB
Ras-dependent ||| S:12692 E:12705 ||| JJ
.  ||| S:12705 E:12707 ||| .
Indeed ||| S:12707 E:12713 ||| RB
,  ||| S:12713 E:12715 ||| ,
when  ||| S:12715 E:12720 ||| WRB
activated  ||| S:12720 E:12730 ||| JJ
Ras  ||| S:12730 E:12734 ||| NNP
is  ||| S:12734 E:12747 ||| VBZ
co-transfected  ||| S:12747 E:12762 ||| JJ
along  ||| S:12762 E:12768 ||| IN
with  ||| S:12768 E:12773 ||| IN
Elk-1  ||| S:12773 E:12779 ||| NNP
and  ||| S:12779 E:12783 ||| CC
histidine-tagged  ||| S:12783 E:12810 ||| NNP
p35-C ||| S:12810 E:12815 ||| NNP
/ ||| S:12815 E:12816 ||| NNP
EBPβ ||| S:12816 E:12820 ||| NNP
,  ||| S:12820 E:12822 ||| ,
the  ||| S:12822 E:12826 ||| DT
Elk-1  ||| S:12826 E:12832 ||| JJ
protein  ||| S:12832 E:12840 ||| NN
is  ||| S:12840 E:12843 ||| VBZ
precipitated  ||| S:12843 E:12856 ||| VBN
with  ||| S:12856 E:12861 ||| IN
the  ||| S:12861 E:12875 ||| DT
p35-C ||| S:12875 E:12880 ||| NNP
/ ||| S:12880 E:12881 ||| NNP
EBPβ  ||| S:12881 E:12886 ||| NNP
( ||| S:12886 E:12887 ||| -LRB-
lane  ||| S:12887 E:12892 ||| CD
6 ||| S:12892 E:12893 ||| CD
) ||| S:12893 E:12894 ||| -RRB-
.  ||| S:12894 E:12896 ||| .
One  ||| S:12896 E:12900 ||| CD
possible  ||| S:12900 E:12909 ||| JJ
explanation  ||| S:12909 E:12921 ||| NN
for  ||| S:12921 E:12925 ||| IN
this  ||| S:12925 E:12940 ||| DT
result  ||| S:12940 E:12947 ||| NN
is  ||| S:12947 E:12950 ||| VBZ
that  ||| S:12950 E:12955 ||| IN
Ras  ||| S:12955 E:12959 ||| NNP
increases  ||| S:12959 E:12969 ||| VBZ
the  ||| S:12969 E:12973 ||| DT
amount  ||| S:12973 E:12980 ||| NN
of  ||| S:12980 E:12983 ||| IN
p35-C ||| S:12983 E:12988 ||| NNP
/ ||| S:12988 E:12989 ||| NNP
EBPβ  ||| S:12989 E:12994 ||| NNP
or  ||| S:12994 E:13007 ||| CC
Elk-1  ||| S:13007 E:13013 ||| CD
protein  ||| S:13013 E:13021 ||| NN
in  ||| S:13021 E:13024 ||| IN
the  ||| S:13024 E:13028 ||| DT
COS-7  ||| S:13028 E:13034 ||| CD
cells ||| S:13034 E:13039 ||| NNS
,  ||| S:13039 E:13041 ||| ,
but  ||| S:13041 E:13045 ||| CC
Western  ||| S:13045 E:13053 ||| JJ
blot  ||| S:13053 E:13068 ||| JJ
analysis  ||| S:13068 E:13077 ||| NN
showed  ||| S:13077 E:13084 ||| VBD
that  ||| S:13084 E:13089 ||| IN
both  ||| S:13089 E:13094 ||| DT
p35-C ||| S:13094 E:13099 ||| NNP
/ ||| S:13099 E:13100 ||| NNP
EBPβ  ||| S:13100 E:13105 ||| NNP
and  ||| S:13105 E:13109 ||| CC
Elk-1  ||| S:13109 E:13115 ||| CD
protein  ||| S:13115 E:13133 ||| NN
levels  ||| S:13133 E:13140 ||| NNS
are  ||| S:13140 E:13144 ||| VBP
the  ||| S:13144 E:13148 ||| DT
same  ||| S:13148 E:13153 ||| JJ
in  ||| S:13153 E:13156 ||| IN
the  ||| S:13156 E:13160 ||| DT
absence  ||| S:13160 E:13168 ||| NN
and  ||| S:13168 E:13172 ||| CC
presence  ||| S:13172 E:13181 ||| NN
of  ||| S:13181 E:13184 ||| IN
Ras  ||| S:13184 E:13198 ||| NNP
( ||| S:13198 E:13199 ||| -LRB-
data  ||| S:13199 E:13204 ||| NNS
not  ||| S:13204 E:13208 ||| RB
shown ||| S:13208 E:13213 ||| VBN
) ||| S:13213 E:13214 ||| -RRB-
.  ||| S:13214 E:13216 ||| .
Therefore ||| S:13216 E:13225 ||| RB
,  ||| S:13225 E:13227 ||| ,
p35-C ||| S:13227 E:13232 ||| NNP
/ ||| S:13232 E:13233 ||| NNP
EBPβ  ||| S:13233 E:13238 ||| NNP
and  ||| S:13238 E:13242 ||| CC
Elk-1  ||| S:13242 E:13258 ||| CD
interact  ||| S:13258 E:13267 ||| NN
in  ||| S:13267 E:13281 ||| IN
vivo  ||| S:13281 E:13286 ||| NN
,  ||| S:13286 E:13288 ||| ,
but  ||| S:13288 E:13292 ||| CC
only  ||| S:13292 E:13297 ||| RB
in  ||| S:13297 E:13300 ||| IN
response  ||| S:13300 E:13309 ||| NN
to  ||| S:13309 E:13322 ||| TO
activation  ||| S:13322 E:13333 ||| VB
of  ||| S:13333 E:13336 ||| IN
Ras-dependent  ||| S:13336 E:13350 ||| JJ
signaling  ||| S:13350 E:13360 ||| JJ
pathways ||| S:13360 E:13368 ||| NN
.  ||| S:13368 E:13398 ||| .
The  ||| S:13398 E:13402 ||| DT
C-terminal  ||| S:13402 E:13413 ||| JJ
domain  ||| S:13413 E:13420 ||| NN
of  ||| S:13420 E:13423 ||| IN
C ||| S:13423 E:13424 ||| NNP
/ ||| S:13424 E:13425 ||| NNP
EBPβ  ||| S:13425 E:13430 ||| NNP
is  ||| S:13430 E:13433 ||| VBZ
necessary  ||| S:13433 E:13443 ||| JJ
to  ||| S:13443 E:13456 ||| TO
interact  ||| S:13456 E:13465 ||| VB
with  ||| S:13465 E:13470 ||| IN
Elk-1  ||| S:13470 E:13476 ||| CD
in  ||| S:13476 E:13479 ||| IN
vitro  ||| S:13479 E:13495 ||| NN
Since  ||| S:13495 E:13501 ||| IN
C ||| S:13501 E:13502 ||| NNP
/ ||| S:13502 E:13503 ||| NNP
EBPβ  ||| S:13503 E:13508 ||| NNP
and  ||| S:13508 E:13512 ||| CC
Elk-1  ||| S:13512 E:13518 ||| CD
interact ||| S:13518 E:13526 ||| NN
,  ||| S:13526 E:13528 ||| ,
we  ||| S:13528 E:13531 ||| PRP
next  ||| S:13531 E:13536 ||| RB
wanted  ||| S:13536 E:13543 ||| VBD
to  ||| S:13543 E:13556 ||| TO
narrow  ||| S:13556 E:13563 ||| VB
down  ||| S:13563 E:13568 ||| RP
the  ||| S:13568 E:13572 ||| DT
domains  ||| S:13572 E:13580 ||| NN
of  ||| S:13580 E:13583 ||| IN
the  ||| S:13583 E:13587 ||| DT
proteins  ||| S:13587 E:13596 ||| NNS
that  ||| S:13596 E:13601 ||| WDT
are  ||| S:13601 E:13605 ||| VBP
required  ||| S:13605 E:13624 ||| VBN
for  ||| S:13624 E:13628 ||| IN
their  ||| S:13628 E:13634 ||| PRP$
interaction ||| S:13634 E:13645 ||| NN
.  ||| S:13645 E:13647 ||| .
To  ||| S:13647 E:13650 ||| TO
determine  ||| S:13650 E:13660 ||| VB
the  ||| S:13660 E:13664 ||| DT
domain  ||| S:13664 E:13671 ||| NN
of  ||| S:13671 E:13674 ||| IN
C ||| S:13674 E:13675 ||| $
/ ||| S:13675 E:13676 ||| CD
EBPβ  ||| S:13676 E:13691 ||| NN
that  ||| S:13691 E:13696 ||| WDT
is  ||| S:13696 E:13699 ||| VBZ
necessary  ||| S:13699 E:13709 ||| JJ
to  ||| S:13709 E:13712 ||| TO
interact  ||| S:13712 E:13721 ||| VB
with  ||| S:13721 E:13726 ||| IN
Elk-1 ||| S:13726 E:13731 ||| NNP
,  ||| S:13731 E:13733 ||| ,
a  ||| S:13733 E:13745 ||| DT
p20-C ||| S:13745 E:13750 ||| CD
/ ||| S:13750 E:13751 ||| CD
EBPβ-GST  ||| S:13751 E:13760 ||| JJ
fusion  ||| S:13760 E:13767 ||| NN
protein  ||| S:13767 E:13775 ||| NN
was  ||| S:13775 E:13779 ||| VBD
constructed.  ||| S:13779 E:13792 ||| CD
p20-C ||| S:13792 E:13797 ||| CD
/ ||| S:13797 E:13798 ||| CD
EBPβ  ||| S:13798 E:13813 ||| JJ
encodes  ||| S:13813 E:13821 ||| NNS
the  ||| S:13821 E:13825 ||| DT
20  ||| S:13825 E:13828 ||| CD
kDa  ||| S:13828 E:13832 ||| JJ
form  ||| S:13832 E:13837 ||| NN
of  ||| S:13837 E:13840 ||| IN
C ||| S:13840 E:13841 ||| NNP
/ ||| S:13841 E:13842 ||| NNP
EBPβ ||| S:13842 E:13846 ||| NNP
,  ||| S:13846 E:13848 ||| ,
which  ||| S:13848 E:13854 ||| WDT
lacks  ||| S:13854 E:13860 ||| VBZ
the  ||| S:13860 E:13874 ||| DT
N-terminal  ||| S:13874 E:13885 ||| JJ
transactivation  ||| S:13885 E:13901 ||| JJ
domain  ||| S:13901 E:13908 ||| NN
of  ||| S:13908 E:13911 ||| IN
the  ||| S:13911 E:13915 ||| DT
longer  ||| S:13915 E:13932 ||| RB
p35-C ||| S:13932 E:13937 ||| CD
/ ||| S:13937 E:13938 ||| CD
EBPβ  ||| S:13938 E:13943 ||| JJ
isoform ||| S:13943 E:13950 ||| NN
.  ||| S:13950 E:13952 ||| .
This  ||| S:13952 E:13957 ||| DT
isoform ||| S:13957 E:13964 ||| NN
,  ||| S:13964 E:13966 ||| ,
however ||| S:13966 E:13973 ||| RB
,  ||| S:13973 E:13975 ||| ,
shares  ||| S:13975 E:13982 ||| NNS
the  ||| S:13982 E:13996 ||| DT
C-terminal  ||| S:13996 E:14007 ||| JJ
DNA  ||| S:14007 E:14011 ||| NN
binding  ||| S:14011 E:14019 ||| NNS
and  ||| S:14019 E:14023 ||| CC
dimerization  ||| S:14023 E:14036 ||| JJ
domain  ||| S:14036 E:14043 ||| NN
with  ||| S:14043 E:14058 ||| IN
p35-C ||| S:14058 E:14063 ||| NNP
/ ||| S:14063 E:14064 ||| NNP
EBPβ ||| S:14064 E:14068 ||| NNP
.  ||| S:14068 E:14070 ||| .
As  ||| S:14070 E:14073 ||| RB
shown  ||| S:14073 E:14079 ||| VBN
in  ||| S:14079 E:14082 ||| IN
Fig.  ||| S:14082 E:14087 ||| CD
5 ||| S:14087 E:14088 ||| CD
,  ||| S:14088 E:14090 ||| ,
approximately  ||| S:14090 E:14104 ||| RB
the  ||| S:14104 E:14108 ||| DT
same  ||| S:14108 E:14123 ||| JJ
amount  ||| S:14123 E:14130 ||| NN
of  ||| S:14130 E:14133 ||| IN
[  ||| S:14133 E:14135 ||| -LRB-
35S ||| S:14135 E:14138 ||| NNP
] ||| S:14138 E:14139 ||| -RRB-
-labeled  ||| S:14139 E:14148 ||| NNP
Elk-1  ||| S:14148 E:14154 ||| NNP
is  ||| S:14154 E:14157 ||| VBZ
retained  ||| S:14157 E:14166 ||| VBN
on  ||| S:14166 E:14169 ||| IN
both  ||| S:14169 E:14174 ||| PDT
the  ||| S:14174 E:14188 ||| DT
GST-p20-C ||| S:14188 E:14197 ||| NNP
/ ||| S:14197 E:14198 ||| NNP
EBPβ  ||| S:14198 E:14203 ||| NNP
and  ||| S:14203 E:14207 ||| CC
GST-p35-C ||| S:14207 E:14216 ||| CD
/ ||| S:14216 E:14217 ||| CD
EBPβ  ||| S:14217 E:14222 ||| JJ
beads  ||| S:14222 E:14228 ||| NNS
( ||| S:14228 E:14229 ||| -LRB-
compare  ||| S:14229 E:14237 ||| VB
lanes  ||| S:14237 E:14243 ||| CD
2  ||| S:14243 E:14255 ||| CD
and  ||| S:14255 E:14259 ||| CC
3 ||| S:14259 E:14260 ||| LS
) ||| S:14260 E:14261 ||| -RRB-
.  ||| S:14261 E:14263 ||| .
Therefore ||| S:14263 E:14272 ||| RB
,  ||| S:14272 E:14274 ||| ,
deletion  ||| S:14274 E:14283 ||| NN
of  ||| S:14283 E:14286 ||| IN
the  ||| S:14286 E:14290 ||| DT
N-terminus  ||| S:14290 E:14301 ||| JJ
of  ||| S:14301 E:14304 ||| IN
C ||| S:14304 E:14305 ||| NNP
/ ||| S:14305 E:14306 ||| NNP
EBPβ  ||| S:14306 E:14321 ||| NNP
has  ||| S:14321 E:14325 ||| VBZ
no  ||| S:14325 E:14328 ||| DT
effect  ||| S:14328 E:14335 ||| NN
on  ||| S:14335 E:14338 ||| IN
its  ||| S:14338 E:14342 ||| PRP$
ability  ||| S:14342 E:14350 ||| NN
to  ||| S:14350 E:14353 ||| TO
interact  ||| S:14353 E:14362 ||| VB
with  ||| S:14362 E:14367 ||| IN
Elk-1 ||| S:14367 E:14372 ||| CD
.  ||| S:14372 E:14374 ||| .
This  ||| S:14374 E:14389 ||| DT
data  ||| S:14389 E:14394 ||| NN
demonstrates  ||| S:14394 E:14407 ||| VBZ
that  ||| S:14407 E:14412 ||| IN
the  ||| S:14412 E:14416 ||| DT
C-terminal  ||| S:14416 E:14427 ||| JJ
region  ||| S:14427 E:14434 ||| NN
of  ||| S:14434 E:14437 ||| IN
C ||| S:14437 E:14438 ||| NNP
/ ||| S:14438 E:14439 ||| NNP
EBPβ  ||| S:14439 E:14444 ||| NNP
is  ||| S:14444 E:14457 ||| VBZ
sufficient  ||| S:14457 E:14468 ||| JJ
to  ||| S:14468 E:14471 ||| TO
mediate  ||| S:14471 E:14479 ||| VB
interaction  ||| S:14479 E:14491 ||| VBN
with  ||| S:14491 E:14496 ||| IN
Elk-1  ||| S:14496 E:14513 ||| CD
in  ||| S:14513 E:14516 ||| IN
vitro  ||| S:14516 E:14522 ||| NN
.  ||| S:14522 E:14552 ||| .
The  ||| S:14552 E:14556 ||| DT
N-terminal  ||| S:14556 E:14567 ||| JJ
A-box  ||| S:14567 E:14573 ||| NN
of  ||| S:14573 E:14576 ||| IN
Elk-1  ||| S:14576 E:14582 ||| NNP
is  ||| S:14582 E:14585 ||| VBZ
sufficient  ||| S:14585 E:14596 ||| JJ
to  ||| S:14596 E:14609 ||| TO
interact  ||| S:14609 E:14618 ||| VB
with  ||| S:14618 E:14623 ||| IN
C ||| S:14623 E:14624 ||| $
/ ||| S:14624 E:14625 ||| CD
EBPβ  ||| S:14625 E:14630 ||| NN
in  ||| S:14630 E:14633 ||| IN
vitro  ||| S:14633 E:14649 ||| NN
In  ||| S:14649 E:14652 ||| IN
order  ||| S:14652 E:14658 ||| NN
to  ||| S:14658 E:14661 ||| TO
narrow  ||| S:14661 E:14668 ||| VB
down  ||| S:14668 E:14673 ||| RP
the  ||| S:14673 E:14677 ||| DT
domain  ||| S:14677 E:14684 ||| NN
of  ||| S:14684 E:14687 ||| IN
Elk-1  ||| S:14687 E:14693 ||| NNP
that  ||| S:14693 E:14698 ||| WDT
is  ||| S:14698 E:14711 ||| VBZ
necessary  ||| S:14711 E:14721 ||| JJ
to  ||| S:14721 E:14724 ||| TO
interact  ||| S:14724 E:14733 ||| VB
with  ||| S:14733 E:14738 ||| IN
C ||| S:14738 E:14739 ||| $
/ ||| S:14739 E:14740 ||| CD
EBPβ  ||| S:14740 E:14756 ||| NN
in  ||| S:14756 E:14759 ||| IN
vitro  ||| S:14759 E:14765 ||| NN
,  ||| S:14765 E:14767 ||| ,
we  ||| S:14767 E:14770 ||| PRP
made  ||| S:14770 E:14775 ||| VBD
several  ||| S:14775 E:14783 ||| JJ
Elk-1  ||| S:14783 E:14799 ||| FW
deletion  ||| S:14799 E:14808 ||| FW
mutants  ||| S:14808 E:14816 ||| FW
( ||| S:14816 E:14817 ||| -LRB-
Fig.  ||| S:14817 E:14822 ||| NNP
6A ||| S:14822 E:14824 ||| NNP
)  ||| S:14824 E:14826 ||| -RRB-
and  ||| S:14826 E:14830 ||| CC
tested  ||| S:14830 E:14837 ||| VBD
these  ||| S:14837 E:14843 ||| DT
constructs  ||| S:14843 E:14854 ||| NN
in  ||| S:14854 E:14867 ||| IN
a  ||| S:14867 E:14869 ||| DT
pulldown  ||| S:14869 E:14878 ||| JJ
assay  ||| S:14878 E:14884 ||| NN
with  ||| S:14884 E:14889 ||| IN
GST-p35-C ||| S:14889 E:14898 ||| NNP
/ ||| S:14898 E:14899 ||| NNP
EBPβ ||| S:14899 E:14903 ||| NNP
.  ||| S:14903 E:14905 ||| .
Elk-1 ||| S:14905 E:14910 ||| NNP
( ||| S:14910 E:14911 ||| -LRB-
1-209 ||| S:14911 E:14916 ||| NNP
)  ||| S:14916 E:14918 ||| -RRB-
is  ||| S:14918 E:14921 ||| VBZ
a  ||| S:14921 E:14933 ||| DT
C-terminal  ||| S:14933 E:14944 ||| JJ
deletion  ||| S:14944 E:14953 ||| NN
mutant  ||| S:14953 E:14960 ||| NNS
that  ||| S:14960 E:14965 ||| WDT
lacks  ||| S:14965 E:14971 ||| VBZ
the  ||| S:14971 E:14975 ||| DT
C-box ||| S:14975 E:14980 ||| JJ
.  ||| S:14980 E:14992 ||| .
Elk-1 ||| S:14992 E:14997 ||| NNP
( ||| S:14997 E:14998 ||| -LRB-
1-140 ||| S:14998 E:15003 ||| NNP
)  ||| S:15003 E:15005 ||| -RRB-
is  ||| S:15005 E:15008 ||| VBZ
also  ||| S:15008 E:15013 ||| RB
a  ||| S:15013 E:15015 ||| DT
C-terminal  ||| S:15015 E:15026 ||| JJ
deletion ||| S:15026 E:15034 ||| NN
,  ||| S:15034 E:15036 ||| ,
but  ||| S:15036 E:15040 ||| CC
it  ||| S:15040 E:15043 ||| PRP
lacks  ||| S:15043 E:15059 ||| VBZ
both  ||| S:15059 E:15064 ||| PDT
the  ||| S:15064 E:15068 ||| DT
B-  ||| S:15068 E:15071 ||| JJ
and  ||| S:15071 E:15075 ||| CC
C-boxes ||| S:15075 E:15082 ||| JJ
.  ||| S:15082 E:15084 ||| .
Therefore ||| S:15084 E:15093 ||| RB
,  ||| S:15093 E:15095 ||| ,
this  ||| S:15095 E:15100 ||| DT
mutant  ||| S:15100 E:15107 ||| NN
contains  ||| S:15107 E:15126 ||| VBZ
neither  ||| S:15126 E:15134 ||| RB
a  ||| S:15134 E:15136 ||| DT
transactivation  ||| S:15136 E:15152 ||| JJ
domain  ||| S:15152 E:15159 ||| NN
nor  ||| S:15159 E:15163 ||| CC
an  ||| S:15163 E:15166 ||| DT
SRF  ||| S:15166 E:15170 ||| NNP
binding  ||| S:15170 E:15188 ||| JJ
domain ||| S:15188 E:15194 ||| NN
.  ||| S:15194 E:15196 ||| .
Finally ||| S:15196 E:15203 ||| RB
,  ||| S:15203 E:15205 ||| ,
Elk-1 ||| S:15205 E:15210 ||| NNP
( ||| S:15210 E:15211 ||| -LRB-
89-428 ||| S:15211 E:15217 ||| NNP
)  ||| S:15217 E:15219 ||| -RRB-
is  ||| S:15219 E:15222 ||| VBZ
a  ||| S:15222 E:15224 ||| DT
deletion  ||| S:15224 E:15233 ||| NN
of  ||| S:15233 E:15236 ||| IN
the  ||| S:15236 E:15250 ||| DT
N-terminal  ||| S:15250 E:15261 ||| JJ
A-box ||| S:15261 E:15266 ||| NN
.  ||| S:15266 E:15268 ||| .
Glutathione  ||| S:15268 E:15280 ||| FW
agarose  ||| S:15280 E:15288 ||| FW
beads  ||| S:15288 E:15294 ||| FW
containing  ||| S:15294 E:15315 ||| FW
GST-p35-C ||| S:15315 E:15324 ||| FW
/ ||| S:15324 E:15325 ||| FW
EBPβ  ||| S:15325 E:15330 ||| FW
or  ||| S:15330 E:15333 ||| CC
GST  ||| S:15333 E:15337 ||| NNP
alone  ||| S:15337 E:15343 ||| RB
were  ||| S:15343 E:15348 ||| VBD
incubated  ||| S:15348 E:15358 ||| VBN
with  ||| S:15358 E:15374 ||| IN
in  ||| S:15374 E:15377 ||| IN
vitro  ||| S:15377 E:15383 ||| JJ
-translated  ||| S:15383 E:15395 ||| JJ
Elk-1  ||| S:15395 E:15401 ||| NN
mutants  ||| S:15401 E:15419 ||| VBZ
labeled  ||| S:15419 E:15427 ||| VBN
with  ||| S:15427 E:15432 ||| IN
[  ||| S:15432 E:15434 ||| -LRB-
35S ||| S:15434 E:15437 ||| NNP
]  ||| S:15437 E:15439 ||| -RRB-
methionine ||| S:15439 E:15449 ||| NN
.  ||| S:15449 E:15451 ||| .
As  ||| S:15451 E:15454 ||| RB
shown  ||| S:15454 E:15460 ||| VBN
in  ||| S:15460 E:15463 ||| IN
Fig.  ||| S:15463 E:15468 ||| CD
6B ||| S:15468 E:15470 ||| CD
,  ||| S:15470 E:15472 ||| ,
the  ||| S:15472 E:15486 ||| DT
C-terminal  ||| S:15486 E:15497 ||| JJ
Elk-1  ||| S:15497 E:15503 ||| CD
mutants ||| S:15503 E:15510 ||| NN
,  ||| S:15510 E:15512 ||| ,
Elk-1 ||| S:15512 E:15517 ||| NNP
( ||| S:15517 E:15518 ||| -LRB-
1-209 ||| S:15518 E:15523 ||| NNP
)  ||| S:15523 E:15525 ||| -RRB-
and  ||| S:15525 E:15529 ||| CC
Elk-1 ||| S:15529 E:15534 ||| NNP
( ||| S:15534 E:15535 ||| -LRB-
1-140 ||| S:15535 E:15540 ||| NNP
) ||| S:15540 E:15541 ||| -RRB-
,  ||| S:15541 E:15553 ||| ,
bound  ||| S:15553 E:15559 ||| VBN
to  ||| S:15559 E:15562 ||| TO
the  ||| S:15562 E:15566 ||| DT
GST-p35-C ||| S:15566 E:15575 ||| CD
/ ||| S:15575 E:15576 ||| CD
EBPβ  ||| S:15576 E:15581 ||| JJ
beads  ||| S:15581 E:15587 ||| NN
to  ||| S:15587 E:15590 ||| TO
the  ||| S:15590 E:15594 ||| DT
same  ||| S:15594 E:15599 ||| JJ
extent  ||| S:15599 E:15606 ||| NN
as  ||| S:15606 E:15619 ||| IN
wild-type  ||| S:15619 E:15629 ||| NNP
Elk-1  ||| S:15629 E:15635 ||| NNP
( ||| S:15635 E:15636 ||| -LRB-
compare  ||| S:15636 E:15644 ||| VB
lane  ||| S:15644 E:15649 ||| CD
3  ||| S:15649 E:15651 ||| CD
of  ||| S:15651 E:15654 ||| IN
top  ||| S:15654 E:15658 ||| JJ
3  ||| S:15658 E:15660 ||| CD
panels ||| S:15660 E:15666 ||| NNS
) ||| S:15666 E:15667 ||| -RRB-
.  ||| S:15667 E:15679 ||| .
However ||| S:15679 E:15686 ||| RB
,  ||| S:15686 E:15688 ||| ,
the  ||| S:15688 E:15692 ||| DT
A-box  ||| S:15692 E:15698 ||| JJ
deletion  ||| S:15698 E:15707 ||| JJ
mutant ||| S:15707 E:15713 ||| NN
,  ||| S:15713 E:15715 ||| ,
Elk-1 ||| S:15715 E:15720 ||| NNP
( ||| S:15720 E:15721 ||| -LRB-
89-428 ||| S:15721 E:15727 ||| NNP
) ||| S:15727 E:15728 ||| -RRB-
,  ||| S:15728 E:15730 ||| ,
no  ||| S:15730 E:15743 ||| DT
longer  ||| S:15743 E:15750 ||| RBR
binds  ||| S:15750 E:15756 ||| JJ
to  ||| S:15756 E:15759 ||| TO
the  ||| S:15759 E:15763 ||| DT
GST-p35-C ||| S:15763 E:15772 ||| NNP
/ ||| S:15772 E:15773 ||| NNP
EBPβ  ||| S:15773 E:15778 ||| NNP
( ||| S:15778 E:15779 ||| -LRB-
lane  ||| S:15779 E:15784 ||| CD
3 ||| S:15784 E:15785 ||| CD
,  ||| S:15785 E:15787 ||| ,
bottom  ||| S:15787 E:15804 ||| JJ
panel ||| S:15804 E:15809 ||| NN
) ||| S:15809 E:15810 ||| -RRB-
.  ||| S:15810 E:15812 ||| .
Therefore ||| S:15812 E:15821 ||| RB
,  ||| S:15821 E:15823 ||| ,
this  ||| S:15823 E:15828 ||| DT
data  ||| S:15828 E:15833 ||| NN
demonstrates  ||| S:15833 E:15846 ||| VBZ
that  ||| S:15846 E:15851 ||| IN
the  ||| S:15851 E:15855 ||| DT
A-box  ||| S:15855 E:15871 ||| JJ
of  ||| S:15871 E:15874 ||| IN
Elk-1  ||| S:15874 E:15880 ||| NNP
is  ||| S:15880 E:15883 ||| VBZ
necessary  ||| S:15883 E:15893 ||| JJ
to  ||| S:15893 E:15896 ||| TO
interact  ||| S:15896 E:15905 ||| VB
with  ||| S:15905 E:15910 ||| IN
C ||| S:15910 E:15911 ||| $
/ ||| S:15911 E:15912 ||| CD
EBPβ  ||| S:15912 E:15928 ||| NN
in  ||| S:15928 E:15931 ||| IN
vitro  ||| S:15931 E:15937 ||| NN
.  ||| S:15937 E:15970 ||| .
Discussion  ||| S:15970 E:15989 ||| NN
We  ||| S:15989 E:15992 ||| PRP
have  ||| S:15992 E:15997 ||| VBP
shown  ||| S:15997 E:16003 ||| VBN
that  ||| S:16003 E:16008 ||| IN
the  ||| S:16008 E:16012 ||| DT
transcription  ||| S:16012 E:16026 ||| JJ
factors  ||| S:16026 E:16034 ||| NNS
Elk-1  ||| S:16034 E:16040 ||| NNP
and  ||| S:16040 E:16052 ||| CC
p35-C ||| S:16052 E:16057 ||| CD
/ ||| S:16057 E:16058 ||| CD
EBPβ  ||| S:16058 E:16063 ||| JJ
synergize  ||| S:16063 E:16073 ||| NN
in  ||| S:16073 E:16076 ||| IN
transactivation  ||| S:16076 E:16092 ||| NN
of  ||| S:16092 E:16095 ||| IN
SRF-dependent  ||| S:16095 E:16117 ||| JJ
transcription  ||| S:16117 E:16131 ||| NNS
using  ||| S:16131 E:16137 ||| VBG
both  ||| S:16137 E:16142 ||| DT
GAL4  ||| S:16142 E:16147 ||| NNP
and  ||| S:16147 E:16151 ||| CC
SRE-driven  ||| S:16151 E:16162 ||| JJ
reporter  ||| S:16162 E:16179 ||| NN
constructs ||| S:16179 E:16189 ||| NN
.  ||| S:16189 E:16191 ||| .
Interestingly ||| S:16191 E:16204 ||| RB
,  ||| S:16204 E:16206 ||| ,
this  ||| S:16206 E:16211 ||| DT
synergy  ||| S:16211 E:16219 ||| NN
is  ||| S:16219 E:16222 ||| VBZ
only  ||| S:16222 E:16227 ||| RB
observed  ||| S:16227 E:16236 ||| VBN
in  ||| S:16236 E:16247 ||| IN
response  ||| S:16247 E:16256 ||| NN
to  ||| S:16256 E:16259 ||| TO
mitogenic  ||| S:16259 E:16269 ||| VB
stimulation  ||| S:16269 E:16281 ||| VBN
by  ||| S:16281 E:16284 ||| IN
Ras ||| S:16284 E:16287 ||| NNP
.  ||| S:16287 E:16289 ||| .
We  ||| S:16289 E:16292 ||| PRP
have  ||| S:16292 E:16297 ||| VBP
also  ||| S:16297 E:16310 ||| RB
demonstrated  ||| S:16310 E:16323 ||| VBN
that  ||| S:16323 E:16328 ||| IN
the  ||| S:16328 E:16332 ||| DT
Elk-1  ||| S:16332 E:16338 ||| NNP
and  ||| S:16338 E:16342 ||| CC
p35-C ||| S:16342 E:16347 ||| CD
/ ||| S:16347 E:16348 ||| CD
EBPβ  ||| S:16348 E:16353 ||| JJ
proteins  ||| S:16353 E:16370 ||| NNS
interact  ||| S:16370 E:16379 ||| VBP
using  ||| S:16379 E:16385 ||| VBG
both  ||| S:16385 E:16399 ||| DT
in  ||| S:16399 E:16402 ||| IN
vitro  ||| S:16402 E:16408 ||| JJ
GST-pulldown  ||| S:16408 E:16421 ||| JJ
and  ||| S:16421 E:16434 ||| CC
in  ||| S:16434 E:16437 ||| IN
vivo  ||| S:16437 E:16442 ||| JJ
coimmunoprecipitation  ||| S:16442 E:16464 ||| JJ
assays ||| S:16464 E:16470 ||| NN
.  ||| S:16470 E:16480 ||| .
The  ||| S:16480 E:16493 ||| DT
in  ||| S:16493 E:16496 ||| IN
vivo  ||| S:16496 E:16501 ||| JJ
interaction ||| S:16501 E:16512 ||| NN
,  ||| S:16512 E:16514 ||| ,
however ||| S:16514 E:16521 ||| RB
,  ||| S:16521 E:16523 ||| ,
is  ||| S:16523 E:16534 ||| VBZ
dependent  ||| S:16534 E:16544 ||| JJ
on  ||| S:16544 E:16547 ||| IN
the  ||| S:16547 E:16551 ||| DT
presence  ||| S:16551 E:16560 ||| NN
of  ||| S:16560 E:16563 ||| IN
activated  ||| S:16563 E:16573 ||| JJ
Ras ||| S:16573 E:16576 ||| NNP
.  ||| S:16576 E:16578 ||| .
Finally ||| S:16578 E:16585 ||| RB
,  ||| S:16585 E:16587 ||| ,
we  ||| S:16587 E:16598 ||| PRP
demonstrate  ||| S:16598 E:16610 ||| VBP
that  ||| S:16610 E:16615 ||| IN
the  ||| S:16615 E:16628 ||| DT
in  ||| S:16628 E:16631 ||| IN
vitro  ||| S:16631 E:16637 ||| JJ
interaction  ||| S:16637 E:16649 ||| JJ
domains  ||| S:16649 E:16657 ||| NN
of  ||| S:16657 E:16660 ||| IN
the  ||| S:16660 E:16672 ||| DT
two  ||| S:16672 E:16676 ||| CD
proteins  ||| S:16676 E:16685 ||| NNS
are  ||| S:16685 E:16689 ||| VBP
the  ||| S:16689 E:16693 ||| DT
C-terminal  ||| S:16693 E:16704 ||| JJ
domain  ||| S:16704 E:16711 ||| NN
of  ||| S:16711 E:16714 ||| IN
C ||| S:16714 E:16715 ||| NNP
/ ||| S:16715 E:16716 ||| NNP
EBPβ  ||| S:16716 E:16721 ||| NNP
and  ||| S:16721 E:16725 ||| CC
the  ||| S:16725 E:16737 ||| DT
N-terminal  ||| S:16737 E:16748 ||| JJ
domain  ||| S:16748 E:16755 ||| NN
of  ||| S:16755 E:16758 ||| IN
Elk-1 ||| S:16758 E:16763 ||| CD
.  ||| S:16763 E:16773 ||| .
These  ||| S:16773 E:16779 ||| DT
results  ||| S:16779 E:16787 ||| NNS
suggest  ||| S:16787 E:16795 ||| VBP
a  ||| S:16795 E:16797 ||| DT
new  ||| S:16797 E:16801 ||| JJ
mechanism  ||| S:16801 E:16811 ||| NN
for  ||| S:16811 E:16823 ||| IN
transactivation  ||| S:16823 E:16839 ||| NN
of  ||| S:16839 E:16842 ||| IN
the  ||| S:16842 E:16846 ||| DT
SRE ||| S:16846 E:16849 ||| NNP
,  ||| S:16849 E:16851 ||| ,
where  ||| S:16851 E:16857 ||| WRB
a  ||| S:16857 E:16859 ||| DT
competent  ||| S:16859 E:16877 ||| JJ
transcriptional  ||| S:16877 E:16893 ||| JJ
complex  ||| S:16893 E:16901 ||| NN
consisting  ||| S:16901 E:16912 ||| VBG
of  ||| S:16912 E:16915 ||| IN
at  ||| S:16915 E:16918 ||| IN
least  ||| S:16918 E:16924 ||| JJS
SRF ||| S:16924 E:16927 ||| NNP
,  ||| S:16927 E:16929 ||| ,
TCF ||| S:16929 E:16932 ||| NNP
,  ||| S:16932 E:16942 ||| ,
and  ||| S:16942 E:16946 ||| CC
p35-C ||| S:16946 E:16951 ||| CD
/ ||| S:16951 E:16952 ||| CD
EBPβ  ||| S:16952 E:16957 ||| JJ
participate  ||| S:16957 E:16969 ||| NN
in  ||| S:16969 E:16972 ||| IN
transactivation  ||| S:16972 E:16988 ||| NN
in  ||| S:16988 E:16991 ||| IN
response  ||| S:16991 E:17008 ||| NN
to  ||| S:17008 E:17011 ||| TO
Ras ||| S:17011 E:17014 ||| NNP
.  ||| S:17014 E:17016 ||| .
To  ||| S:17016 E:17019 ||| TO
this  ||| S:17019 E:17024 ||| DT
point ||| S:17024 E:17029 ||| NN
,  ||| S:17029 E:17031 ||| ,
the  ||| S:17031 E:17035 ||| DT
TCF  ||| S:17035 E:17039 ||| NNP
family  ||| S:17039 E:17046 ||| NN
members  ||| S:17046 E:17054 ||| NNS
have  ||| S:17054 E:17059 ||| VBP
been  ||| S:17059 E:17072 ||| VBN
thought  ||| S:17072 E:17080 ||| VBN
to  ||| S:17080 E:17083 ||| TO
be  ||| S:17083 E:17086 ||| VB
the  ||| S:17086 E:17090 ||| DT
main  ||| S:17090 E:17095 ||| JJ
targets  ||| S:17095 E:17103 ||| NNS
of  ||| S:17103 E:17106 ||| IN
Ras  ||| S:17106 E:17110 ||| NNP
signaling  ||| S:17110 E:17120 ||| VBG
to  ||| S:17120 E:17123 ||| TO
the  ||| S:17123 E:17127 ||| DT
SRE ||| S:17127 E:17130 ||| NNP
,  ||| S:17130 E:17140 ||| ,
and  ||| S:17140 E:17144 ||| CC
activation  ||| S:17144 E:17155 ||| NN
of  ||| S:17155 E:17158 ||| IN
TCF  ||| S:17158 E:17162 ||| NNP
by  ||| S:17162 E:17165 ||| IN
Ras  ||| S:17165 E:17169 ||| NNP
has  ||| S:17169 E:17173 ||| VBZ
been  ||| S:17173 E:17178 ||| VBN
shown  ||| S:17178 E:17184 ||| VBN
to  ||| S:17184 E:17187 ||| TO
result  ||| S:17187 E:17194 ||| VB
in  ||| S:17194 E:17205 ||| IN
transactivation  ||| S:17205 E:17221 ||| NN
of  ||| S:17221 E:17224 ||| IN
the  ||| S:17224 E:17228 ||| DT
SRE  ||| S:17228 E:17232 ||| NNP
[  ||| S:17232 E:17234 ||| -LRB-
16 ||| S:17234 E:17236 ||| CD
] ||| S:17236 E:17237 ||| -RRB-
.  ||| S:17237 E:17239 ||| .
However ||| S:17239 E:17246 ||| RB
,  ||| S:17246 E:17248 ||| ,
we  ||| S:17248 E:17251 ||| PRP
show  ||| S:17251 E:17256 ||| VBP
that  ||| S:17256 E:17261 ||| IN
Ras  ||| S:17261 E:17273 ||| NNP
activation  ||| S:17273 E:17284 ||| NN
of  ||| S:17284 E:17287 ||| IN
TCF  ||| S:17287 E:17291 ||| NNP
alone  ||| S:17291 E:17297 ||| RB
does  ||| S:17297 E:17302 ||| VBZ
not  ||| S:17302 E:17306 ||| RB
result  ||| S:17306 E:17313 ||| VB
in  ||| S:17313 E:17316 ||| IN
maximal  ||| S:17316 E:17324 ||| FW
SRE  ||| S:17324 E:17336 ||| FW
transactivation ||| S:17336 E:17351 ||| FW
,  ||| S:17351 E:17353 ||| ,
but  ||| S:17353 E:17357 ||| CC
instead ||| S:17357 E:17364 ||| RB
,  ||| S:17364 E:17366 ||| ,
is  ||| S:17366 E:17369 ||| VBZ
greatly  ||| S:17369 E:17377 ||| RB
enhanced  ||| S:17377 E:17386 ||| VBN
in  ||| S:17386 E:17389 ||| IN
the  ||| S:17389 E:17401 ||| DT
presence  ||| S:17401 E:17410 ||| NN
of  ||| S:17410 E:17413 ||| IN
p35-C ||| S:17413 E:17418 ||| NNP
/ ||| S:17418 E:17419 ||| NNP
EBPβ ||| S:17419 E:17423 ||| NNP
.  ||| S:17423 E:17433 ||| .
SRF  ||| S:17433 E:17437 ||| NNP
and  ||| S:17437 E:17441 ||| CC
TCF  ||| S:17441 E:17445 ||| NNP
have  ||| S:17445 E:17450 ||| VBP
been  ||| S:17450 E:17455 ||| VBN
shown  ||| S:17455 E:17461 ||| VBN
to  ||| S:17461 E:17464 ||| TO
form  ||| S:17464 E:17469 ||| VB
a  ||| S:17469 E:17471 ||| DT
ternary  ||| S:17471 E:17479 ||| JJ
complex  ||| S:17479 E:17487 ||| NN
at  ||| S:17487 E:17498 ||| IN
the  ||| S:17498 E:17502 ||| DT
SRE  ||| S:17502 E:17515 ||| NNP
in  ||| S:17515 E:17518 ||| IN
vitro  ||| S:17518 E:17524 ||| NN
.  ||| S:17524 E:17526 ||| .
We  ||| S:17526 E:17529 ||| PRP
as  ||| S:17529 E:17532 ||| RB
yet  ||| S:17532 E:17536 ||| RB
have  ||| S:17536 E:17541 ||| VBP
not  ||| S:17541 E:17545 ||| RB
been  ||| S:17545 E:17558 ||| VBN
able  ||| S:17558 E:17563 ||| JJ
to  ||| S:17563 E:17566 ||| TO
observe  ||| S:17566 E:17574 ||| VB
a  ||| S:17574 E:17576 ||| DT
ternary  ||| S:17576 E:17584 ||| JJ
complex  ||| S:17584 E:17592 ||| NN
between  ||| S:17592 E:17600 ||| IN
SRF  ||| S:17600 E:17604 ||| NNP
and  ||| S:17604 E:17616 ||| CC
p35-C ||| S:17616 E:17621 ||| CD
/ ||| S:17621 E:17622 ||| CD
EBPβ  ||| S:17622 E:17627 ||| NN
at  ||| S:17627 E:17630 ||| IN
the  ||| S:17630 E:17634 ||| DT
SRE  ||| S:17634 E:17647 ||| NNP
in  ||| S:17647 E:17650 ||| IN
vitro  ||| S:17650 E:17656 ||| NN
.  ||| S:17656 E:17658 ||| .
The  ||| S:17658 E:17662 ||| DT
mechanisms  ||| S:17662 E:17673 ||| NNS
of  ||| S:17673 E:17676 ||| IN
SRE  ||| S:17676 E:17688 ||| NNP
transactivation  ||| S:17688 E:17704 ||| VBD
described  ||| S:17704 E:17714 ||| VBN
above  ||| S:17714 E:17720 ||| RB
may  ||| S:17720 E:17724 ||| MD
help  ||| S:17724 E:17729 ||| VB
to  ||| S:17729 E:17732 ||| TO
explain  ||| S:17732 E:17740 ||| VB
the  ||| S:17740 E:17753 ||| DT
in  ||| S:17753 E:17756 ||| IN
vitro  ||| S:17756 E:17762 ||| JJ
results ||| S:17762 E:17769 ||| NNS
.  ||| S:17769 E:17771 ||| .
The  ||| S:17771 E:17775 ||| DT
C ||| S:17775 E:17776 ||| $
/ ||| S:17776 E:17777 ||| CD
EBPβ  ||| S:17777 E:17790 ||| JJ
recognition  ||| S:17790 E:17802 ||| NN
site  ||| S:17802 E:17807 ||| NN
in  ||| S:17807 E:17810 ||| IN
the  ||| S:17810 E:17814 ||| DT
SRE  ||| S:17814 E:17818 ||| NNP
is  ||| S:17818 E:17821 ||| VBZ
a  ||| S:17821 E:17823 ||| DT
weak  ||| S:17823 E:17828 ||| JJ
binding  ||| S:17828 E:17836 ||| JJ
site  ||| S:17836 E:17841 ||| NN
[  ||| S:17841 E:17843 ||| -LRB-
25 ||| S:17843 E:17845 ||| CD
] ||| S:17845 E:17846 ||| -RRB-
.  ||| S:17846 E:17856 ||| .
Upon  ||| S:17856 E:17861 ||| IN
activation  ||| S:17861 E:17872 ||| NN
of  ||| S:17872 E:17875 ||| IN
Ras-dependent  ||| S:17875 E:17889 ||| JJ
signaling  ||| S:17889 E:17899 ||| JJ
pathways ||| S:17899 E:17907 ||| NN
,  ||| S:17907 E:17909 ||| ,
the  ||| S:17909 E:17921 ||| DT
presence  ||| S:17921 E:17930 ||| NN
of  ||| S:17930 E:17933 ||| IN
p35-C ||| S:17933 E:17938 ||| CD
/ ||| S:17938 E:17939 ||| CD
EBPβ  ||| S:17939 E:17944 ||| NN
at  ||| S:17944 E:17947 ||| IN
the  ||| S:17947 E:17951 ||| DT
SRE  ||| S:17951 E:17955 ||| NNP
would  ||| S:17955 E:17961 ||| MD
be  ||| S:17961 E:17964 ||| VB
stabilized  ||| S:17964 E:17975 ||| VBN
due  ||| S:17975 E:17987 ||| JJ
to  ||| S:17987 E:17990 ||| TO
its  ||| S:17990 E:17994 ||| PRP$
strong  ||| S:17994 E:18001 ||| JJ
protein-protein  ||| S:18001 E:18017 ||| JJ
interactions  ||| S:18017 E:18030 ||| NNS
not  ||| S:18030 E:18034 ||| RB
only  ||| S:18034 E:18039 ||| RB
with  ||| S:18039 E:18052 ||| IN
SRF ||| S:18052 E:18055 ||| NNP
,  ||| S:18055 E:18057 ||| ,
as  ||| S:18057 E:18060 ||| IN
we  ||| S:18060 E:18063 ||| PRP
have  ||| S:18063 E:18068 ||| VBP
shown  ||| S:18068 E:18074 ||| VBN
previously  ||| S:18074 E:18085 ||| RB
[  ||| S:18085 E:18087 ||| -LRB-
23 ||| S:18087 E:18089 ||| CD
] ||| S:18089 E:18090 ||| -RRB-
,  ||| S:18090 E:18092 ||| ,
but  ||| S:18092 E:18096 ||| CC
also  ||| S:18096 E:18101 ||| RB
with  ||| S:18101 E:18114 ||| IN
Elk-1 ||| S:18114 E:18119 ||| CD
.  ||| S:18119 E:18121 ||| .
It  ||| S:18121 E:18124 ||| PRP
is  ||| S:18124 E:18127 ||| VBZ
possible  ||| S:18127 E:18136 ||| JJ
that  ||| S:18136 E:18141 ||| IN
p35-C ||| S:18141 E:18146 ||| NNP
/ ||| S:18146 E:18147 ||| NNP
EBPβ  ||| S:18147 E:18152 ||| NNP
and  ||| S:18152 E:18156 ||| CC
SRF  ||| S:18156 E:18160 ||| NNP
are  ||| S:18160 E:18164 ||| VBP
not  ||| S:18164 E:18176 ||| RB
sufficient  ||| S:18176 E:18187 ||| JJ
to  ||| S:18187 E:18190 ||| TO
form  ||| S:18190 E:18195 ||| VB
a  ||| S:18195 E:18197 ||| DT
ternary  ||| S:18197 E:18205 ||| JJ
complex  ||| S:18205 E:18213 ||| NN
with  ||| S:18213 E:18218 ||| IN
the  ||| S:18218 E:18222 ||| DT
SRE  ||| S:18222 E:18235 ||| NNP
in  ||| S:18235 E:18238 ||| IN
vitro  ||| S:18238 E:18244 ||| NN
,  ||| S:18244 E:18246 ||| ,
but  ||| S:18246 E:18250 ||| CC
Elk-1  ||| S:18250 E:18256 ||| NNP
may  ||| S:18256 E:18260 ||| MD
also  ||| S:18260 E:18265 ||| RB
be  ||| S:18265 E:18276 ||| VB
necessary ||| S:18276 E:18285 ||| JJ
.  ||| S:18285 E:18287 ||| .
In  ||| S:18287 E:18290 ||| IN
addition ||| S:18290 E:18298 ||| NN
,  ||| S:18298 E:18300 ||| ,
it  ||| S:18300 E:18303 ||| PRP
is  ||| S:18303 E:18306 ||| VBZ
likely  ||| S:18306 E:18313 ||| RB
that  ||| S:18313 E:18318 ||| IN
p35-C ||| S:18318 E:18323 ||| NNP
/ ||| S:18323 E:18324 ||| NNP
EBPβ ||| S:18324 E:18328 ||| NNP
,  ||| S:18328 E:18338 ||| ,
Elk-1 ||| S:18338 E:18343 ||| NNP
,  ||| S:18343 E:18345 ||| ,
or  ||| S:18345 E:18348 ||| CC
both ||| S:18348 E:18352 ||| DT
,  ||| S:18352 E:18354 ||| ,
may  ||| S:18354 E:18358 ||| MD
need  ||| S:18358 E:18363 ||| VB
to  ||| S:18363 E:18366 ||| TO
be  ||| S:18366 E:18369 ||| VB
activated  ||| S:18369 E:18379 ||| VBN
by  ||| S:18379 E:18382 ||| IN
one  ||| S:18382 E:18386 ||| CD
or  ||| S:18386 E:18389 ||| CC
more  ||| S:18389 E:18402 ||| RBR
MAPK  ||| S:18402 E:18407 ||| JJ
family  ||| S:18407 E:18414 ||| NN
members  ||| S:18414 E:18422 ||| NNS
for  ||| S:18422 E:18426 ||| IN
a  ||| S:18426 E:18428 ||| DT
multiprotein  ||| S:18428 E:18441 ||| JJ
complex  ||| S:18441 E:18449 ||| NN
to  ||| S:18449 E:18452 ||| TO
form  ||| S:18452 E:18457 ||| VB
with  ||| S:18457 E:18470 ||| IN
SRF  ||| S:18470 E:18474 ||| NNP
at  ||| S:18474 E:18477 ||| IN
the  ||| S:18477 E:18481 ||| DT
SRE ||| S:18481 E:18484 ||| NNP
.  ||| S:18484 E:18486 ||| .
Further  ||| S:18486 E:18494 ||| JJ
studies  ||| S:18494 E:18502 ||| NNS
utilizing  ||| S:18502 E:18512 ||| VBP
the  ||| S:18512 E:18516 ||| DT
information  ||| S:18516 E:18536 ||| NN
from  ||| S:18536 E:18541 ||| IN
the  ||| S:18541 E:18554 ||| DT
in  ||| S:18554 E:18557 ||| IN
vivo  ||| S:18557 E:18562 ||| JJ
studies  ||| S:18562 E:18570 ||| NNS
performed  ||| S:18570 E:18580 ||| VBD
here  ||| S:18580 E:18585 ||| RB
may  ||| S:18585 E:18597 ||| MD
permit  ||| S:18597 E:18604 ||| VB
us  ||| S:18604 E:18607 ||| PRP
to  ||| S:18607 E:18610 ||| TO
optimize  ||| S:18610 E:18619 ||| VB
the  ||| S:18619 E:18632 ||| DT
in  ||| S:18632 E:18635 ||| IN
vitro  ||| S:18635 E:18641 ||| JJ
conditions  ||| S:18641 E:18652 ||| NNS
necessary  ||| S:18652 E:18662 ||| JJ
to  ||| S:18662 E:18673 ||| TO
observe  ||| S:18673 E:18681 ||| VB
such  ||| S:18681 E:18686 ||| PDT
a  ||| S:18686 E:18688 ||| DT
multiprotein  ||| S:18688 E:18701 ||| JJ
complex ||| S:18701 E:18708 ||| NN
.  ||| S:18708 E:18718 ||| .
We  ||| S:18718 E:18721 ||| PRP
observe  ||| S:18721 E:18729 ||| VBP
a  ||| S:18729 E:18731 ||| DT
direct  ||| S:18731 E:18738 ||| JJ
interaction  ||| S:18738 E:18750 ||| NN
between  ||| S:18750 E:18758 ||| IN
C ||| S:18758 E:18759 ||| NNP
/ ||| S:18759 E:18760 ||| NNP
EBPβ  ||| S:18760 E:18765 ||| NNP
and  ||| S:18765 E:18769 ||| CC
Elk-1  ||| S:18769 E:18783 ||| CD
in  ||| S:18783 E:18786 ||| IN
a  ||| S:18786 E:18788 ||| DT
GST  ||| S:18788 E:18792 ||| FW
pulldown  ||| S:18792 E:18801 ||| FW
assay ||| S:18801 E:18806 ||| FW
.  ||| S:18806 E:18808 ||| .
Another  ||| S:18808 E:18816 ||| DT
ets  ||| S:18816 E:18820 ||| JJ
family  ||| S:18820 E:18827 ||| NN
member ||| S:18827 E:18833 ||| NN
,  ||| S:18833 E:18835 ||| ,
Ets-1 ||| S:18835 E:18840 ||| NNP
,  ||| S:18840 E:18850 ||| ,
has  ||| S:18850 E:18854 ||| VBZ
previously  ||| S:18854 E:18865 ||| RB
been  ||| S:18865 E:18870 ||| VBN
shown  ||| S:18870 E:18876 ||| VBN
to  ||| S:18876 E:18879 ||| TO
interact  ||| S:18879 E:18888 ||| VB
with  ||| S:18888 E:18893 ||| IN
C ||| S:18893 E:18894 ||| $
/ ||| S:18894 E:18895 ||| CD
EBPβ  ||| S:18895 E:18909 ||| NN
in  ||| S:18909 E:18912 ||| IN
vitro  ||| S:18912 E:18918 ||| NNS
[  ||| S:18918 E:18920 ||| -LRB-
26 ||| S:18920 E:18922 ||| CD
] ||| S:18922 E:18923 ||| -RRB-
.  ||| S:18923 E:18925 ||| .
We  ||| S:18925 E:18928 ||| PRP
have  ||| S:18928 E:18933 ||| VBP
not  ||| S:18933 E:18937 ||| RB
directly  ||| S:18937 E:18954 ||| RB
tested  ||| S:18954 E:18961 ||| VBN
the  ||| S:18961 E:18965 ||| DT
ability  ||| S:18965 E:18973 ||| NN
of  ||| S:18973 E:18976 ||| IN
the  ||| S:18976 E:18980 ||| DT
other  ||| S:18980 E:18986 ||| JJ
TCF  ||| S:18986 E:18990 ||| NNP
famlily  ||| S:18990 E:18998 ||| NN
members ||| S:18998 E:19005 ||| NNS
,  ||| S:19005 E:19007 ||| ,
SAP1  ||| S:19007 E:19020 ||| NNP
and  ||| S:19020 E:19024 ||| CC
SAP2 ||| S:19024 E:19028 ||| NNP
/ ||| S:19028 E:19029 ||| NNP
ERP ||| S:19029 E:19032 ||| NNP
/ ||| S:19032 E:19033 ||| NNP
NET ||| S:19033 E:19036 ||| NNP
,  ||| S:19036 E:19038 ||| ,
to  ||| S:19038 E:19041 ||| TO
interact  ||| S:19041 E:19050 ||| VB
with  ||| S:19050 E:19055 ||| IN
C ||| S:19055 E:19056 ||| NNP
/ ||| S:19056 E:19057 ||| NNP
EBPβ ||| S:19057 E:19061 ||| NNP
.  ||| S:19061 E:19063 ||| .
We  ||| S:19063 E:19066 ||| PRP
find  ||| S:19066 E:19071 ||| VBP
that  ||| S:19071 E:19076 ||| IN
the  ||| S:19076 E:19088 ||| DT
domain  ||| S:19088 E:19095 ||| NN
of  ||| S:19095 E:19098 ||| IN
Elk-1  ||| S:19098 E:19104 ||| CD
that  ||| S:19104 E:19109 ||| IN
interacts  ||| S:19109 E:19119 ||| NN
with  ||| S:19119 E:19124 ||| IN
C ||| S:19124 E:19125 ||| NNP
/ ||| S:19125 E:19126 ||| NNP
EBPβ  ||| S:19126 E:19131 ||| NNP
is  ||| S:19131 E:19134 ||| VBZ
the  ||| S:19134 E:19138 ||| DT
ets  ||| S:19138 E:19150 ||| JJ
domain ||| S:19150 E:19156 ||| NN
,  ||| S:19156 E:19158 ||| ,
which  ||| S:19158 E:19164 ||| WDT
is  ||| S:19164 E:19167 ||| VBZ
conserved  ||| S:19167 E:19177 ||| VBN
among  ||| S:19177 E:19183 ||| IN
the  ||| S:19183 E:19187 ||| DT
other  ||| S:19187 E:19193 ||| JJ
TCF  ||| S:19193 E:19197 ||| NNP
family  ||| S:19197 E:19212 ||| NN
members  ||| S:19212 E:19220 ||| NNS
[  ||| S:19220 E:19222 ||| -LRB-
16 ||| S:19222 E:19224 ||| CD
] ||| S:19224 E:19225 ||| -RRB-
.  ||| S:19225 E:19227 ||| .
We  ||| S:19227 E:19230 ||| PRP
would  ||| S:19230 E:19236 ||| MD
therefore  ||| S:19236 E:19246 ||| RB
also  ||| S:19246 E:19251 ||| RB
expect  ||| S:19251 E:19258 ||| VB
SAP1  ||| S:19258 E:19263 ||| NNP
and  ||| S:19263 E:19275 ||| CC
SAP2 ||| S:19275 E:19279 ||| NNP
/ ||| S:19279 E:19280 ||| NNP
ERP ||| S:19280 E:19283 ||| NNP
/ ||| S:19283 E:19284 ||| NNP
NET  ||| S:19284 E:19288 ||| NNP
to  ||| S:19288 E:19291 ||| TO
interact  ||| S:19291 E:19300 ||| VB
with  ||| S:19300 E:19305 ||| IN
C ||| S:19305 E:19306 ||| NNP
/ ||| S:19306 E:19307 ||| NNP
EBPβ ||| S:19307 E:19311 ||| NNP
.  ||| S:19311 E:19313 ||| .
Interestingly ||| S:19313 E:19326 ||| RB
,  ||| S:19326 E:19328 ||| ,
the  ||| S:19328 E:19341 ||| DT
in  ||| S:19341 E:19344 ||| IN
vivo  ||| S:19344 E:19349 ||| JJ
interaction  ||| S:19349 E:19361 ||| NN
of  ||| S:19361 E:19364 ||| IN
Elk-1  ||| S:19364 E:19370 ||| NNP
and  ||| S:19370 E:19382 ||| CC
C ||| S:19382 E:19383 ||| NNP
/ ||| S:19383 E:19384 ||| NNP
EBPβ  ||| S:19384 E:19389 ||| NNP
is  ||| S:19389 E:19392 ||| VBZ
dependent  ||| S:19392 E:19402 ||| JJ
on  ||| S:19402 E:19405 ||| IN
activation  ||| S:19405 E:19416 ||| NN
of  ||| S:19416 E:19419 ||| IN
Ras-dependent  ||| S:19419 E:19441 ||| JJ
signaling  ||| S:19441 E:19451 ||| JJ
pathways ||| S:19451 E:19459 ||| NN
.  ||| S:19459 E:19461 ||| .
The  ||| S:19461 E:19465 ||| DT
target ||| S:19465 E:19471 ||| NN
( ||| S:19471 E:19472 ||| -LRB-
s ||| S:19472 E:19473 ||| LS
)  ||| S:19473 E:19475 ||| -RRB-
of  ||| S:19475 E:19478 ||| IN
the  ||| S:19478 E:19482 ||| DT
Ras  ||| S:19482 E:19486 ||| JJ
signaling  ||| S:19486 E:19504 ||| JJ
pathway  ||| S:19504 E:19512 ||| NN
is  ||| S:19512 E:19515 ||| VBZ
as  ||| S:19515 E:19518 ||| RB
yet  ||| S:19518 E:19522 ||| RB
unknown ||| S:19522 E:19529 ||| JJ
.  ||| S:19529 E:19531 ||| .
It  ||| S:19531 E:19534 ||| PRP
has  ||| S:19534 E:19538 ||| VBZ
been  ||| S:19538 E:19543 ||| VBN
shown  ||| S:19543 E:19549 ||| VBN
that  ||| S:19549 E:19562 ||| IN
transfection  ||| S:19562 E:19575 ||| NN
of  ||| S:19575 E:19578 ||| IN
activated  ||| S:19578 E:19588 ||| JJ
Ras  ||| S:19588 E:19592 ||| JJ
results  ||| S:19592 E:19600 ||| NNS
in  ||| S:19600 E:19603 ||| IN
phosphorylation  ||| S:19603 E:19619 ||| NN
of  ||| S:19619 E:19630 ||| IN
Thr235  ||| S:19630 E:19637 ||| NNP
( ||| S:19637 E:19638 ||| -LRB-
numbering  ||| S:19638 E:19648 ||| NN
for  ||| S:19648 E:19652 ||| IN
human  ||| S:19652 E:19658 ||| JJ
protein ||| S:19658 E:19665 ||| NN
)  ||| S:19665 E:19667 ||| -RRB-
in  ||| S:19667 E:19670 ||| IN
the  ||| S:19670 E:19674 ||| DT
C-terminal  ||| S:19674 E:19693 ||| JJ
domain  ||| S:19693 E:19700 ||| NN
of  ||| S:19700 E:19703 ||| IN
C ||| S:19703 E:19704 ||| NNP
/ ||| S:19704 E:19705 ||| NNP
EBPβ ||| S:19705 E:19709 ||| NNP
,  ||| S:19709 E:19711 ||| ,
and  ||| S:19711 E:19715 ||| CC
that  ||| S:19715 E:19720 ||| IN
Thr235  ||| S:19720 E:19727 ||| NNP
could  ||| S:19727 E:19733 ||| MD
be  ||| S:19733 E:19736 ||| VB
phosphorylated  ||| S:19736 E:19759 ||| VBN
by  ||| S:19759 E:19762 ||| IN
a  ||| S:19762 E:19764 ||| DT
partially  ||| S:19764 E:19774 ||| FW
purified  ||| S:19774 E:19783 ||| FW
MAPK  ||| S:19783 E:19788 ||| FW
preparation  ||| S:19788 E:19809 ||| FW
in  ||| S:19809 E:19812 ||| FW
vitro  ||| S:19812 E:19818 ||| FW
[  ||| S:19818 E:19820 ||| -LRB-
19 ||| S:19820 E:19822 ||| CD
] ||| S:19822 E:19823 ||| -RRB-
.  ||| S:19823 E:19825 ||| .
We  ||| S:19825 E:19828 ||| PRP
have  ||| S:19828 E:19833 ||| VBP
also  ||| S:19833 E:19838 ||| RB
shown  ||| S:19838 E:19852 ||| VBN
that  ||| S:19852 E:19857 ||| IN
this  ||| S:19857 E:19862 ||| DT
same  ||| S:19862 E:19867 ||| JJ
residue  ||| S:19867 E:19875 ||| NN
is  ||| S:19875 E:19878 ||| VBZ
necessary  ||| S:19878 E:19888 ||| JJ
for  ||| S:19888 E:19892 ||| IN
Ras  ||| S:19892 E:19896 ||| NNP
stimultion  ||| S:19896 E:19907 ||| NN
of  ||| S:19907 E:19918 ||| IN
the  ||| S:19918 E:19922 ||| DT
interaction  ||| S:19922 E:19934 ||| NN
between  ||| S:19934 E:19942 ||| IN
C ||| S:19942 E:19943 ||| NNP
/ ||| S:19943 E:19944 ||| NNP
EBPβ  ||| S:19944 E:19949 ||| NNP
and  ||| S:19949 E:19953 ||| CC
SRF ||| S:19953 E:19956 ||| NNP
.  ||| S:19956 E:19958 ||| .
Therefore ||| S:19958 E:19967 ||| RB
,  ||| S:19967 E:19969 ||| ,
it  ||| S:19969 E:19972 ||| PRP
will  ||| S:19972 E:19985 ||| MD
be  ||| S:19985 E:19988 ||| VB
interesting  ||| S:19988 E:20000 ||| JJ
to  ||| S:20000 E:20003 ||| TO
determine  ||| S:20003 E:20013 ||| VB
if  ||| S:20013 E:20016 ||| IN
this  ||| S:20016 E:20021 ||| DT
site  ||| S:20021 E:20026 ||| NN
is  ||| S:20026 E:20029 ||| VBZ
also  ||| S:20029 E:20034 ||| RB
critical  ||| S:20034 E:20051 ||| JJ
for  ||| S:20051 E:20055 ||| IN
stimulation  ||| S:20055 E:20067 ||| NN
of  ||| S:20067 E:20070 ||| IN
the  ||| S:20070 E:20074 ||| DT
interaction  ||| S:20074 E:20086 ||| NN
between  ||| S:20086 E:20094 ||| IN
C ||| S:20094 E:20095 ||| NNP
/ ||| S:20095 E:20096 ||| NNP
EBPβ  ||| S:20096 E:20101 ||| NNP
and  ||| S:20101 E:20113 ||| CC
Elk-1 ||| S:20113 E:20118 ||| NNP
.  ||| S:20118 E:20120 ||| .
Elk-1  ||| S:20120 E:20126 ||| NNP
also  ||| S:20126 E:20131 ||| RB
has  ||| S:20131 E:20135 ||| VBZ
several  ||| S:20135 E:20143 ||| JJ
MAPK  ||| S:20143 E:20148 ||| NN
sites  ||| S:20148 E:20154 ||| NNS
in  ||| S:20154 E:20157 ||| IN
its  ||| S:20157 E:20161 ||| PRP$
C-terminal  ||| S:20161 E:20180 ||| JJ
domain ||| S:20180 E:20186 ||| NN
,  ||| S:20186 E:20188 ||| ,
and  ||| S:20188 E:20192 ||| CC
therefore  ||| S:20192 E:20202 ||| RB
this  ||| S:20202 E:20207 ||| DT
region  ||| S:20207 E:20214 ||| NN
could  ||| S:20214 E:20220 ||| MD
also  ||| S:20220 E:20225 ||| RB
be  ||| S:20225 E:20228 ||| VB
a  ||| S:20228 E:20230 ||| DT
target  ||| S:20230 E:20245 ||| NN
for  ||| S:20245 E:20249 ||| IN
Ras ||| S:20249 E:20252 ||| NNP
.  ||| S:20252 E:20262 ||| .
We  ||| S:20262 E:20265 ||| PRP
are  ||| S:20265 E:20269 ||| VBP
currently  ||| S:20269 E:20279 ||| RB
investigating  ||| S:20279 E:20293 ||| VBG
the  ||| S:20293 E:20297 ||| DT
mechanism  ||| S:20297 E:20307 ||| NN
of  ||| S:20307 E:20310 ||| IN
the  ||| S:20310 E:20322 ||| DT
observed  ||| S:20322 E:20331 ||| JJ
synergy  ||| S:20331 E:20339 ||| NN
between  ||| S:20339 E:20347 ||| IN
Elk-1  ||| S:20347 E:20353 ||| NNP
and  ||| S:20353 E:20357 ||| CC
p35-C ||| S:20357 E:20362 ||| NNP
/ ||| S:20362 E:20363 ||| NNP
EBPβ ||| S:20363 E:20367 ||| NNP
.  ||| S:20367 E:20369 ||| .
We  ||| S:20369 E:20372 ||| PRP
have  ||| S:20372 E:20385 ||| VBP
shown  ||| S:20385 E:20391 ||| VBN
that  ||| S:20391 E:20396 ||| IN
C ||| S:20396 E:20397 ||| $
/ ||| S:20397 E:20398 ||| CD
EBPβ  ||| S:20398 E:20403 ||| JJ
interacts  ||| S:20403 E:20413 ||| NN
with  ||| S:20413 E:20418 ||| IN
the  ||| S:20418 E:20422 ||| DT
A-box  ||| S:20422 E:20428 ||| JJ
of  ||| S:20428 E:20431 ||| IN
Elk-1 ||| S:20431 E:20436 ||| NNP
,  ||| S:20436 E:20438 ||| ,
while  ||| S:20438 E:20452 ||| IN
SRF  ||| S:20452 E:20456 ||| NNP
has  ||| S:20456 E:20460 ||| VBZ
previously  ||| S:20460 E:20471 ||| RB
been  ||| S:20471 E:20476 ||| VBN
shown  ||| S:20476 E:20482 ||| VBN
to  ||| S:20482 E:20485 ||| TO
interact  ||| S:20485 E:20494 ||| VB
with  ||| S:20494 E:20499 ||| IN
the  ||| S:20499 E:20503 ||| DT
B-box  ||| S:20503 E:20509 ||| JJ
[  ||| S:20509 E:20519 ||| -LRB-
16 ||| S:20519 E:20521 ||| CD
] ||| S:20521 E:20522 ||| -RRB-
.  ||| S:20522 E:20524 ||| .
Therefore ||| S:20524 E:20533 ||| RB
,  ||| S:20533 E:20535 ||| ,
C ||| S:20535 E:20536 ||| NNP
/ ||| S:20536 E:20537 ||| NNP
EBPβ  ||| S:20537 E:20542 ||| NNP
and  ||| S:20542 E:20546 ||| CC
SRF  ||| S:20546 E:20550 ||| NNP
interact  ||| S:20550 E:20559 ||| NN
with  ||| S:20559 E:20564 ||| IN
two  ||| S:20564 E:20568 ||| CD
distinct  ||| S:20568 E:20585 ||| JJ
domains  ||| S:20585 E:20593 ||| NN
of  ||| S:20593 E:20596 ||| IN
Elk-1 ||| S:20596 E:20601 ||| NNP
,  ||| S:20601 E:20603 ||| ,
as  ||| S:20603 E:20606 ||| RB
well  ||| S:20606 E:20611 ||| RB
as  ||| S:20611 E:20614 ||| RB
with  ||| S:20614 E:20619 ||| IN
each  ||| S:20619 E:20624 ||| DT
other ||| S:20624 E:20629 ||| JJ
,  ||| S:20629 E:20631 ||| ,
which  ||| S:20631 E:20637 ||| WDT
could  ||| S:20637 E:20651 ||| MD
allow  ||| S:20651 E:20657 ||| VB
formation  ||| S:20657 E:20667 ||| NN
of  ||| S:20667 E:20670 ||| IN
a  ||| S:20670 E:20672 ||| DT
complex  ||| S:20672 E:20680 ||| NN
of  ||| S:20680 E:20683 ||| IN
the  ||| S:20683 E:20687 ||| DT
three  ||| S:20687 E:20693 ||| CD
transcription  ||| S:20693 E:20715 ||| CD
factors ||| S:20715 E:20722 ||| NNS
.  ||| S:20722 E:20724 ||| .
This  ||| S:20724 E:20729 ||| DT
would  ||| S:20729 E:20735 ||| MD
create  ||| S:20735 E:20742 ||| VB
an  ||| S:20742 E:20745 ||| DT
active  ||| S:20745 E:20752 ||| JJ
transcriptional  ||| S:20752 E:20776 ||| JJ
complex  ||| S:20776 E:20784 ||| NN
at  ||| S:20784 E:20787 ||| IN
the  ||| S:20787 E:20791 ||| DT
SRE  ||| S:20791 E:20795 ||| NNP
and  ||| S:20795 E:20799 ||| CC
result  ||| S:20799 E:20806 ||| NN
in  ||| S:20806 E:20809 ||| IN
enhanced  ||| S:20809 E:20818 ||| JJ
transactivation ||| S:20818 E:20833 ||| NN
.  ||| S:20833 E:20843 ||| .
It  ||| S:20843 E:20846 ||| PRP
is  ||| S:20846 E:20849 ||| VBZ
possible  ||| S:20849 E:20858 ||| JJ
that  ||| S:20858 E:20863 ||| IN
the  ||| S:20863 E:20867 ||| DT
p35-C ||| S:20867 E:20872 ||| CD
/ ||| S:20872 E:20873 ||| CD
EBPβ-SRF-Elk-1  ||| S:20873 E:20888 ||| CD
complex  ||| S:20888 E:20896 ||| NN
could  ||| S:20896 E:20910 ||| MD
interact  ||| S:20910 E:20919 ||| VB
more  ||| S:20919 E:20924 ||| RBR
strongly  ||| S:20924 E:20933 ||| RB
with  ||| S:20933 E:20938 ||| IN
coactivators  ||| S:20938 E:20951 ||| NN
and ||| S:20951 E:20954 ||| CC
/ ||| S:20954 E:20955 ||| NNP
or  ||| S:20955 E:20958 ||| CC
the  ||| S:20958 E:20962 ||| DT
basal  ||| S:20962 E:20976 ||| JJ
transcriptional  ||| S:20976 E:20992 ||| JJ
machinery  ||| S:20992 E:21002 ||| NN
than  ||| S:21002 E:21007 ||| IN
each  ||| S:21007 E:21012 ||| DT
individual  ||| S:21012 E:21031 ||| JJ
transcription  ||| S:21031 E:21045 ||| JJ
factor ||| S:21045 E:21051 ||| NN
.  ||| S:21051 E:21053 ||| .
It  ||| S:21053 E:21056 ||| PRP
has  ||| S:21056 E:21060 ||| VBZ
been  ||| S:21060 E:21065 ||| VBN
shown  ||| S:21065 E:21071 ||| VBN
that  ||| S:21071 E:21076 ||| IN
SRF ||| S:21076 E:21079 ||| NNP
,  ||| S:21079 E:21081 ||| ,
TCF ||| S:21081 E:21084 ||| NNP
,  ||| S:21084 E:21086 ||| ,
and  ||| S:21086 E:21098 ||| CC
C ||| S:21098 E:21099 ||| NNP
/ ||| S:21099 E:21100 ||| NNP
EBPβ  ||| S:21100 E:21105 ||| NNP
can  ||| S:21105 E:21109 ||| MD
all  ||| S:21109 E:21113 ||| RB
interact  ||| S:21113 E:21122 ||| VBN
with  ||| S:21122 E:21127 ||| IN
components  ||| S:21127 E:21138 ||| NNS
of  ||| S:21138 E:21141 ||| IN
transcriptional  ||| S:21141 E:21165 ||| JJ
machinery  ||| S:21165 E:21175 ||| NN
such  ||| S:21175 E:21180 ||| JJ
as  ||| S:21180 E:21183 ||| IN
p300 ||| S:21183 E:21187 ||| NNP
/ ||| S:21187 E:21188 ||| NNP
CBP ||| S:21188 E:21191 ||| NNP
,  ||| S:21191 E:21193 ||| ,
SRC-1 ||| S:21193 E:21198 ||| NNP
,  ||| S:21198 E:21200 ||| ,
and  ||| S:21200 E:21204 ||| CC
TFII-I  ||| S:21204 E:21211 ||| NNP
[  ||| S:21211 E:21213 ||| -LRB-
27 ||| S:21213 E:21215 ||| CD
,  ||| S:21215 E:21217 ||| ,
28 ||| S:21217 E:21219 ||| CD
,  ||| S:21219 E:21221 ||| ,
29 ||| S:21221 E:21223 ||| CD
,  ||| S:21223 E:21233 ||| ,
30 ||| S:21233 E:21235 ||| CD
] ||| S:21235 E:21236 ||| -RRB-
.  ||| S:21236 E:21238 ||| .
There  ||| S:21238 E:21244 ||| EX
is  ||| S:21244 E:21247 ||| VBZ
most  ||| S:21247 E:21252 ||| RBS
likely  ||| S:21252 E:21259 ||| JJ
a  ||| S:21259 E:21261 ||| DT
large  ||| S:21261 E:21267 ||| JJ
protein  ||| S:21267 E:21275 ||| NN
complex  ||| S:21275 E:21283 ||| NN
assembled  ||| S:21283 E:21301 ||| VBN
at  ||| S:21301 E:21304 ||| IN
the  ||| S:21304 E:21308 ||| DT
SRE  ||| S:21308 E:21312 ||| NN
composed  ||| S:21312 E:21321 ||| VBN
of  ||| S:21321 E:21324 ||| IN
regulated  ||| S:21324 E:21334 ||| JJ
transcription  ||| S:21334 E:21348 ||| JJ
factors ||| S:21348 E:21355 ||| NNS
,  ||| S:21355 E:21365 ||| ,
coactivators ||| S:21365 E:21377 ||| NN
,  ||| S:21377 E:21379 ||| ,
and  ||| S:21379 E:21383 ||| CC
the  ||| S:21383 E:21387 ||| DT
basal  ||| S:21387 E:21393 ||| JJ
transcriptional  ||| S:21393 E:21409 ||| JJ
machinery ||| S:21409 E:21418 ||| NN
,  ||| S:21418 E:21428 ||| ,
resulting  ||| S:21428 E:21438 ||| VBG
in  ||| S:21438 E:21441 ||| IN
rapid  ||| S:21441 E:21447 ||| JJ
transcription  ||| S:21447 E:21461 ||| NN
of  ||| S:21461 E:21464 ||| IN
the  ||| S:21464 E:21477 ||| DT
c-fos  ||| S:21477 E:21483 ||| JJ
gene  ||| S:21483 E:21488 ||| NN
in  ||| S:21488 E:21491 ||| IN
response  ||| S:21491 E:21500 ||| NN
to  ||| S:21500 E:21503 ||| TO
mitogenic  ||| S:21503 E:21521 ||| VB
stimulation ||| S:21521 E:21532 ||| NN
.  ||| S:21532 E:21556 ||| .
Conclusions  ||| S:21556 E:21576 ||| NNS
This  ||| S:21576 E:21581 ||| DT
report  ||| S:21581 E:21588 ||| NN
demonstrates  ||| S:21588 E:21601 ||| VBZ
a  ||| S:21601 E:21603 ||| DT
new  ||| S:21603 E:21607 ||| JJ
model  ||| S:21607 E:21613 ||| NN
for  ||| S:21613 E:21626 ||| IN
c-fos  ||| S:21626 E:21632 ||| NNP
SRE  ||| S:21632 E:21636 ||| NNP
activation  ||| S:21636 E:21647 ||| NN
in  ||| S:21647 E:21650 ||| IN
response  ||| S:21650 E:21659 ||| NN
to  ||| S:21659 E:21670 ||| TO
Ras-dependent  ||| S:21670 E:21684 ||| JJ
signaling  ||| S:21684 E:21694 ||| JJ
pathways ||| S:21694 E:21702 ||| NN
.  ||| S:21702 E:21704 ||| .
We  ||| S:21704 E:21707 ||| PRP
show  ||| S:21707 E:21712 ||| VBP
that  ||| S:21712 E:21717 ||| IN
SRF ||| S:21717 E:21720 ||| NNP
,  ||| S:21720 E:21722 ||| ,
Elk-1 ||| S:21722 E:21727 ||| NNP
,  ||| S:21727 E:21737 ||| ,
and  ||| S:21737 E:21741 ||| CC
p35-C ||| S:21741 E:21746 ||| CD
/ ||| S:21746 E:21747 ||| CD
EBPβ  ||| S:21747 E:21752 ||| NNS
are  ||| S:21752 E:21756 ||| VBP
all  ||| S:21756 E:21760 ||| DT
necessary  ||| S:21760 E:21770 ||| JJ
for  ||| S:21770 E:21774 ||| IN
maximal  ||| S:21774 E:21782 ||| JJ
Ras-stimulated  ||| S:21782 E:21805 ||| JJ
transactivation  ||| S:21805 E:21821 ||| NN
of  ||| S:21821 E:21824 ||| IN
the  ||| S:21824 E:21828 ||| DT
SRE ||| S:21828 E:21831 ||| NNP
.  ||| S:21831 E:21855 ||| .
Materials  ||| S:21855 E:21865 ||| NNS
and  ||| S:21865 E:21869 ||| CC
Methods  ||| S:21869 E:21896 ||| NNP
Cell  ||| S:21896 E:21901 ||| NNP
Culture  ||| S:21901 E:21909 ||| NNP
and  ||| S:21909 E:21913 ||| CC
Transfections  ||| S:21913 E:21937 ||| NNP
NIH  ||| S:21937 E:21941 ||| NNP
3T3  ||| S:21941 E:21945 ||| FW
fibroblasts  ||| S:21945 E:21957 ||| FW
( ||| S:21957 E:21958 ||| -LRB-
from  ||| S:21958 E:21963 ||| IN
the  ||| S:21963 E:21967 ||| DT
American  ||| S:21967 E:21976 ||| NNP
Type  ||| S:21976 E:21981 ||| NNP
Culture  ||| S:21981 E:21999 ||| NNP
Collection ||| S:21999 E:22009 ||| NNP
)  ||| S:22009 E:22011 ||| -RRB-
and  ||| S:22011 E:22015 ||| CC
COS-7  ||| S:22015 E:22021 ||| CD
cells  ||| S:22021 E:22027 ||| NNS
( ||| S:22027 E:22028 ||| -LRB-
kindly  ||| S:22028 E:22035 ||| RB
provided  ||| S:22035 E:22044 ||| VBN
by  ||| S:22044 E:22047 ||| IN
Dr.  ||| S:22047 E:22051 ||| NNP
S.  ||| S:22051 E:22064 ||| NNP
Hann ||| S:22064 E:22068 ||| NNP
,  ||| S:22068 E:22070 ||| ,
Vanderbilt  ||| S:22070 E:22081 ||| NNP
University ||| S:22081 E:22091 ||| NNP
)  ||| S:22091 E:22093 ||| -RRB-
were  ||| S:22093 E:22098 ||| VBD
grown  ||| S:22098 E:22104 ||| VBN
in  ||| S:22104 E:22107 ||| IN
Dulbecco ||| S:22107 E:22115 ||| NNP
's  ||| S:22115 E:22128 ||| POS
Modified  ||| S:22128 E:22137 ||| NNP
Eagle  ||| S:22137 E:22143 ||| NNP
Medium  ||| S:22143 E:22150 ||| NNP
( ||| S:22150 E:22151 ||| -LRB-
DMEM ||| S:22151 E:22155 ||| NNP
)  ||| S:22155 E:22157 ||| -RRB-
with  ||| S:22157 E:22162 ||| IN
10 ||| S:22162 E:22164 ||| CD
%  ||| S:22164 E:22166 ||| NN
calf  ||| S:22166 E:22171 ||| NN
serum  ||| S:22171 E:22187 ||| NNS
( ||| S:22187 E:22188 ||| -LRB-
Colorado  ||| S:22188 E:22197 ||| NNP
Serum  ||| S:22197 E:22203 ||| NNP
Company ||| S:22203 E:22210 ||| NNP
) ||| S:22210 E:22211 ||| -RRB-
,  ||| S:22211 E:22213 ||| ,
0.22 ||| S:22213 E:22217 ||| CD
%  ||| S:22217 E:22219 ||| NN
sodium  ||| S:22219 E:22226 ||| NN
bicarbonate ||| S:22226 E:22237 ||| NN
,  ||| S:22237 E:22239 ||| ,
4  ||| S:22239 E:22241 ||| CD
mM  ||| S:22241 E:22254 ||| JJ
L-glutamine ||| S:22254 E:22265 ||| NN
,  ||| S:22265 E:22267 ||| ,
25  ||| S:22267 E:22270 ||| CD
U  ||| S:22270 E:22272 ||| NNP
of  ||| S:22272 E:22275 ||| IN
penicillin  ||| S:22275 E:22286 ||| JJ
G  ||| S:22286 E:22288 ||| NNP
sodium  ||| S:22288 E:22295 ||| FW
per  ||| S:22295 E:22299 ||| FW
mL ||| S:22299 E:22301 ||| FW
,  ||| S:22301 E:22303 ||| ,
and  ||| S:22303 E:22307 ||| CC
25  ||| S:22307 E:22320 ||| CD
mg  ||| S:22320 E:22323 ||| NN
of  ||| S:22323 E:22326 ||| IN
streptomycin  ||| S:22326 E:22339 ||| FW
per  ||| S:22339 E:22343 ||| FW
mL ||| S:22343 E:22345 ||| FW
.  ||| S:22345 E:22357 ||| .
COS-7  ||| S:22357 E:22363 ||| NNP
cell  ||| S:22363 E:22368 ||| NN
transfections  ||| S:22368 E:22382 ||| NNS
were  ||| S:22382 E:22387 ||| VBD
performed  ||| S:22387 E:22397 ||| VBN
by  ||| S:22397 E:22400 ||| IN
the  ||| S:22400 E:22404 ||| DT
calcium  ||| S:22404 E:22422 ||| JJ
phosphate  ||| S:22422 E:22432 ||| NNS
( ||| S:22432 E:22433 ||| -LRB-
CaPO  ||| S:22433 E:22449 ||| NNP
4  ||| S:22449 E:22451 ||| CD
)  ||| S:22451 E:22453 ||| -RRB-
technique  ||| S:22453 E:22463 ||| NN
[  ||| S:22463 E:22465 ||| -LRB-
31 ||| S:22465 E:22467 ||| CD
] ||| S:22467 E:22468 ||| -RRB-
.  ||| S:22468 E:22470 ||| .
Cells  ||| S:22470 E:22476 ||| NNS
at  ||| S:22476 E:22479 ||| IN
60-70 ||| S:22479 E:22484 ||| CD
%  ||| S:22484 E:22496 ||| NN
confluence  ||| S:22496 E:22507 ||| NN
were  ||| S:22507 E:22512 ||| VBD
exposed  ||| S:22512 E:22520 ||| VBN
to  ||| S:22520 E:22523 ||| TO
the  ||| S:22523 E:22527 ||| DT
CaPO  ||| S:22527 E:22543 ||| JJ
4  ||| S:22543 E:22545 ||| CD
-DNA  ||| S:22545 E:22550 ||| JJ
precipitate  ||| S:22550 E:22562 ||| NN
for  ||| S:22562 E:22566 ||| IN
8  ||| S:22566 E:22568 ||| CD
h ||| S:22568 E:22569 ||| NNS
.  ||| S:22569 E:22571 ||| .
The  ||| S:22571 E:22575 ||| DT
medium  ||| S:22575 E:22592 ||| NN
was  ||| S:22592 E:22596 ||| VBD
removed  ||| S:22596 E:22604 ||| VBN
and  ||| S:22604 E:22608 ||| CC
replaced  ||| S:22608 E:22617 ||| VBN
with  ||| S:22617 E:22622 ||| IN
complete  ||| S:22622 E:22631 ||| JJ
medium  ||| S:22631 E:22638 ||| NN
for  ||| S:22638 E:22642 ||| IN
36  ||| S:22642 E:22645 ||| CD
h  ||| S:22645 E:22657 ||| NN
before  ||| S:22657 E:22664 ||| IN
harvesting ||| S:22664 E:22674 ||| NN
.  ||| S:22674 E:22676 ||| .
NIH  ||| S:22676 E:22680 ||| NNP
3T3  ||| S:22680 E:22684 ||| NNP
transfections  ||| S:22684 E:22698 ||| NN
were  ||| S:22698 E:22703 ||| VBD
performed  ||| S:22703 E:22723 ||| VBN
using  ||| S:22723 E:22729 ||| VBG
NovaFector  ||| S:22729 E:22740 ||| JJ
( ||| S:22740 E:22741 ||| -LRB-
Venn  ||| S:22741 E:22746 ||| NNP
Nova ||| S:22746 E:22750 ||| NNP
)  ||| S:22750 E:22752 ||| -RRB-
or  ||| S:22752 E:22755 ||| CC
Trans-IT  ||| S:22755 E:22764 ||| NNP
LT1  ||| S:22764 E:22768 ||| NNP
( ||| S:22768 E:22769 ||| -LRB-
PanVera ||| S:22769 E:22776 ||| NNP
)  ||| S:22776 E:22778 ||| -RRB-
as  ||| S:22778 E:22791 ||| RB
described  ||| S:22791 E:22801 ||| VBN
by  ||| S:22801 E:22804 ||| IN
the  ||| S:22804 E:22808 ||| DT
manufacturers ||| S:22808 E:22821 ||| NNS
.  ||| S:22821 E:22833 ||| .
For  ||| S:22833 E:22837 ||| IN
NovaFector  ||| S:22837 E:22848 ||| JJ
transfections ||| S:22848 E:22861 ||| NN
,  ||| S:22861 E:22863 ||| ,
a  ||| S:22863 E:22865 ||| DT
6 ||| S:22865 E:22866 ||| CD
: ||| S:22866 E:22867 ||| :
1  ||| S:22867 E:22869 ||| CD
ratio  ||| S:22869 E:22875 ||| NN
of  ||| S:22875 E:22888 ||| IN
NovaFector ||| S:22888 E:22898 ||| JJ
: ||| S:22898 E:22899 ||| :
DNA  ||| S:22899 E:22903 ||| NNP
was  ||| S:22903 E:22907 ||| VBD
used  ||| S:22907 E:22912 ||| VBN
for  ||| S:22912 E:22916 ||| IN
each  ||| S:22916 E:22921 ||| DT
transfection ||| S:22921 E:22933 ||| NN
.  ||| S:22933 E:22935 ||| .
Cells  ||| S:22935 E:22941 ||| NNS
at  ||| S:22941 E:22954 ||| IN
60-70 ||| S:22954 E:22959 ||| CD
%  ||| S:22959 E:22961 ||| NN
confluence  ||| S:22961 E:22972 ||| NN
were  ||| S:22972 E:22977 ||| VBD
exposed  ||| S:22977 E:22985 ||| VBN
to  ||| S:22985 E:22988 ||| TO
the  ||| S:22988 E:22992 ||| DT
NovaFector ||| S:22992 E:23002 ||| JJ
: ||| S:23002 E:23003 ||| :
DNA  ||| S:23003 E:23017 ||| NNP
complex  ||| S:23017 E:23025 ||| NN
for  ||| S:23025 E:23029 ||| IN
6-7  ||| S:23029 E:23033 ||| CD
h  ||| S:23033 E:23035 ||| NN
in  ||| S:23035 E:23038 ||| IN
serum  ||| S:23038 E:23044 ||| NN
and  ||| S:23044 E:23048 ||| CC
antibiotic  ||| S:23048 E:23059 ||| JJ
free  ||| S:23059 E:23064 ||| JJ
medium ||| S:23064 E:23070 ||| NN
.  ||| S:23070 E:23082 ||| .
After  ||| S:23082 E:23088 ||| IN
the  ||| S:23088 E:23092 ||| DT
incubation ||| S:23092 E:23102 ||| NN
,  ||| S:23102 E:23104 ||| ,
an  ||| S:23104 E:23107 ||| DT
equal  ||| S:23107 E:23113 ||| JJ
volume  ||| S:23113 E:23120 ||| NN
of  ||| S:23120 E:23123 ||| IN
DMEM  ||| S:23123 E:23128 ||| NNP
containing  ||| S:23128 E:23149 ||| VBG
20 ||| S:23149 E:23151 ||| CD
%  ||| S:23151 E:23153 ||| NN
calf  ||| S:23153 E:23158 ||| NN
serum  ||| S:23158 E:23164 ||| NNS
was  ||| S:23164 E:23168 ||| VBD
added  ||| S:23168 E:23174 ||| VBN
for  ||| S:23174 E:23178 ||| IN
24  ||| S:23178 E:23181 ||| CD
h ||| S:23181 E:23182 ||| NN
,  ||| S:23182 E:23184 ||| ,
bringing  ||| S:23184 E:23193 ||| VBG
the  ||| S:23193 E:23197 ||| DT
final  ||| S:23197 E:23213 ||| JJ
concentration  ||| S:23213 E:23227 ||| NN
of  ||| S:23227 E:23230 ||| IN
calf  ||| S:23230 E:23235 ||| JJ
serum  ||| S:23235 E:23241 ||| NN
to  ||| S:23241 E:23244 ||| TO
10 ||| S:23244 E:23246 ||| CD
% ||| S:23246 E:23247 ||| NN
.  ||| S:23247 E:23249 ||| .
Cells  ||| S:23249 E:23255 ||| NNS
were  ||| S:23255 E:23260 ||| VBD
then  ||| S:23260 E:23265 ||| RB
serum  ||| S:23265 E:23281 ||| VB
deprived  ||| S:23281 E:23290 ||| VBN
for  ||| S:23290 E:23294 ||| IN
36-40  ||| S:23294 E:23300 ||| CD
h  ||| S:23300 E:23302 ||| NN
in  ||| S:23302 E:23305 ||| IN
DMEM  ||| S:23305 E:23310 ||| NNP
supplemented  ||| S:23310 E:23323 ||| NN
as  ||| S:23323 E:23326 ||| IN
above  ||| S:23326 E:23332 ||| JJ
except  ||| S:23332 E:23349 ||| IN
containing  ||| S:23349 E:23360 ||| VBG
0.5 ||| S:23360 E:23363 ||| CD
%  ||| S:23363 E:23365 ||| NN
calf  ||| S:23365 E:23370 ||| NN
serum  ||| S:23370 E:23376 ||| NN
before  ||| S:23376 E:23383 ||| IN
harvesting ||| S:23383 E:23393 ||| NN
.  ||| S:23393 E:23395 ||| .
For  ||| S:23395 E:23409 ||| IN
TransIT-LT1  ||| S:23409 E:23421 ||| CD
transfections ||| S:23421 E:23434 ||| NN
,  ||| S:23434 E:23436 ||| ,
a  ||| S:23436 E:23438 ||| DT
6 ||| S:23438 E:23439 ||| CD
: ||| S:23439 E:23440 ||| :
1  ||| S:23440 E:23442 ||| CD
ratio  ||| S:23442 E:23448 ||| NN
of  ||| S:23448 E:23451 ||| IN
TransIT-LT1 ||| S:23451 E:23462 ||| CD
: ||| S:23462 E:23463 ||| :
DNA  ||| S:23463 E:23477 ||| NNP
was  ||| S:23477 E:23481 ||| VBD
used  ||| S:23481 E:23486 ||| VBN
in  ||| S:23486 E:23489 ||| IN
each  ||| S:23489 E:23494 ||| DT
transfection ||| S:23494 E:23506 ||| NN
.  ||| S:23506 E:23508 ||| .
Cells  ||| S:23508 E:23514 ||| NNS
at  ||| S:23514 E:23517 ||| IN
60-70 ||| S:23517 E:23522 ||| CD
%  ||| S:23522 E:23524 ||| NN
confluence  ||| S:23524 E:23545 ||| NN
were  ||| S:23545 E:23550 ||| VBD
exposed  ||| S:23550 E:23558 ||| VBN
to  ||| S:23558 E:23561 ||| TO
the  ||| S:23561 E:23565 ||| DT
TransIT-LT1 ||| S:23565 E:23576 ||| NNP
: ||| S:23576 E:23577 ||| :
DNA  ||| S:23577 E:23581 ||| NNP
complex  ||| S:23581 E:23589 ||| NN
for  ||| S:23589 E:23593 ||| IN
8  ||| S:23593 E:23595 ||| CD
h  ||| S:23595 E:23597 ||| NN
in  ||| S:23597 E:23610 ||| IN
complete  ||| S:23610 E:23619 ||| JJ
medium  ||| S:23619 E:23626 ||| NN
plus  ||| S:23626 E:23631 ||| CC
freshly  ||| S:23631 E:23639 ||| RB
added  ||| S:23639 E:23645 ||| VBD
30  ||| S:23645 E:23648 ||| CD
mg ||| S:23648 E:23650 ||| CD
/ ||| S:23650 E:23651 ||| CD
mL  ||| S:23651 E:23654 ||| JJ
polymyxin  ||| S:23654 E:23664 ||| JJ
B  ||| S:23664 E:23676 ||| NN
antibiotic  ||| S:23676 E:23687 ||| NN
[  ||| S:23687 E:23689 ||| -LRB-
32 ||| S:23689 E:23691 ||| CD
] ||| S:23691 E:23692 ||| -RRB-
.  ||| S:23692 E:23694 ||| .
The  ||| S:23694 E:23698 ||| DT
medium  ||| S:23698 E:23705 ||| NN
was  ||| S:23705 E:23709 ||| VBD
then  ||| S:23709 E:23714 ||| RB
removed  ||| S:23714 E:23722 ||| VBN
and  ||| S:23722 E:23736 ||| CC
replaced  ||| S:23736 E:23745 ||| VBN
with  ||| S:23745 E:23750 ||| IN
complete  ||| S:23750 E:23759 ||| JJ
medium  ||| S:23759 E:23766 ||| NN
for  ||| S:23766 E:23770 ||| IN
24  ||| S:23770 E:23773 ||| CD
h ||| S:23773 E:23774 ||| NNS
.  ||| S:23774 E:23776 ||| .
Cells  ||| S:23776 E:23782 ||| NNS
were  ||| S:23782 E:23787 ||| VBD
then  ||| S:23787 E:23802 ||| RB
serum  ||| S:23802 E:23808 ||| VB
deprived  ||| S:23808 E:23817 ||| VBN
in  ||| S:23817 E:23820 ||| IN
DMEM  ||| S:23820 E:23825 ||| NNP
containing  ||| S:23825 E:23836 ||| VBG
0.5 ||| S:23836 E:23839 ||| CD
%  ||| S:23839 E:23841 ||| NN
calf  ||| S:23841 E:23846 ||| NN
serum  ||| S:23846 E:23852 ||| NN
for  ||| S:23852 E:23866 ||| IN
36-40  ||| S:23866 E:23872 ||| CD
h  ||| S:23872 E:23874 ||| NN
before  ||| S:23874 E:23881 ||| IN
harvesting ||| S:23881 E:23891 ||| NN
.  ||| S:23891 E:23893 ||| .
Cell  ||| S:23893 E:23898 ||| NN
extracts  ||| S:23898 E:23907 ||| NNS
were  ||| S:23907 E:23912 ||| VBD
prepared  ||| S:23912 E:23931 ||| VBN
and  ||| S:23931 E:23935 ||| CC
chloramphenicol  ||| S:23935 E:23951 ||| FW
acetyl  ||| S:23951 E:23958 ||| FW
transferase  ||| S:23958 E:23970 ||| FW
( ||| S:23970 E:23971 ||| -LRB-
CAT ||| S:23971 E:23974 ||| NNP
)  ||| S:23974 E:23976 ||| -RRB-
assays  ||| S:23976 E:23983 ||| NN
were  ||| S:23983 E:23998 ||| VBD
performed  ||| S:23998 E:24008 ||| VBN
on  ||| S:24008 E:24011 ||| IN
extracts  ||| S:24011 E:24020 ||| NNS
containing  ||| S:24020 E:24031 ||| VBG
equivalent  ||| S:24031 E:24042 ||| JJ
cell  ||| S:24042 E:24047 ||| NN
protein  ||| S:24047 E:24065 ||| NN
as  ||| S:24065 E:24068 ||| IN
previously  ||| S:24068 E:24079 ||| RB
described  ||| S:24079 E:24089 ||| VBN
[  ||| S:24089 E:24091 ||| -LRB-
33 ||| S:24091 E:24093 ||| CD
] ||| S:24093 E:24094 ||| -RRB-
.  ||| S:24094 E:24096 ||| .
An  ||| S:24096 E:24099 ||| DT
internal  ||| S:24099 E:24108 ||| JJ
control  ||| S:24108 E:24126 ||| NN
plasmid  ||| S:24126 E:24134 ||| NN
to  ||| S:24134 E:24137 ||| TO
measure  ||| S:24137 E:24145 ||| VB
transfection  ||| S:24145 E:24158 ||| JJ
efficiency  ||| S:24158 E:24169 ||| NN
could  ||| S:24169 E:24175 ||| MD
not  ||| S:24175 E:24179 ||| RB
be  ||| S:24179 E:24192 ||| VB
used  ||| S:24192 E:24197 ||| VBN
because  ||| S:24197 E:24205 ||| IN
C ||| S:24205 E:24206 ||| NNP
/ ||| S:24206 E:24207 ||| NNP
EBPβ  ||| S:24207 E:24212 ||| NNP
regulates  ||| S:24212 E:24222 ||| VBZ
transcrption  ||| S:24222 E:24235 ||| VBN
from  ||| S:24235 E:24240 ||| IN
the  ||| S:24240 E:24254 ||| DT
control  ||| S:24254 E:24262 ||| NN
plasmid ||| S:24262 E:24269 ||| NN
,  ||| S:24269 E:24271 ||| ,
and  ||| S:24271 E:24275 ||| CC
thus  ||| S:24275 E:24280 ||| RB
makes  ||| S:24280 E:24286 ||| VBZ
the  ||| S:24286 E:24290 ||| DT
internal  ||| S:24290 E:24299 ||| JJ
control  ||| S:24299 E:24317 ||| NN
invalid ||| S:24317 E:24324 ||| NN
.  ||| S:24324 E:24326 ||| .
Therefore ||| S:24326 E:24335 ||| RB
,  ||| S:24335 E:24337 ||| ,
the  ||| S:24337 E:24341 ||| DT
transfections  ||| S:24341 E:24355 ||| NN
were  ||| S:24355 E:24360 ||| VBD
repeated  ||| S:24360 E:24379 ||| VBN
multiple  ||| S:24379 E:24388 ||| JJ
times  ||| S:24388 E:24394 ||| NNS
to  ||| S:24394 E:24397 ||| TO
control  ||| S:24397 E:24405 ||| VB
for  ||| S:24405 E:24409 ||| IN
variability  ||| S:24409 E:24421 ||| NN
in  ||| S:24421 E:24424 ||| IN
transfection  ||| S:24424 E:24447 ||| JJ
efficiency ||| S:24447 E:24457 ||| NN
.  ||| S:24457 E:24487 ||| .
Plasmids  ||| S:24487 E:24506 ||| VBG
The  ||| S:24506 E:24510 ||| DT
pGAL4  ||| S:24510 E:24516 ||| NNP
and  ||| S:24516 E:24520 ||| CC
pG5CAT  ||| S:24520 E:24527 ||| CD
plasmids  ||| S:24527 E:24536 ||| NNS
were  ||| S:24536 E:24541 ||| VBD
obtained  ||| S:24541 E:24550 ||| VBN
from  ||| S:24550 E:24555 ||| IN
the  ||| S:24555 E:24569 ||| DT
Mammalian  ||| S:24569 E:24579 ||| NNP
MATCHMAKER  ||| S:24579 E:24590 ||| NNP
Two-Hybrid  ||| S:24590 E:24601 ||| NNP
Assay  ||| S:24601 E:24607 ||| NNP
Kit  ||| S:24607 E:24611 ||| NNP
( ||| S:24611 E:24612 ||| -LRB-
CLONTECH ||| S:24612 E:24620 ||| NNP
) ||| S:24620 E:24621 ||| -RRB-
.  ||| S:24621 E:24633 ||| NNP
pGAL4-SRF  ||| S:24633 E:24643 ||| NNP
was  ||| S:24643 E:24647 ||| VBD
constructed  ||| S:24647 E:24659 ||| VBN
as  ||| S:24659 E:24662 ||| IN
previously  ||| S:24662 E:24673 ||| RB
described  ||| S:24673 E:24683 ||| VBN
[  ||| S:24683 E:24685 ||| -LRB-
23 ||| S:24685 E:24687 ||| CD
] ||| S:24687 E:24688 ||| -RRB-
.  ||| S:24688 E:24700 ||| .
The  ||| S:24700 E:24704 ||| DT
SRE-CAT  ||| S:24704 E:24712 ||| JJ
reporter  ||| S:24712 E:24721 ||| NN
gene  ||| S:24721 E:24726 ||| NN
was  ||| S:24726 E:24730 ||| VBD
constructed  ||| S:24730 E:24742 ||| VBN
as  ||| S:24742 E:24745 ||| IN
previously  ||| S:24745 E:24766 ||| RB
described  ||| S:24766 E:24776 ||| VBN
[  ||| S:24776 E:24778 ||| -LRB-
22 ||| S:24778 E:24780 ||| CD
] ||| S:24780 E:24781 ||| -RRB-
.  ||| S:24781 E:24783 ||| .
pGST-p35-C ||| S:24783 E:24793 ||| FW
/ ||| S:24793 E:24794 ||| FW
EBPβ  ||| S:24794 E:24799 ||| NNP
was  ||| S:24799 E:24803 ||| VBD
constructed  ||| S:24803 E:24815 ||| VBN
by  ||| S:24815 E:24828 ||| IN
inserting  ||| S:24828 E:24838 ||| VBG
the  ||| S:24838 E:24842 ||| DT
1,739  ||| S:24842 E:24848 ||| JJ
bp  ||| S:24848 E:24851 ||| JJ
EcoRI  ||| S:24851 E:24857 ||| JJ
fragment  ||| S:24857 E:24866 ||| NN
from  ||| S:24866 E:24871 ||| IN
pRSETB-EFII  ||| S:24871 E:24883 ||| NNP
[  ||| S:24883 E:24895 ||| -LRB-
34 ||| S:24895 E:24897 ||| CD
]  ||| S:24897 E:24899 ||| -RRB-
into  ||| S:24899 E:24904 ||| IN
EcoRI  ||| S:24904 E:24910 ||| JJ
cut  ||| S:24910 E:24914 ||| NN
pGEX-4T-1  ||| S:24914 E:24924 ||| NNP
( ||| S:24924 E:24925 ||| -LRB-
Amersham-Pharmacia ||| S:24925 E:24943 ||| NNP
) ||| S:24943 E:24944 ||| -RRB-
.  ||| S:24944 E:24956 ||| .
pGST-p20-C ||| S:24956 E:24966 ||| FW
/ ||| S:24966 E:24967 ||| FW
EBPβ  ||| S:24967 E:24972 ||| NNP
was  ||| S:24972 E:24976 ||| VBD
constructed  ||| S:24976 E:24988 ||| VBN
by  ||| S:24988 E:24991 ||| IN
inserting  ||| S:24991 E:25001 ||| VBG
the  ||| S:25001 E:25005 ||| DT
581  ||| S:25005 E:25009 ||| CD
bp  ||| S:25009 E:25022 ||| CD
BamHI ||| S:25022 E:25027 ||| JJ
/ ||| S:25027 E:25028 ||| CD
EcoRI  ||| S:25028 E:25034 ||| JJ
fragment  ||| S:25034 E:25043 ||| NN
from  ||| S:25043 E:25048 ||| IN
pRsetA-LIP  ||| S:25048 E:25059 ||| NNP
[  ||| S:25059 E:25061 ||| -LRB-
34 ||| S:25061 E:25063 ||| CD
]  ||| S:25063 E:25065 ||| -RRB-
into  ||| S:25065 E:25070 ||| IN
similarly  ||| S:25070 E:25090 ||| FW
digested  ||| S:25090 E:25099 ||| FW
pGEX4T-1.  ||| S:25099 E:25109 ||| FW
pcDNA3 ||| S:25109 E:25115 ||| FW
/ ||| S:25115 E:25116 ||| FW
Elk-1 ||| S:25116 E:25121 ||| FW
( ||| S:25121 E:25122 ||| -LRB-
1-209 ||| S:25122 E:25127 ||| NNP
)  ||| S:25127 E:25129 ||| -RRB-
and  ||| S:25129 E:25143 ||| CC
pcDNA3 ||| S:25143 E:25149 ||| NNP
/ ||| S:25149 E:25150 ||| NNP
Elk-1 ||| S:25150 E:25155 ||| NNP
( ||| S:25155 E:25156 ||| -LRB-
1-140 ||| S:25156 E:25161 ||| NNP
)  ||| S:25161 E:25163 ||| -RRB-
were  ||| S:25163 E:25168 ||| VBD
constructed  ||| S:25168 E:25180 ||| VBN
by  ||| S:25180 E:25183 ||| IN
using  ||| S:25183 E:25189 ||| VBG
the  ||| S:25189 E:25203 ||| DT
Erase-A-Base  ||| S:25203 E:25216 ||| JJ
system  ||| S:25216 E:25223 ||| NN
( ||| S:25223 E:25224 ||| -LRB-
Promega ||| S:25224 E:25231 ||| NNP
)  ||| S:25231 E:25233 ||| -RRB-
with  ||| S:25233 E:25238 ||| IN
pcDNA3 ||| S:25238 E:25244 ||| CD
/ ||| S:25244 E:25245 ||| CD
Elk-1  ||| S:25245 E:25251 ||| CD
( ||| S:25251 E:25252 ||| -LRB-
gift  ||| S:25252 E:25257 ||| NN
of  ||| S:25257 E:25270 ||| IN
J.  ||| S:25270 E:25273 ||| NNP
Schwartz ||| S:25273 E:25281 ||| NNP
,  ||| S:25281 E:25283 ||| ,
Univ.  ||| S:25283 E:25289 ||| NNP
of  ||| S:25289 E:25292 ||| IN
Michigan ||| S:25292 E:25300 ||| NNP
)  ||| S:25300 E:25302 ||| -RRB-
as  ||| S:25302 E:25305 ||| RB
described  ||| S:25305 E:25315 ||| VBN
by  ||| S:25315 E:25318 ||| IN
the  ||| S:25318 E:25332 ||| DT
manufacturer.  ||| S:25332 E:25346 ||| NNP
pcDNA3.1 ||| S:25346 E:25354 ||| NNP
/ ||| S:25354 E:25355 ||| NNP
His-p35-C ||| S:25355 E:25364 ||| NNP
/ ||| S:25364 E:25365 ||| NNP
EBPβ  ||| S:25365 E:25370 ||| NNP
was  ||| S:25370 E:25374 ||| VBD
constructed  ||| S:25374 E:25386 ||| VBN
by  ||| S:25386 E:25399 ||| IN
inserting  ||| S:25399 E:25409 ||| VBG
an  ||| S:25409 E:25412 ||| DT
1,739  ||| S:25412 E:25418 ||| JJ
bp  ||| S:25418 E:25421 ||| JJ
EcoRI  ||| S:25421 E:25427 ||| JJ
fragment  ||| S:25427 E:25436 ||| NN
from  ||| S:25436 E:25441 ||| IN
pRSETB-EFII  ||| S:25441 E:25463 ||| JJ
into  ||| S:25463 E:25468 ||| IN
an  ||| S:25468 E:25471 ||| DT
EcoRI  ||| S:25471 E:25477 ||| JJ
cut  ||| S:25477 E:25481 ||| NN
pcDNA3.1 ||| S:25481 E:25489 ||| FW
/ ||| S:25489 E:25490 ||| FW
HisC  ||| S:25490 E:25495 ||| FW
vector  ||| S:25495 E:25502 ||| FW
( ||| S:25502 E:25503 ||| -LRB-
Invitrogen ||| S:25503 E:25513 ||| NNP
) ||| S:25513 E:25514 ||| -RRB-
.  ||| S:25514 E:25526 ||| .
CMV-LAP  ||| S:25526 E:25534 ||| NNP
was  ||| S:25534 E:25538 ||| VBD
a  ||| S:25538 E:25540 ||| DT
gift  ||| S:25540 E:25545 ||| NN
of  ||| S:25545 E:25548 ||| IN
U.  ||| S:25548 E:25551 ||| NNP
Schibler  ||| S:25551 E:25560 ||| NNP
( ||| S:25560 E:25561 ||| -LRB-
Univ.  ||| S:25561 E:25567 ||| NNP
of  ||| S:25567 E:25570 ||| IN
Geneva ||| S:25570 E:25576 ||| NNP
,  ||| S:25576 E:25588 ||| ,
Geneva ||| S:25588 E:25594 ||| NNP
,  ||| S:25594 E:25596 ||| ,
Switzerland ||| S:25596 E:25607 ||| NNP
)  ||| S:25607 E:25609 ||| -RRB-
and  ||| S:25609 E:25613 ||| CC
CMV-Ras.V12  ||| S:25613 E:25625 ||| NNP
was  ||| S:25625 E:25629 ||| VBD
a  ||| S:25629 E:25631 ||| DT
gift  ||| S:25631 E:25636 ||| NN
of  ||| S:25636 E:25639 ||| IN
E.  ||| S:25639 E:25652 ||| NNP
Ruley  ||| S:25652 E:25658 ||| NNP
( ||| S:25658 E:25659 ||| -LRB-
Vanderbilt  ||| S:25659 E:25670 ||| NNP
Univ. ||| S:25670 E:25675 ||| NNP
) ||| S:25675 E:25676 ||| -RRB-
.  ||| S:25676 E:25706 ||| .
Analysis  ||| S:25706 E:25715 ||| NN
of  ||| S:25715 E:25718 ||| IN
ELK-1  ||| S:25718 E:25724 ||| NNP
and  ||| S:25724 E:25728 ||| CC
C ||| S:25728 E:25729 ||| NNP
/ ||| S:25729 E:25730 ||| FW
EBPβ  ||| S:25730 E:25735 ||| FW
interaction  ||| S:25735 E:25747 ||| FW
in  ||| S:25747 E:25760 ||| FW
vitro  ||| S:25760 E:25776 ||| FW
GST-p35-C ||| S:25776 E:25785 ||| FW
/ ||| S:25785 E:25786 ||| FW
EBPβ ||| S:25786 E:25790 ||| FW
,  ||| S:25790 E:25792 ||| ,
GST-p20-C ||| S:25792 E:25801 ||| NNP
/ ||| S:25801 E:25802 ||| NNP
EBPβ ||| S:25802 E:25806 ||| NNP
,  ||| S:25806 E:25808 ||| ,
or  ||| S:25808 E:25811 ||| CC
GST  ||| S:25811 E:25815 ||| NNP
alone  ||| S:25815 E:25821 ||| RB
was  ||| S:25821 E:25835 ||| VBD
produced  ||| S:25835 E:25844 ||| VBN
in  ||| S:25844 E:25847 ||| IN
BL21  ||| S:25847 E:25852 ||| NNP
E.  ||| S:25852 E:25855 ||| NNP
Coli  ||| S:25855 E:25860 ||| NNP
by  ||| S:25860 E:25863 ||| IN
80  ||| S:25863 E:25866 ||| CD
mM  ||| S:25866 E:25879 ||| JJ
isopropyl-β-D-thiogalactopyranoside  ||| S:25879 E:25915 ||| NN
( ||| S:25915 E:25916 ||| -LRB-
IPTG ||| S:25916 E:25920 ||| NNP
)  ||| S:25920 E:25922 ||| -RRB-
induction  ||| S:25922 E:25942 ||| JJ
overnight  ||| S:25942 E:25952 ||| JJ
at  ||| S:25952 E:25955 ||| IN
37°C ||| S:25955 E:25959 ||| CD
.  ||| S:25959 E:25961 ||| .
Cells  ||| S:25961 E:25967 ||| NNS
were  ||| S:25967 E:25972 ||| VBD
harvested  ||| S:25972 E:25982 ||| VBN
by  ||| S:25982 E:25985 ||| IN
centrifugation  ||| S:25985 E:26010 ||| NN
and  ||| S:26010 E:26014 ||| CC
washed  ||| S:26014 E:26021 ||| VBD
once  ||| S:26021 E:26026 ||| RB
with  ||| S:26026 E:26031 ||| IN
phosphate-buffered  ||| S:26031 E:26050 ||| JJ
saline  ||| S:26050 E:26057 ||| NNS
( ||| S:26057 E:26058 ||| -LRB-
PBS ||| S:26058 E:26061 ||| NNP
)  ||| S:26061 E:26073 ||| -RRB-
containing  ||| S:26073 E:26084 ||| VBG
the  ||| S:26084 E:26088 ||| DT
following  ||| S:26088 E:26098 ||| JJ
protease  ||| S:26098 E:26107 ||| JJ
inhibitors ||| S:26107 E:26117 ||| NN
:  ||| S:26117 E:26119 ||| :
2  ||| S:26119 E:26121 ||| CD
mg ||| S:26121 E:26123 ||| CD
/ ||| S:26123 E:26124 ||| CD
ml  ||| S:26124 E:26137 ||| JJ
aprotinin ||| S:26137 E:26146 ||| NN
,  ||| S:26146 E:26148 ||| ,
2  ||| S:26148 E:26150 ||| CD
mg ||| S:26150 E:26152 ||| CD
/ ||| S:26152 E:26153 ||| CD
ml  ||| S:26153 E:26156 ||| JJ
leupeptin ||| S:26156 E:26165 ||| NN
,  ||| S:26165 E:26167 ||| ,
2  ||| S:26167 E:26169 ||| CD
mM  ||| S:26169 E:26172 ||| JJ
phenylmethylsulfonyl  ||| S:26172 E:26203 ||| JJ
fluoride  ||| S:26203 E:26212 ||| NNS
( ||| S:26212 E:26213 ||| -LRB-
PMSF ||| S:26213 E:26217 ||| NNP
) ||| S:26217 E:26218 ||| -RRB-
,  ||| S:26218 E:26220 ||| ,
and  ||| S:26220 E:26224 ||| CC
0.2  ||| S:26224 E:26228 ||| CD
mM  ||| S:26228 E:26231 ||| JJ
pepstatin ||| S:26231 E:26240 ||| NN
.  ||| S:26240 E:26242 ||| .
The  ||| S:26242 E:26246 ||| DT
bacteria  ||| S:26246 E:26255 ||| NNS
were  ||| S:26255 E:26270 ||| VBD
lysed  ||| S:26270 E:26276 ||| VBN
by  ||| S:26276 E:26279 ||| IN
sonication  ||| S:26279 E:26290 ||| NN
at  ||| S:26290 E:26293 ||| IN
4  ||| S:26293 E:26295 ||| CD
oC  ||| S:26295 E:26298 ||| NN
in  ||| S:26298 E:26301 ||| IN
PBS  ||| S:26301 E:26305 ||| NNP
containing  ||| S:26305 E:26316 ||| VBG
the  ||| S:26316 E:26330 ||| DT
protease  ||| S:26330 E:26339 ||| JJ
inhibitors  ||| S:26339 E:26350 ||| NN
described  ||| S:26350 E:26360 ||| VBD
above ||| S:26360 E:26365 ||| RB
.  ||| S:26365 E:26367 ||| .
Triton  ||| S:26367 E:26374 ||| NNP
X-100  ||| S:26374 E:26380 ||| NNP
was  ||| S:26380 E:26394 ||| VBD
added  ||| S:26394 E:26400 ||| VBN
to  ||| S:26400 E:26403 ||| TO
a  ||| S:26403 E:26405 ||| DT
final  ||| S:26405 E:26411 ||| JJ
concentration  ||| S:26411 E:26425 ||| NN
of  ||| S:26425 E:26428 ||| IN
0.1 ||| S:26428 E:26431 ||| CD
% ||| S:26431 E:26432 ||| NN
,  ||| S:26432 E:26434 ||| ,
followed  ||| S:26434 E:26443 ||| VBN
by  ||| S:26443 E:26456 ||| IN
gentle  ||| S:26456 E:26463 ||| JJ
mixing  ||| S:26463 E:26470 ||| NN
for  ||| S:26470 E:26474 ||| IN
30  ||| S:26474 E:26477 ||| CD
min  ||| S:26477 E:26481 ||| NN
at  ||| S:26481 E:26484 ||| IN
4°C ||| S:26484 E:26487 ||| CD
.  ||| S:26487 E:26489 ||| .
The  ||| S:26489 E:26493 ||| DT
lysate  ||| S:26493 E:26500 ||| NN
was  ||| S:26500 E:26504 ||| VBD
clarified  ||| S:26504 E:26524 ||| VBN
at  ||| S:26524 E:26527 ||| IN
12,000  ||| S:26527 E:26534 ||| CD
×  ||| S:26534 E:26536 ||| CD
g  ||| S:26536 E:26538 ||| NN
for  ||| S:26538 E:26542 ||| IN
10  ||| S:26542 E:26545 ||| CD
min  ||| S:26545 E:26549 ||| NN
at  ||| S:26549 E:26552 ||| IN
4°C ||| S:26552 E:26555 ||| CD
.  ||| S:26555 E:26557 ||| .
The  ||| S:26557 E:26561 ||| DT
supernatant  ||| S:26561 E:26573 ||| NN
was  ||| S:26573 E:26587 ||| VBD
gently  ||| S:26587 E:26594 ||| RB
mixed  ||| S:26594 E:26600 ||| VBN
with  ||| S:26600 E:26605 ||| IN
glutathione-sepharose  ||| S:26605 E:26627 ||| JJ
beads  ||| S:26627 E:26643 ||| NNS
( ||| S:26643 E:26644 ||| -LRB-
Amersham-Pharmacia ||| S:26644 E:26662 ||| NNP
)  ||| S:26662 E:26664 ||| -RRB-
at  ||| S:26664 E:26667 ||| IN
4°C  ||| S:26667 E:26671 ||| CD
for  ||| S:26671 E:26675 ||| IN
30  ||| S:26675 E:26678 ||| CD
min ||| S:26678 E:26681 ||| NNS
.  ||| S:26681 E:26683 ||| .
Beads  ||| S:26683 E:26689 ||| RB
containing  ||| S:26689 E:26710 ||| VBG
GST  ||| S:26710 E:26714 ||| NNP
proteins  ||| S:26714 E:26723 ||| NNS
were  ||| S:26723 E:26728 ||| VBD
collected  ||| S:26728 E:26738 ||| VBN
by  ||| S:26738 E:26741 ||| IN
low  ||| S:26741 E:26745 ||| JJ
speed  ||| S:26745 E:26751 ||| NN
centrifugation ||| S:26751 E:26765 ||| NN
,  ||| S:26765 E:26777 ||| ,
followed  ||| S:26777 E:26786 ||| VBN
by  ||| S:26786 E:26789 ||| IN
three  ||| S:26789 E:26795 ||| CD
successive  ||| S:26795 E:26806 ||| JJ
washes  ||| S:26806 E:26813 ||| NN
with  ||| S:26813 E:26818 ||| IN
PBS  ||| S:26818 E:26822 ||| NNP
containing  ||| S:26822 E:26843 ||| VBG
0.1 ||| S:26843 E:26846 ||| CD
%  ||| S:26846 E:26848 ||| NN
Triton  ||| S:26848 E:26855 ||| NNP
X-100  ||| S:26855 E:26861 ||| NNP
and  ||| S:26861 E:26865 ||| CC
the  ||| S:26865 E:26869 ||| DT
protease  ||| S:26869 E:26878 ||| JJ
inhibitors  ||| S:26878 E:26889 ||| NN
described  ||| S:26889 E:26909 ||| VBD
above ||| S:26909 E:26914 ||| RB
.  ||| S:26914 E:26926 ||| .
The  ||| S:26926 E:26930 ||| DT
ELK-1 ||| S:26930 E:26935 ||| NNP
,  ||| S:26935 E:26937 ||| ,
ELK-1 ||| S:26937 E:26942 ||| NNP
( ||| S:26942 E:26943 ||| -LRB-
1-209 ||| S:26943 E:26948 ||| NNP
) ||| S:26948 E:26949 ||| -RRB-
,  ||| S:26949 E:26951 ||| ,
ELK-1 ||| S:26951 E:26956 ||| NNP
( ||| S:26956 E:26957 ||| -LRB-
1-140 ||| S:26957 E:26962 ||| NNP
) ||| S:26962 E:26963 ||| -RRB-
,  ||| S:26963 E:26965 ||| ,
and  ||| S:26965 E:26979 ||| CC
ELK-1 ||| S:26979 E:26984 ||| NNP
( ||| S:26984 E:26985 ||| -LRB-
89-428 ||| S:26985 E:26991 ||| NNP
)  ||| S:26991 E:26993 ||| -RRB-
proteins  ||| S:26993 E:27002 ||| NNS
were  ||| S:27002 E:27007 ||| VBD
transcribed  ||| S:27007 E:27019 ||| JJ
and  ||| S:27019 E:27023 ||| CC
translated  ||| S:27023 E:27034 ||| VBN
in  ||| S:27034 E:27047 ||| IN
vitro  ||| S:27047 E:27053 ||| NNS
using  ||| S:27053 E:27059 ||| VBG
the  ||| S:27059 E:27063 ||| DT
TNT  ||| S:27063 E:27067 ||| NNP
T7  ||| S:27067 E:27070 ||| FW
coupled  ||| S:27070 E:27078 ||| FW
reticulocyte  ||| S:27078 E:27091 ||| FW
lysate  ||| S:27091 E:27098 ||| FW
system  ||| S:27098 E:27115 ||| NN
( ||| S:27115 E:27116 ||| -LRB-
Promega ||| S:27116 E:27123 ||| NNP
)  ||| S:27123 E:27125 ||| -RRB-
according  ||| S:27125 E:27135 ||| VBG
to  ||| S:27135 E:27138 ||| TO
the  ||| S:27138 E:27142 ||| DT
manufacture ||| S:27142 E:27153 ||| NN
's  ||| S:27153 E:27156 ||| POS
instructions ||| S:27156 E:27168 ||| NNS
.  ||| S:27168 E:27180 ||| .
Translated  ||| S:27180 E:27191 ||| VBN
proteins  ||| S:27191 E:27200 ||| NNS
were  ||| S:27200 E:27205 ||| VBD
radiolabeled  ||| S:27205 E:27218 ||| VBN
with  ||| S:27218 E:27223 ||| IN
the  ||| S:27223 E:27227 ||| DT
EXPRE  ||| S:27227 E:27233 ||| FW
35S  ||| S:27233 E:27247 ||| FW
35S  ||| S:27247 E:27251 ||| FW
protein  ||| S:27251 E:27259 ||| FW
labeling  ||| S:27259 E:27268 ||| FW
mix  ||| S:27268 E:27272 ||| FW
( ||| S:27272 E:27273 ||| -LRB-
Dupont  ||| S:27273 E:27280 ||| NNP
NEN ||| S:27280 E:27283 ||| NNP
) ||| S:27283 E:27284 ||| -RRB-
.  ||| S:27284 E:27286 ||| .
The  ||| S:27286 E:27290 ||| DT
GST-pulldown  ||| S:27290 E:27313 ||| JJ
assay  ||| S:27313 E:27319 ||| NN
was  ||| S:27319 E:27323 ||| VBD
done  ||| S:27323 E:27328 ||| VBN
as  ||| S:27328 E:27331 ||| IN
previously  ||| S:27331 E:27342 ||| RB
described  ||| S:27342 E:27352 ||| VBN
[  ||| S:27352 E:27354 ||| -LRB-
22 ||| S:27354 E:27356 ||| CD
] ||| S:27356 E:27357 ||| -RRB-
.  ||| S:27357 E:27387 ||| .
Co-Immunoprecipitation  ||| S:27387 E:27420 ||| JJ
COS-7  ||| S:27420 E:27426 ||| CD
cells  ||| S:27426 E:27432 ||| NNS
were  ||| S:27432 E:27437 ||| VBD
harvested  ||| S:27437 E:27447 ||| VBN
in  ||| S:27447 E:27450 ||| IN
PBS  ||| S:27450 E:27454 ||| NNP
containing  ||| S:27454 E:27465 ||| VBG
0.1  ||| S:27465 E:27469 ||| CD
mM  ||| S:27469 E:27482 ||| JJ
sodium  ||| S:27482 E:27489 ||| NN
vanadate  ||| S:27489 E:27498 ||| NNS
and  ||| S:27498 E:27502 ||| CC
collected  ||| S:27502 E:27512 ||| VBN
by  ||| S:27512 E:27515 ||| IN
low  ||| S:27515 E:27519 ||| JJ
speed  ||| S:27519 E:27535 ||| NN
centrifugation ||| S:27535 E:27549 ||| NN
.  ||| S:27549 E:27551 ||| .
Cells  ||| S:27551 E:27557 ||| NNS
were  ||| S:27557 E:27562 ||| VBD
resuspended  ||| S:27562 E:27574 ||| VBN
in  ||| S:27574 E:27577 ||| IN
lysis  ||| S:27577 E:27583 ||| JJ
buffer  ||| S:27583 E:27600 ||| NN
( ||| S:27600 E:27601 ||| -LRB-
10  ||| S:27601 E:27604 ||| CD
mM  ||| S:27604 E:27607 ||| JJ
Tris  ||| S:27607 E:27612 ||| NNP
( ||| S:27612 E:27613 ||| -LRB-
pH  ||| S:27613 E:27616 ||| NNP
7.5 ||| S:27616 E:27619 ||| CD
) ||| S:27619 E:27620 ||| -RRB-
,  ||| S:27620 E:27622 ||| ,
1  ||| S:27622 E:27624 ||| CD
mM  ||| S:27624 E:27627 ||| JJ
EDTA ||| S:27627 E:27631 ||| NNP
,  ||| S:27631 E:27633 ||| ,
50  ||| S:27633 E:27636 ||| CD
mM  ||| S:27636 E:27639 ||| JJ
NaCl ||| S:27639 E:27643 ||| NN
,  ||| S:27643 E:27645 ||| ,
0.25 ||| S:27645 E:27649 ||| CD
%  ||| S:27649 E:27661 ||| NN
Nonidet  ||| S:27661 E:27669 ||| NNP
P-40 ||| S:27669 E:27673 ||| NNP
,  ||| S:27673 E:27675 ||| ,
1  ||| S:27675 E:27677 ||| CD
mM  ||| S:27677 E:27680 ||| JJ
PMSF ||| S:27680 E:27684 ||| NNP
,  ||| S:27684 E:27686 ||| ,
1  ||| S:27686 E:27688 ||| CD
mg  ||| S:27688 E:27691 ||| NN
of  ||| S:27691 E:27694 ||| IN
aprotinin ||| S:27694 E:27703 ||| JJ
/ ||| S:27703 E:27704 ||| NNP
mL ||| S:27704 E:27706 ||| NNP
,  ||| S:27706 E:27708 ||| ,
0.1  ||| S:27708 E:27712 ||| CD
mM  ||| S:27712 E:27725 ||| JJ
sodium  ||| S:27725 E:27732 ||| JJ
vanadate ||| S:27732 E:27740 ||| NN
,  ||| S:27740 E:27742 ||| ,
10  ||| S:27742 E:27745 ||| CD
mM  ||| S:27745 E:27748 ||| JJ
sodium  ||| S:27748 E:27755 ||| JJ
molybdate ||| S:27755 E:27764 ||| NN
,  ||| S:27764 E:27766 ||| ,
and  ||| S:27766 E:27770 ||| CC
10  ||| S:27770 E:27773 ||| CD
mM  ||| S:27773 E:27786 ||| JJ
β-glycerol  ||| S:27786 E:27797 ||| JJ
phosphate ||| S:27797 E:27806 ||| NN
)  ||| S:27806 E:27808 ||| -RRB-
and  ||| S:27808 E:27812 ||| CC
lysed  ||| S:27812 E:27818 ||| NN
by  ||| S:27818 E:27821 ||| IN
sonication  ||| S:27821 E:27832 ||| NN
with  ||| S:27832 E:27837 ||| IN
a  ||| S:27837 E:27849 ||| DT
microtip  ||| S:27849 E:27858 ||| NN
on  ||| S:27858 E:27861 ||| IN
setting  ||| S:27861 E:27869 ||| VBG
2  ||| S:27869 E:27871 ||| CD
and  ||| S:27871 E:27875 ||| CC
20 ||| S:27875 E:27877 ||| CD
%  ||| S:27877 E:27879 ||| NN
duty  ||| S:27879 E:27884 ||| NN
cycle  ||| S:27884 E:27890 ||| NN
for  ||| S:27890 E:27894 ||| IN
10  ||| S:27894 E:27897 ||| CD
s ||| S:27897 E:27898 ||| NNS
.  ||| S:27898 E:27900 ||| .
After  ||| S:27900 E:27916 ||| IN
clarification  ||| S:27916 E:27930 ||| NN
by  ||| S:27930 E:27933 ||| IN
centrifugation  ||| S:27933 E:27948 ||| NN
at  ||| S:27948 E:27951 ||| IN
12,000  ||| S:27951 E:27958 ||| CD
×  ||| S:27958 E:27960 ||| CD
g  ||| S:27960 E:27962 ||| NN
for  ||| S:27962 E:27966 ||| IN
10  ||| S:27966 E:27969 ||| CD
min ||| S:27969 E:27972 ||| NN
,  ||| S:27972 E:27984 ||| ,
the  ||| S:27984 E:27988 ||| DT
cell  ||| S:27988 E:27993 ||| NN
extract  ||| S:27993 E:28001 ||| NN
was  ||| S:28001 E:28005 ||| VBD
incubated  ||| S:28005 E:28015 ||| VBN
with  ||| S:28015 E:28020 ||| IN
T7  ||| S:28020 E:28023 ||| CD
tag  ||| S:28023 E:28027 ||| NN
antibody  ||| S:28027 E:28046 ||| NN
( ||| S:28046 E:28047 ||| -LRB-
Ab ||| S:28047 E:28049 ||| NNP
) ||| S:28049 E:28050 ||| -RRB-
-agarose  ||| S:28050 E:28059 ||| JJ
beads  ||| S:28059 E:28065 ||| NNS
( ||| S:28065 E:28066 ||| -LRB-
Novagen ||| S:28066 E:28073 ||| NNP
)  ||| S:28073 E:28075 ||| -RRB-
for  ||| S:28075 E:28079 ||| IN
2  ||| S:28079 E:28081 ||| CD
h ||| S:28081 E:28082 ||| NNS
.  ||| S:28082 E:28084 ||| .
The  ||| S:28084 E:28088 ||| DT
beads  ||| S:28088 E:28094 ||| NN
were  ||| S:28094 E:28109 ||| VBD
collected  ||| S:28109 E:28119 ||| VBN
by  ||| S:28119 E:28122 ||| IN
low  ||| S:28122 E:28126 ||| JJ
speed  ||| S:28126 E:28132 ||| NN
centrifugation  ||| S:28132 E:28147 ||| NNS
and  ||| S:28147 E:28151 ||| CC
washed  ||| S:28151 E:28158 ||| VBD
3  ||| S:28158 E:28160 ||| CD
times  ||| S:28160 E:28176 ||| NNS
with  ||| S:28176 E:28181 ||| IN
lysis  ||| S:28181 E:28187 ||| JJ
buffer ||| S:28187 E:28193 ||| NN
.  ||| S:28193 E:28195 ||| .
All  ||| S:28195 E:28199 ||| DT
steps  ||| S:28199 E:28205 ||| NNS
were  ||| S:28205 E:28210 ||| VBD
performed  ||| S:28210 E:28220 ||| VBN
at  ||| S:28220 E:28223 ||| IN
4°C ||| S:28223 E:28226 ||| CD
.  ||| S:28226 E:28228 ||| .
After  ||| S:28228 E:28244 ||| IN
washing ||| S:28244 E:28251 ||| NN
,  ||| S:28251 E:28253 ||| ,
the  ||| S:28253 E:28257 ||| DT
beads  ||| S:28257 E:28263 ||| NN
were  ||| S:28263 E:28268 ||| VBD
boiled  ||| S:28268 E:28275 ||| VBN
for  ||| S:28275 E:28279 ||| IN
5  ||| S:28279 E:28281 ||| CD
min  ||| S:28281 E:28285 ||| NN
in  ||| S:28285 E:28288 ||| IN
Laemmli  ||| S:28288 E:28306 ||| NNP
sample  ||| S:28306 E:28313 ||| NN
buffer ||| S:28313 E:28319 ||| NN
.  ||| S:28319 E:28349 ||| .
Immunoblots  ||| S:28349 E:28371 ||| VBG
The  ||| S:28371 E:28375 ||| DT
samples  ||| S:28375 E:28383 ||| NNS
from  ||| S:28383 E:28388 ||| IN
the  ||| S:28388 E:28392 ||| DT
coimmunoprecipitations  ||| S:28392 E:28415 ||| NN
described  ||| S:28415 E:28435 ||| VBD
above  ||| S:28435 E:28441 ||| RB
were  ||| S:28441 E:28446 ||| VBD
analyzed  ||| S:28446 E:28455 ||| VBN
by  ||| S:28455 E:28458 ||| IN
electrophoresis  ||| S:28458 E:28474 ||| NN
on  ||| S:28474 E:28477 ||| IN
an  ||| S:28477 E:28480 ||| DT
SDS-12 ||| S:28480 E:28486 ||| JJ
%  ||| S:28486 E:28498 ||| NN
polyacrylamide  ||| S:28498 E:28513 ||| NN
gel  ||| S:28513 E:28517 ||| NN
for  ||| S:28517 E:28521 ||| IN
3  ||| S:28521 E:28523 ||| CD
h  ||| S:28523 E:28525 ||| NN
at  ||| S:28525 E:28528 ||| IN
160  ||| S:28528 E:28532 ||| CD
V.  ||| S:28532 E:28535 ||| CD
The  ||| S:28535 E:28539 ||| DT
gel  ||| S:28539 E:28543 ||| NN
was  ||| S:28543 E:28557 ||| VBD
equilibrated  ||| S:28557 E:28570 ||| VBN
in  ||| S:28570 E:28573 ||| IN
transfer  ||| S:28573 E:28582 ||| NN
buffer  ||| S:28582 E:28589 ||| NN
( ||| S:28589 E:28590 ||| -LRB-
33  ||| S:28590 E:28593 ||| CD
mM  ||| S:28593 E:28596 ||| JJ
Tris  ||| S:28596 E:28601 ||| JJ
base ||| S:28601 E:28605 ||| NN
,  ||| S:28605 E:28607 ||| ,
192  ||| S:28607 E:28611 ||| CD
mM  ||| S:28611 E:28624 ||| JJ
glycine ||| S:28624 E:28631 ||| NN
,  ||| S:28631 E:28633 ||| ,
20 ||| S:28633 E:28635 ||| CD
%  ||| S:28635 E:28637 ||| NN
methanol ||| S:28637 E:28645 ||| NN
)  ||| S:28645 E:28647 ||| -RRB-
for  ||| S:28647 E:28651 ||| IN
15  ||| S:28651 E:28654 ||| CD
min  ||| S:28654 E:28658 ||| NN
before  ||| S:28658 E:28665 ||| IN
transfer  ||| S:28665 E:28674 ||| NN
of  ||| S:28674 E:28687 ||| IN
proteins  ||| S:28687 E:28696 ||| NNS
to  ||| S:28696 E:28699 ||| TO
Immobilon-P  ||| S:28699 E:28711 ||| JJ
membrane  ||| S:28711 E:28720 ||| NNS
( ||| S:28720 E:28721 ||| -LRB-
Millipore  ||| S:28721 E:28731 ||| NNP
Corp. ||| S:28731 E:28736 ||| NNP
) ||| S:28736 E:28737 ||| -RRB-
.  ||| S:28737 E:28739 ||| .
After  ||| S:28739 E:28755 ||| IN
transfer ||| S:28755 E:28763 ||| NN
,  ||| S:28763 E:28765 ||| ,
an  ||| S:28765 E:28768 ||| DT
immunoblot  ||| S:28768 E:28779 ||| NN
was  ||| S:28779 E:28783 ||| VBD
performed  ||| S:28783 E:28793 ||| VBN
as  ||| S:28793 E:28796 ||| RB
described  ||| S:28796 E:28816 ||| VBN
previously  ||| S:28816 E:28827 ||| RB
[  ||| S:28827 E:28829 ||| -LRB-
22 ||| S:28829 E:28831 ||| CD
] ||| S:28831 E:28832 ||| -RRB-
.  ||| S:28832 E:28834 ||| .
A  ||| S:28834 E:28836 ||| DT
1 ||| S:28836 E:28837 ||| CD
: ||| S:28837 E:28838 ||| :
2000  ||| S:28838 E:28843 ||| CD
dilution  ||| S:28843 E:28852 ||| NN
of  ||| S:28852 E:28855 ||| IN
anti-Elk-1  ||| S:28855 E:28866 ||| NNP
Ab  ||| S:28866 E:28879 ||| NNP
( ||| S:28879 E:28880 ||| -LRB-
Santa  ||| S:28880 E:28886 ||| NNP
Cruz  ||| S:28886 E:28891 ||| NNP
Biotechnology ||| S:28891 E:28904 ||| NNP
)  ||| S:28904 E:28906 ||| -RRB-
and  ||| S:28906 E:28910 ||| CC
a  ||| S:28910 E:28912 ||| DT
1 ||| S:28912 E:28913 ||| CD
: ||| S:28913 E:28914 ||| :
5000  ||| S:28914 E:28919 ||| CD
dilution  ||| S:28919 E:28928 ||| NN
of  ||| S:28928 E:28931 ||| IN
goat  ||| S:28931 E:28946 ||| JJ
anti-rabbit  ||| S:28946 E:28958 ||| JJ
secondary  ||| S:28958 E:28968 ||| JJ
Ab  ||| S:28968 E:28971 ||| NNP
( ||| S:28971 E:28972 ||| -LRB-
Roche  ||| S:28972 E:28978 ||| NNP
Molecular  ||| S:28978 E:28988 ||| NNP
Biochemicals ||| S:28988 E:29000 ||| NNP
)  ||| S:29000 E:29012 ||| -RRB-
were  ||| S:29012 E:29017 ||| VBD
used ||| S:29017 E:29021 ||| VBN
.  ||| S:29021 E:29023 ||| .
The  ||| S:29023 E:29027 ||| DT
secondary  ||| S:29027 E:29037 ||| JJ
Ab  ||| S:29037 E:29040 ||| NNP
was  ||| S:29040 E:29044 ||| VBD
detected  ||| S:29044 E:29053 ||| VBN
using  ||| S:29053 E:29069 ||| VBG
SuperSignal  ||| S:29069 E:29081 ||| JJ
Chemiluminescent  ||| S:29081 E:29098 ||| NNP
Substrate  ||| S:29098 E:29108 ||| NNP
( ||| S:29108 E:29109 ||| -LRB-
Pierce ||| S:29109 E:29115 ||| NNP
) ||| S:29115 E:29116 ||| -RRB-
.  ||| S:29116 E:29149 ||| .
Abbreviations  ||| S:29149 E:29171 ||| JJ
aa ||| S:29171 E:29173 ||| NN
,  ||| S:29173 E:29175 ||| ,
amino  ||| S:29175 E:29181 ||| JJ
acid ||| S:29181 E:29185 ||| NN
;  ||| S:29185 E:29187 ||| :
Ab ||| S:29187 E:29189 ||| NNP
,  ||| S:29189 E:29191 ||| ,
antibody ||| S:29191 E:29199 ||| NN
;  ||| S:29199 E:29201 ||| :
bp ||| S:29201 E:29203 ||| CD
,  ||| S:29203 E:29205 ||| ,
base  ||| S:29205 E:29210 ||| NN
pair ||| S:29210 E:29214 ||| NN
;  ||| S:29214 E:29216 ||| :
CaPO  ||| S:29216 E:29230 ||| JJ
4  ||| S:29230 E:29232 ||| CD
,  ||| S:29232 E:29234 ||| ,
calcium  ||| S:29234 E:29242 ||| JJ
phosphate ||| S:29242 E:29251 ||| NN
;  ||| S:29251 E:29253 ||| :
C ||| S:29253 E:29254 ||| NNP
/ ||| S:29254 E:29255 ||| NNP
EBPβ ||| S:29255 E:29259 ||| NNP
,  ||| S:29259 E:29269 ||| ,
CCAAT-enhancer  ||| S:29269 E:29284 ||| JJ
binding  ||| S:29284 E:29292 ||| JJ
protein-beta ||| S:29292 E:29304 ||| NN
;  ||| S:29304 E:29306 ||| :
CAT ||| S:29306 E:29309 ||| NNP
,  ||| S:29309 E:29311 ||| ,
chloramphenicol  ||| S:29311 E:29335 ||| FW
acetyl  ||| S:29335 E:29342 ||| FW
transferase ||| S:29342 E:29353 ||| FW
;  ||| S:29353 E:29355 ||| :
DMEM ||| S:29355 E:29359 ||| NNP
,  ||| S:29359 E:29361 ||| ,
Dulbecco ||| S:29361 E:29369 ||| NNP
's  ||| S:29369 E:29372 ||| POS
Modified  ||| S:29372 E:29381 ||| NNP
Eagle  ||| S:29381 E:29387 ||| NNP
Medium ||| S:29387 E:29393 ||| NNP
;  ||| S:29393 E:29403 ||| :
GST ||| S:29403 E:29406 ||| NNP
,  ||| S:29406 E:29408 ||| ,
glutathione-S-transferase ||| S:29408 E:29433 ||| JJ
;  ||| S:29433 E:29435 ||| :
MAPK ||| S:29435 E:29439 ||| NNP
,  ||| S:29439 E:29441 ||| ,
mitogen  ||| S:29441 E:29449 ||| FW
activated  ||| S:29449 E:29467 ||| FW
protein  ||| S:29467 E:29475 ||| FW
kinase ||| S:29475 E:29481 ||| FW
;  ||| S:29481 E:29483 ||| :
PBS ||| S:29483 E:29486 ||| NNP
,  ||| S:29486 E:29488 ||| ,
phosphate  ||| S:29488 E:29498 ||| FW
buffered  ||| S:29498 E:29507 ||| FW
saline ||| S:29507 E:29513 ||| FW
;  ||| S:29513 E:29515 ||| :
PMSF ||| S:29515 E:29519 ||| NNP
,  ||| S:29519 E:29529 ||| ,
phenylmethylsulfonyl  ||| S:29529 E:29550 ||| JJ
fluoride ||| S:29550 E:29558 ||| NN
;  ||| S:29558 E:29560 ||| :
SRE ||| S:29560 E:29563 ||| NNP
,  ||| S:29563 E:29565 ||| ,
serum  ||| S:29565 E:29571 ||| JJ
response  ||| S:29571 E:29580 ||| NN
element ||| S:29580 E:29587 ||| NN
;  ||| S:29587 E:29597 ||| :
SRF ||| S:29597 E:29600 ||| NNP
,  ||| S:29600 E:29602 ||| ,
serum  ||| S:29602 E:29608 ||| JJ
response  ||| S:29608 E:29617 ||| NN
factor ||| S:29617 E:29623 ||| NN
;  ||| S:29623 E:29625 ||| :
TCF ||| S:29625 E:29628 ||| NNP
,  ||| S:29628 E:29630 ||| ,
ternary  ||| S:29630 E:29638 ||| JJ
complex  ||| S:29638 E:29654 ||| JJ
factor ||| S:29654 E:29660 ||| NN
.  ||| S:29660 E:29677 ||| .
